Bicyclic heterocycles and ligands thereof for targeted delivery of therapeutic agents
By using a bicyclic heterocyclic structure composed of tetrafunctional and trifunctional groups to conjugate to GalNAc, forming a targeted ligand with a unique shape, the problem of insufficient delivery efficiency and bioavailability of existing GalNAc conjugates in oligonucleotides is solved. , significantly improves the activity and targeting of oligonucleotides.
Patent Information
- Application Number
- CN202380028674.X
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2022-11-03
- Filing Date
- 2023-03-24
- Publication Date
- 2024-11-05
AI Technical Summary
The existing GalNAc conjugates still have shortcomings in improving the pharmacological properties of oligonucleotides, especially in terms of delivery efficiency and bioavailability of targeted hepatocytes, which are difficult to meet clinical needs.
Conjugated with GalNAc using bicyclic heterocyclic and polycyclohexane structures including tetrafunctional and trifunctional groups to form targeted ligands with unique shapes and characteristics for connecting oligonucleotides and other therapeutic agents to enhance their Delivery potency and biological activity.
Through the use of these novel GalNAc-bicyclic compounds, the activity of oligonucleotides in vivo and in vitro is significantly improved, the targeted delivery capacity of liver cells is enhanced, and the bioavailability and metabolic stability of drugs is improved.
Smart Images

Figure BDA0005049814030000021 
Figure BDA0005049814030000031 
Figure BDA0005049814030000032
Abstract
Description
Technical Field
[0001] The present invention belongs to the field of medicine and relates to bicyclic heterocycles, GalNAc-conjugated, oligonucleotide therapeutic agents, methods for preparing the same, pharmaceutical compositions containing the compounds, and their medical uses. Background Art
[0002] Targeted delivery of oligonucleotides to hepatocytes using N-acetylgalactosamine (GalNAc) conjugates that bind to the asialoglycoprotein receptor (ASGPR) has emerged as a breakthrough approach in the field of therapeutic oligonucleotides. The ASGPR is an ideal target for delivering therapeutic oligonucleotides to the liver because it combines tissue specificity, high expression levels (500,000 copies / cell), and rapid internalization and turnover (15 min). GalNAC-conjugation has resulted in several FDA-approved siRNA drugs and many clinical candidates against a wide variety of targets in hepatocytes. In addition to oligonucleotides, GalNAc can also be conjugated to small molecules, peptides, proteins, and LNPs for targeting hepatocytes. There is also ample evidence that oligosaccharides of different valence states have a significant hierarchy of inhibitory ability of labeled ligands to hepatic lectin on mammalian hepatocytes: tetraantennary>triantennary>>biantennary>>monantennary. Given the advantages of GalNAc-conjugation as a powerful delivery platform, diverse GalNAc-conjugated structures are critical to improving performance in different modalities.
[0003] Other GalNAc conjugated moieties have been disclosed previously. GalNAc is connected to oligonucleotides via different linkers. Among them, tri-antennary GalNAc is formed using tetrafunctional and trifunctional groups. The tetrafunctional group connects three GalNAcs via different long linkers. The trifunctional group connects GalNAc, oligonucleotides, and solid supports (during synthesis). Derivatives such as Tris, triacids, hydroxyprolinol, glycerol, etc. have been widely used as tetrafunctional and trifunctional groups. Despite progress in the use of oligonucleotides and oligonucleotide analogs as therapeutic agents, there is still a need for oligonucleotides with improved pharmacological properties. Summary of the invention
[0004] The present invention discloses a series of tetrafunctional and trifunctional groups (including bicyclic heterocycles and polycyclohexane structures) that can connect GalNAc and oligonucleotides and other therapeutic agents with unique shapes and properties. On the one hand, a targeting ligand having a structure shown in formula (Ia) is provided:
[0005]
[0006] in:
[0007] X1 and X2 are each independently selected from the following group: NR a (CH2)r -、-O(CH2) r - and -S(CH2) r -, R1 and R2 are connected to N, O or S;
[0008] M1 is C, CH or N;
[0009] M2 does not exist and is O, C(O) or CH2;
[0010] M3 does not exist, it is CH, C, N, O, S;
[0011] Each of M4 and M6 is independently selected from C(O) and CH2;
[0012] M5 is CH, CH2 or NH;
[0013] R a Selected from the group consisting of hydrogen, deuterium, halogen, amino, cyano, hydroxy, alkyl, alkoxy, alkylthio, and haloalkyl;
[0014] R1 is hydrogen or a protecting group;
[0015] R2 is hydrogen or a solid support or phosphoramidite optionally attached via a linker group;
[0016] R3 is independently selected from hydrogen, amino, -(CH2) r COOH, alkylamino, or hydroxyalkyl;
[0017] Alternatively, two of R3 together with the C atom to which they are attached form a heterocyclic group containing a N atom; and the heterocyclic group containing a N atom has a structure shown in formula (II):
[0018]
[0019] R is a carbohydrate or a derivative thereof having a hydroxyl protecting group connected via a linker group;
[0020] R b independently selected from the group consisting of hydrogen, oxo, and alkyl;
[0021] m is 0, 1, 2, 3, 4, 5, or 6;
[0022] n is 0, 1, 2, 3, 4, 5, or 6;
[0023] x is 1, 2, 3, or 4;
[0024] y is 1, 2, 3, or 4; and
[0025] Each r is independently selected from 0, 1, 2 and 3.
[0026] The present invention discloses a series of tetrafunctional and trifunctional groups (including bicyclic heterocycles and polycyclohexane structures) that can connect GalNAc and oligonucleotides and other therapeutic agents with unique shapes and properties. On the one hand, a targeting ligand having a structure shown in formula (I) is provided:
[0027]
[0028] in:
[0029] X1 and X2 are each independently selected from the following group: NR a (CH2) r -、-O(CH2) r - and -S(CH2) r -, R1 and R2 are connected to N, O or S;
[0030] M1 is C, CH or N;
[0031] M2 does not exist and is O, C(O) or CH2;
[0032] M3 does not exist, it is CH, C, N, O, S;
[0033] Each of M4 and M6 is independently selected from C(O) and CH2;
[0034] M5 is CH, CH2 or NH;
[0035] R a Selected from the group consisting of hydrogen, deuterium, halogen, amino, cyano, hydroxy, alkyl, alkoxy, alkylthio, and haloalkyl;
[0036] R1 is hydrogen or a protecting group;
[0037] R2 is hydrogen, or a solid support optionally attached via a linker group, or a phosphoramidite;
[0038] R3 is independently selected from hydrogen, amino, -(CH2) r COOH, alkylamino, or hydroxyalkyl;
[0039] Alternatively, two of R3 together with the C atom to which they are attached form a heterocyclic group containing a N atom; and the heterocyclic group containing a N atom has a structure shown in formula (II):
[0040]
[0041] R is a carbohydrate or a derivative thereof having a hydroxyl protecting group connected via a linker group;
[0042] R b independently selected from the group consisting of hydrogen, oxo, and alkyl;
[0043] m is 0, 1, 2, 3, 4, 5, or 6;
[0044] n is 0, 1, 2, 3, 4, 5, or 6;
[0045] x is 1, 2, 3, or 4;
[0046] y is 1, 2, 3, or 4; and
[0047] Each r is independently selected from 0, 1, 2 and 3.
[0048] In an embodiment, the targeting ligand has a structure shown in formula (III) or (III-a):
[0049]
[0050] is a single bond or a double bond;
[0051] R b are independently selected from the group consisting of hydrogen and oxo;
[0052] Each of m and n is independently selected from 1, 2, 3, 4 and 5
[0053] Each of m1 and n1 is independently selected from 0, 1, 2, 3 and 4.
[0054] In an embodiment, the targeting ligand has a structure shown in Formula (III-b), (III-c) or (III-d):
[0055]
[0056] m is independently selected from 0, 1, 2, 3, 4 and 5;
[0057] n is independently selected from 1, 2, 3, 4 and 5;
[0058] Each of r, s and t is independently selected from 0, 1 and 2;
[0059] Each of m1 and n1 is independently selected from 0, 1, 2, 3 and 4.
[0060] In a preferred embodiment, R is connected via a linker group and has the following structure:
[0061] -Linker-R9, wherein R9 is a carbohydrate.
[0062] In a more preferred embodiment, R9 is selected from the group consisting of galactose, galactosamine, N-acetylgalactosamine (GalNAc), D-galactosamine alcohol, mannose, mannosamine, mannose-6-phosphate, glucose, glucosamine, N-acetyl-glucosamine (GluNAc), glucose-6-phosphate, glucosamine alcohol, glucose glyceraldehyde, fucose, fucosamine, fucose, lactose, allose, altrose, arabinose, cladinose, erythrose, erythrulose, fructose, D-fucitol, L-fucitol, L-glycero-D-mannoheptose, glycerol, glycerone, gulose, idose, lyxose, psicose, quinovose, quinovosamine, rhamnose, rhamnitol, rhamnosamine, ribose, ribulose, sedoheptulose, sorbose, tagatose, talose, tartaric acid, threose, xylose and xylulose.
[0063] In some embodiments, R9 is N-acetylgalactosamine.
[0064] In an embodiment, R is connected via a linker group and has a structure shown in formula (IV), (IV-a), (IV-b) or (IV-c):
[0065]
[0066] A is for C 3-10 Cycloalkyl or 4-12 membered heterocyclic group;
[0067] Each of L1, L2, L3, L4 and L5 is independently selected from the group consisting of: absent, O, S, SS, NH, CO, CONH, NHCO and 4-10 membered heterocyclyl;
[0068] Each of R4, R6, R7 and R8 is independently selected from the group consisting of CH2, OCH2CH2 and CH2CH2O;
[0069] R5 is independently selected from the group consisting of absent, CH2, OCH2, CH2O, OCH2CH2, CH2CH2O, NHCH2, CH2NH, NHCH2CH2, CH2CH2NH, C 0-6 Alkyl (C 3-8 Cycloalkyl) and C 0-6 Alkyl (4-10 membered heterocyclic group);
[0070] R9 is carbohydrate;
[0071] Each of t1, t2, t3, t4 and t5 is independently selected from 0, 1, 2, 3, 4, 5 and 6.
[0072] In an embodiment, R has a structure shown in formula (IV-1), (IV-a-1), (IV-b-1) or (IV-c-1):
[0073]
[0074] Among them, A is
[0075] Each of L1, L3, L4 and L5 is independently selected from the group consisting of absent, O, S, SS, NH, CO, CONH and NHCO;
[0076] L2 does not exist, and is O, S, SS, NH, CO, CONH, NHCO and
[0077] R5 is independently selected from the group consisting of: absent, CH2, CH2O, CH2NH, C 3-6 Cycloalkyl, C 3-6 Cycloalkyl C 1-3 Alkyl, 4-8 membered heterocyclic group containing 1, 2 or 3 ring heteroatoms selected from N or O 1-3 alkyl, and a 4-8 membered heterocyclic group containing 1, 2 or 3 heteroatoms selected from N or O.
[0078] In some embodiments, R has a structure shown in Formula (IV-d), (IV-e), (IV-f), (IV-da), (IV-ea) or (IV-fa):
[0079]
[0080]
[0081] in,
[0082] R5 is independently selected from the group consisting of OCH2, NHCH2, and a 4-6 membered heterocyclic group containing 1 or 2 heteroatoms selected from N or O;
[0083] m is independently selected from 0, 1, 2, 3, 4, 5 and 6;
[0084] n is 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10; and
[0085] r is 0, 1, 2, 3, 4 or 5.
[0086] In some embodiments, R9 is N-acetylgalactosamine.
[0087] In some embodiments, R5 is independently selected from -OCH2-, -NHCH2-,
[0088] In some embodiments, R is:
[0089]
[0090]
[0091]
[0092]
[0093] s is independently selected from 0, 1, 2 and 3;
[0094] r is independently selected from 0, 1, 2, 3, 4 and 5;
[0095] n is independently selected from 1, 2, 3, 4, 5, 6, 7, 8, 9 and 10.
[0096] In some embodiments, R is:
[0097]
[0098]
[0099]
[0100] r is independently selected from 0, 1, 2, 3, 4 and 5;
[0101] n is independently selected from 1, 2, 3, 4, 5, 6, 7, 8, 9 and 10.
[0102] In some embodiments, n is 7 or 8.
[0103] In some embodiments, R is:
[0104]
[0105]
[0106]
[0107]
[0108] In some embodiments, the Targeting Ligand is:
[0109]
[0110]
[0111]
[0112]
[0113] R p is H or a hydroxyl protecting group, preferably, the hydroxyl protecting group is acetyl;
[0114] X is O or S;
[0115] Each of m and n is independently selected from 1 or 2;
[0116] Each of m1 and n1 is independently selected from 1, 2 or 3.
[0117] In some embodiments, R1 is hydrogen.
[0118] In some embodiments, R1 is a substituted or unsubstituted triphenylmethyl hydroxy protecting group.
[0119] In some embodiments, R1 is
[0120] In some embodiments, R1 is
[0121] In some embodiments, R2 is hydrogen.
[0122] In some embodiments, R2 is It is a solid support.
[0123] In some embodiments, R2 is
[0124] The targeting ligand of the present invention can be linked to a therapeutic agent and used as a medicament. The therapeutic agent is selected from small molecule drugs and macromolecular drugs.
[0125] In preferred embodiments, the therapeutic agent is siRNA.
[0126] On the other hand, the present invention also provides spiro and fused bicyclic heterocycles having formula (V) and (VI). Bicyclic compounds are molecules containing two rings connected to each other. There are three different ways of connecting the rings, including (1) fused bicyclic - two atoms and the bond between them are shared; (2) bridged bicyclic - more than two atoms are shared; (3) spiro - two rings are connected together by one atom. Bicyclic compounds can be fully carbocyclic (all carbon) or heterocyclic (with one or more non-carbon atoms). Bicyclic heterocycles are key intermediates in drug synthesis and can be divided into nitrogen-containing compounds, sulfur-containing compounds and oxygen-containing compounds. Bicyclic heterocycles have recently attracted attention due to their interesting conformational features and their structural significance to biological systems. Strained bicyclic compounds are important targets because they exhibit a variety of new biological activities for unique shapes and properties. In addition, in addition to potentially regulating binding potency and specificity, bicyclic scaffolds can also improve bioavailability and metabolic stability, which are key issues when developing new pharmacological entities. This patent designs a series of novel spiro and fused bicyclic heterocycles with multiple functional groups as shown below. These spirocyclic and fused bicyclic compounds can be used to link different moieties, such as GalNAc, oligonucleotides, and solid supports.
[0127]
[0128] is a single bond or a double bond;
[0129] R b are independently selected from the group consisting of hydrogen and oxo;
[0130] Each of m and n is independently selected from 1, 2, 3, 4 and 5
[0131] Each of m1 and n1 is independently selected from 0, 1, 2, 3 and 4.
[0132] On the other hand, the present invention also provides a bicyclic heterocycle having formula (VI-a), (VI-b), or (VI-c), or a tautomer, or a pharmaceutically acceptable salt thereof:
[0133]
[0134] m is independently selected from 0, 1, 2, 3, 4 and 5;
[0135] n is independently selected from 1, 2, 3, 4 and 5;
[0136] Each of r, s and t is independently selected from 0, 1 and 2;
[0137] Each of m1 and n1 is independently selected from 0, 1, 2, 3 and 4.
[0138] In a preferred embodiment, the compound is selected from the following structures:
[0139]
[0140] or a tautomer or a pharmaceutically acceptable salt thereof.
[0141] GalNAc-spirocyclic / fused bicyclic conjugation
[0142] GalNAc can be conjugated with different modes through different joints and tethering groups. Spirocycle / bicyclic compounds can provide unique conformation for the whole conjugation. In order to introduce GalNAc into oligonucleotides, first the GalNAc ligand is assembled into a single so-called triantennary ligand, then conjugated with a solid support or converted into its phosphoramidite form. However, an alternative method has also been described, which uses a monovalent GalNAc support and adds twice monovalent GalNAc phosphoramidites, and produces a structure as shown below. This (1+1+1) trivalent GalNAc structure causes the effectiveness of GalNAc-modified siRNA oligonucleotides in vitro and in vivo to be equal to the equivalent siRNA with triantennary GalNAc ligands.
[0143]
[0144] The present invention provides a series of novel GalNAc-bicyclic compounds, which can be conjugated to oligonucleotides or loaded onto solid supports for solid phase oligonucleotide synthesis via phosphoramidite chemistry, for example:
[0145]
[0146] The four functional groups are selected from
[0147]
[0148]
[0149] In another aspect, the present invention provides a therapeutic compound comprising at least one therapeutic oligonucleotide conjugated to a targeting ligand.
[0150] In some embodiments, the targeting ligand is conjugated to the 3' end or the 5' end of the oligonucleotide; more preferably, the oligonucleotide is an siRNA; more preferably, the siRNA is C3, C5, CFB, PCSK9, TTR, AGT, LPA, Agtr1, ALK, VEGF, ANGPTL3, ANGPTL4, ANGPTL8, APOA, APOC3, ASGR1, CIDEB, COL1A1, COL3A1, CTGF, DGAT2, DMPK, DNAJC15 / MCJ, DPP4, Factor VIII, Factor X, Factor IX, Factor XI, Factor XII, GPR146, GPR75, GRB10 / 14, TLR7 / 8 / RIG- 1. HSD17B13, INHBE, ITGV6, KHK, KLK1, MASP2, MTARC1, MUC5B, NPC1L1, PNPLA3, ASGR1, SCAP, SERPINA1, SERPINF2, SREBF2, HMGCR, TGFB1, COX-2, TP53, CD 4. CD8, CD40, CD71, DUX4,
[0151] The novel GalNAc conjugates of the present invention have better activities in vitro and in vivo than previous GalNAc conjugates.
[0152] The present invention also provides a pharmaceutical composition comprising a therapeutic compound or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, diluent or excipient.
[0153] In another aspect, the present invention relates to a method for treating a disease or condition, which comprises administering to a subject in need thereof an effective amount of a therapeutic compound or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition comprising the therapeutic compound or a pharmaceutically acceptable salt thereof.
[0154] In some embodiments, the disease or disorder is liver disease, a genetic disease, a bleeding disorder (e.g., hemophilia), a rare disease (e.g., acromegaly), a metabolic disease (e.g., hypercholesterolemia, dyslipidemia, hypertriglyceridemia), cardiovascular disease, obesity, hemochromatosis, alcohol dependence, and anemia (e.g., anemia of chronic disease, thalassemia).
[0155] In some embodiments, the liver disease is liver damage, liver fibrosis, alcoholic liver disease, non-alcoholic steatohepatitis (NASH), non-alcoholic fatty liver disease (NAFLD), or viral hepatitis.
[0156] In another aspect, the invention relates to a method of synthesizing a therapeutic compound, the method comprising: providing a targeting ligand having formula (I), and conjugating the targeting ligand to an oligonucleotide.
[0157] In preferred embodiments, the targeting ligand is conjugated to the 3' end or the 5' end of the oligonucleotide.
[0158] In preferred embodiments, targeting ligands may be conjugated to both the 3' and 5' ends of the oligonucleotide.
[0159] As mentioned above, GalNAc can be conjugated to oligonucleotides in a single piece or in a stepwise (1+1+1) format.
[0160]
[0161] In order to achieve 1+1+1 assembly, it is necessary to synthesize a mono-GalNAc phosphoramidite and a mono-GalNAc solid support.
[0162]
[0163] R b , m, n, m1 and n1 are defined as shown in formula (Va) and (Vb). The specific method is as follows:
[0164]
[0165]
[0166] BRIEF DESCRIPTION OF THE DRAWINGS
[0167] Figure 1 The effects of siRNA-24 and siRNA-25 on serum mC3 protein in in vivo studies are shown.
[0168] Figure 2 The effects of siRNA-24 and siRNA-25 on hepatic mC3 mRNA levels in in vivo studies are shown. DETAILED DESCRIPTION
[0169] The following are definitions of terms used in this application. Any term not defined herein has its normal meaning as understood by those skilled in the art.
[0170] "Alkyl" refers to a saturated aliphatic hydrocarbon group, including C1-C 20Straight and branched chain groups. Preferably, the alkyl group is an alkyl group having 1 to 12 carbon atoms, sometimes preferably 1 to 6 carbon atoms, and sometimes more preferably 1 to 4 carbon atoms. Representative examples include, but are not limited to, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, sec-butyl, n-pentyl, 1,1-dimethylpropyl, 1,2-dimethylpropyl, 2,2-dimethylpropyl, 1-ethylpropyl, 2-methylbutyl, 3-methylbutyl, n-hexyl, 1-ethyl-2-methylpropyl, 1,1,2-trimethylpropyl, 1,1-dimethylbutyl, 1,2-dimethylbutyl, 2,2-dimethylbutyl, 1,3-dimethylbutyl, 2-ethylbutyl, 2-methylpentyl, 3-methylpentyl, 4-methylpentyl, 2,3-dimethylbutyl, n-heptyl, 2-methylhexyl, 3-methylhexyl, 4-methylhexyl, 5-methylhexyl , 2,3-dimethylpentyl, 2,4-dimethylpentyl, 2,2-dimethylpentyl, 3,3-dimethylpentyl, 2-ethylpentyl, 3-ethylpentyl, n-octyl, 2,3-dimethylhexyl, 2,4-dimethylhexyl, 2,5-dimethylhexyl, 2,2-dimethylhexyl, 3,3-dimethylhexyl, 4,4-dimethylhexyl, 2-ethylhexyl, 3-ethylhexyl, 4-ethylhexyl, 2-methyl-2-ethylpentyl, 2-methyl-3-ethylpentyl, n-nonyl, 2-methyl-2-ethylhexyl, 2-methyl-3-ethylhexyl, 2,2-diethylpentyl, n-decyl, 3,3-diethylhexyl, 2,2-diethylhexyl, and isomers thereof. More preferably, the alkyl group is a lower alkyl group having 1 to 6 carbon atoms. Representative examples include, but are not limited to, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, sec-butyl, n-pentyl, 1,1-dimethylpropyl, 1,2-dimethylpropyl, 2,2-dimethylpropyl, 1-ethylpropyl, 2-methylbutyl, 3-methylbutyl, n-hexyl, 1-ethyl-2-methylpropyl, 1,1,2-trimethylpropyl, 1,1-dimethylbutyl, 1,2-dimethylbutyl, 2,2-dimethylbutyl, 1,3-dimethylbutyl, 2-ethylbutyl, 2-methylpentyl, 3-methylpentyl, 4-methylpentyl, 2,3-dimethylbutyl, etc. The alkyl group can be substituted or unsubstituted. When substituted, the substituent group may be substituted at any available point of attachment, preferably, the substituent group is one or more substituents independently selected from the group consisting of alkyl, halogen, alkoxy, alkenyl, alkynyl, alkylsulfonyl, alkylamino, thiol, hydroxy, nitro, cyano, amino, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, cycloalkyloxy, heterocycle, cycloalkylthio, heterocycloalkylthio and oxo.
[0171] "Alkoxy" refers to both -O-(alkyl) and -O-(unsubstituted cycloalkyl) groups, wherein the alkyl is defined as above. Representative examples include, but are not limited to, methoxy, ethoxy, propoxy, butoxy, cyclopropyloxy, cyclobutyloxy, cyclopentyloxy, cyclohexyloxy, etc. Alkoxy can be substituted or unsubstituted. When substituted, the substituent is preferably one or more, sometimes preferably one to five, sometimes more preferably one to three, independently selected from the group consisting of: alkyl, alkenyl, alkynyl, alkoxy, alkylsulfonyl, alkylamino, halogen, thiol, hydroxyl, nitro, cyano, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, cycloalkyloxy, heterocycloalkyloxy, cycloalkylthio, and heterocycloalkylthio.
[0172] "Alkylthio" refers to both -S-(alkyl) and -S-(unsubstituted cycloalkyl) groups where the alkyl group is as previously described.
[0173] "Haloalkyl" refers to an alkyl group substituted with a halo group, wherein alkyl is as defined above.
[0174] "Halogen" refers to a fluorine, chlorine, bromine or iodine atom.
[0175] "Cycloalkyl" refers to a saturated and / or partially unsaturated monocyclic or polycyclic hydrocarbon group having 3 to 20 carbon atoms, preferably 3 to 12 carbon atoms, more preferably 3 to 10 carbon atoms, and most preferably 3 to 8 carbon atoms or 3 to 6 carbon atoms. Representative examples of monocyclic cycloalkyls include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclopentenyl, cyclohexyl, cyclohexenyl, cyclohexadienyl, cycloheptyl, cycloheptatrienyl, cyclooctyl, etc. Polycyclic cycloalkyls include cycloalkyls having spirocyclic, condensed or bridged rings.
[0176] "Spirocycloalkyl" refers to a 5 to 20 yuan polycyclic group that the ring is connected by a shared carbon atom (called spiral atom), wherein one or more rings may contain one or more double bonds, but no ring has a completely conjugated π electron system. Preferably, spirocycloalkyl is 6 to 14 yuan and more preferably 7 to 10 yuan. According to the shared spiral atom number, spirocycloalkyl is divided into single spiral cycloalkyl, two spiral cycloalkyl or multiple spiral cycloalkyl, and preferably refers to single spiral cycloalkyl or two spiral cycloalkyl, more preferably 4 yuan / 4 yuan, 4 yuan / 5 yuan, 4 yuan / 6 yuan, 5 yuan / 5 yuan or 5 yuan / 6 yuan single spiral cycloalkyl. Representative examples of spirocycloalkyl include but are not limited to the following substituents:
[0177]
[0178] "Fused cycloalkyl" refers to a 5 to 20-membered polycyclic hydrocarbon group, wherein each ring in the system shares a pair of adjacent carbon atoms with another ring, wherein one or more rings may contain one or more double bonds, but no ring has a completely conjugated π electron system. Preferably, the fused cycloalkyl group is 6 to 14 members, more preferably 7 to 10 members. Depending on the number of member rings, the fused cycloalkyl is divided into a bicyclic, tricyclic, tetracyclic or polycyclic fused cycloalkyl, and preferably refers to a bicyclic or tricyclic fused cycloalkyl, more preferably a 5-membered / 5-membered or 5-membered / 6-membered bicyclic fused cycloalkyl. Representative examples of fused cycloalkyls include, but are not limited to, the following substituents:
[0179]
[0180] "Bridged cycloalkyl" refers to a 5 to 20-membered polycyclic hydrocarbon group in which every two rings in the system share two unconnected carbon atoms. These rings may have one or more double bonds, but do not have a completely conjugated π electron system. Preferably, the bridged cycloalkyl is 6 to 14 members, and more preferably 7 to 10 members. Depending on the number of member rings, the bridged cycloalkyl is divided into a bicyclic, tricyclic, tetracyclic or polycyclic bridged cycloalkyl, and preferably refers to a bicyclic, tricyclic or tetracyclic bridged cycloalkyl, more preferably a bicyclic or tricyclic bridged cycloalkyl. Representative examples of bridged cycloalkyls include, but are not limited to, the following substituents:
[0181]
[0182] Cycloalkyl can be fused with the ring of aryl, heteroaryl or heterocycloalkyl, and the ring that wherein is combined with parent structure is cycloalkyl.Representative examples include but are not limited to indanyl acetic acid, tetralin, benzocycloheptyl etc.Cycloalkyl is optionally substituted or unsubstituted.When substituted, substituent group is preferably one or more, preferably one to five, more preferably one to three substituents independently selected from the group consisting of: alkyl, halogen, alkoxy, alkenyl, alkynyl, alkyl sulfonyl, alkylamino, mercaptan, hydroxyl, nitro, cyano, amino, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, cycloalkyloxy, heterocycle, cycloalkylthio, heterocycloalkylthio and oxo group.
[0183] "Heterocyclyl" refers to a 3- to 20-membered saturated and / or partially unsaturated monocyclic or polycyclic hydrocarbon group having one or more, sometimes preferably one to five, sometimes more preferably one to three, selected from N, O and S(O) m(wherein m is 0, 1 or 2) as the ring atom, but in the ring, except -OO-, -OS- or -SS-, the remaining ring atoms are C. Preferably, the heterocyclic group is a 3- to 12-membered heterocyclic group having 1 to 4 heteroatoms, more preferably a 3- to 10-membered heterocyclic group having 1 to 3 heteroatoms, and most preferably a 5- to 6-membered heterocyclic group having 1 to 2 heteroatoms. Representative examples of monocyclic heterocyclic groups include, but are not limited to, pyrrolidinyl, piperidinyl, piperazinyl, morpholinyl, sulfo-morpholinyl, homopiperazinyl, etc. Polycyclic heterocyclic groups include heterocyclic groups having spiro rings, condensed rings or bridged rings.
[0184] "Spiro heterocyclyl" refers to a 5- to 20-membered polycyclic heterocyclic group whose rings are linked through a common carbon atom (called a spiro atom), wherein the rings have one or more, sometimes preferably one to five, sometimes more preferably one to three, selected from N, O and S(O) m (wherein m is 0,1 or 2) the heteroatom of the group consisting of as ring atoms, the remaining ring atoms are C, wherein one or more rings may contain one or more double bonds, but no ring has a completely conjugated π electron system. Preferably, spiro heterocyclic group is 6 to 14 yuan and more preferably 7 to 10 yuan. According to the number of shared spiro atoms, spiro heterocyclic group is divided into monospiro heterocyclic group, dispiro heterocyclic group or polyspiro heterocyclic group, and preferably refers to monospiro heterocyclic group or dispiro heterocyclic group, more preferably 4 yuan / 4 yuan, 4 yuan / 5 yuan, 4 yuan / 6 yuan, 5 yuan / 5 yuan, or 5 yuan / 6 yuan monospiro heterocyclic group. Representative examples of spiro heterocyclic group include but are not limited to the following substituents:
[0185]
[0186] "Fused heterocyclyl" refers to a 5- to 20-membered polycyclic heterocyclyl group, wherein each ring in the system shares a pair of adjacent carbon atoms with another ring, wherein one or more rings may contain one or more double bonds, but no ring has a completely conjugated π electron system, and wherein the rings have one or more, sometimes preferably one to five, sometimes more preferably one to three, selected from N, O and S(O) p (wherein p is 0, 1 or 2) as ring atoms, and the remaining ring atoms are C. Preferably, the fused heterocyclic group is 6 to 14 members, and more preferably 7 to 10 members. According to the number of member rings, the fused heterocyclic group is divided into a bicyclic, tricyclic, tetracyclic or polycyclic fused heterocyclic group, and preferably refers to a bicyclic or tricyclic fused heterocyclic group, more preferably a 5-membered / 5-membered or 5-membered / 6-membered bicyclic fused heterocyclic group. Representative examples of fused heterocyclic groups include, but are not limited to, the following substituents:
[0187]
[0188] "Bridged heterocyclyl" refers to a 5- to 14-membered polycyclic heterocycloalkyl group, wherein each two rings in the system share two non-connected atoms, the rings may have one or more double bonds, but do not have a completely conjugated π-electron system, and the rings have one or more selected from N, O and S(O) m (wherein m is 0, 1 or 2) as ring atoms, and the remaining ring atoms are C. Preferably, the bridged heterocyclic group is 6 to 14 members, and more preferably 7 to 10 members. According to the number of member rings, the bridged heterocyclic group is divided into a bicyclic, tricyclic, tetracyclic or polycyclic bridged heterocyclic group, and preferably refers to a bicyclic, tricyclic or tetracyclic bridged heterocyclic group, more preferably a bicyclic or tricyclic bridged heterocyclic group. Representative examples of bridged heterocyclic groups include, but are not limited to, the following substituents:
[0189]
[0190] The ring of the heterocyclic group can be fused with the ring of aryl, heteroaryl or cycloalkyl, wherein the ring bound to the parent structure is the heterocyclic group. Representative examples include, but are not limited to, the following substituents:
[0191] wait.
[0192] The heterocyclyl group is optionally substituted or unsubstituted. When substituted, the substituent group is preferably one or more, sometimes preferably one to five, sometimes more preferably one to three, independently selected from the group consisting of alkyl, alkenyl, alkynyl, alkoxy, alkylsulfonyl, alkylamino, halogen, thiol, hydroxy, nitro, cyano, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, cycloalkyloxy, heterocycloalkyloxy, cycloalkylthio and heterocycloalkylthio.
[0193] Use of "heterocycle" is intended to include heteroaryl groups.
[0194] "Pharmaceutical composition" refers to a mixture of one or more compounds described in the present invention or their physiologically / pharmaceutically acceptable salts or prodrugs with other chemical components (such as physiologically / pharmaceutically acceptable carriers and excipients). The purpose of a pharmaceutical composition is to facilitate the administration of the compound to an organism, which is beneficial to the absorption of the active ingredient, thereby exerting biological activity.
[0195] "Pharmaceutically acceptable salt" refers to a salt of the compound of the present invention, which is safe and effective when used in mammals and has the corresponding biological activity.
[0196] "Optional" or "optionally" means that the subsequently described event or circumstance can occur but does not have to occur, and the description includes instances where the event or circumstance can occur or instances where it cannot occur. For example, "the heterocyclic group is optionally substituted with an alkyl group" means that the alkyl group can be present but does not have to be present, and the description includes instances where the heterocyclic group is substituted with an alkyl group and instances where the heterocyclic group is not substituted with an alkyl group.
[0197] "Substitution" means that one or more hydrogen atoms, preferably up to 5, more preferably 1 to 3 hydrogen atoms, in a group are independently replaced by a corresponding number of substituents. It is obvious that the substituent is present in its only possible chemical position. Those skilled in the art can determine whether substitution is possible or impossible without excessive effort through experimentation or theory. For example, the combination of an amino or hydroxyl group with free hydrogen and a carbon atom with an unsaturated bond (such as an olefinic bond) may be unstable.
[0198] As used herein, "conjugate" refers to a biomolecule covalently linked to a non-nucleotide moiety. A specific conjugate of the invention is a nucleic acid conjugate, wherein a nucleic acid molecule (eg, an oligonucleotide or siRNA) is covalently linked to a non-nucleotide moiety, such as a GalNAc conjugate moiety of the invention.
[0199] As used herein, "oligonucleotide" is defined as a molecule comprising two or more covalently linked nucleosides as generally understood by those skilled in the art. Such covalently linked nucleosides may also be referred to as nucleic acid molecules or oligomers.
[0200] Oligonucleotides are usually prepared by solid phase chemical synthesis and then purified in the laboratory. When referring to the sequence of an oligonucleotide, it refers to the core base portion of a covalently linked nucleotide or nucleoside or a sequence or order of its modification. Oligonucleotides of the present invention are artificial and chemically synthesized, and are typically purified or separated. Oligonucleotides of the present invention may comprise one or more modified nucleosides or nucleotides.
[0201] "siRNA" may consist of two annealed polynucleotides or a single polynucleotide forming a hairpin structure. The siRNA molecule of the present invention comprises a sense region and an antisense region. The antisense region has a nucleotide sequence that is identical (completely complementary) or almost identical (partially complementary) to the target nucleic acid.
[0202] RNAi molecules are essentially synthetic, man-made molecules and function within the RNA interference (RNAi) pathway, where they interfere with target nucleic acids with complementary nucleotide sequences by degrading mRNA after transcription, rendering them incapable of translation. siRNAs interact via a protein complex called Dicer, which cuts the siRNA into smaller fragments. One strand of these fragments (the antisense strand in most cases) is loaded into another protein complex called the RNA-induced silencing complex (RISC). The RISC-bound strand then connects the complex to the target nucleic acid through base pairing. The target nucleic acid is cut and destroyed, so that protein cannot be synthesized.
[0203] "Inhibiting expression" means reducing or blocking expression or activity, and does not necessarily indicate complete elimination of expression or activity.
[0204] Examples
[0205] The following examples are used to illustrate the present invention, but these examples should not be considered to limit the scope of the present invention. If the specific conditions of the experimental method are not indicated in the examples of the present invention, then the conventional conditions or the conditions recommended by the raw material and product manufacturers are generally followed. Reagents without specifying the specific source are all commercially available conventional reagents.
[0206] The structure of each compound was confirmed by nuclear magnetic resonance (NMR) and / or mass spectrometry (MS). NMR chemical shifts (δ) were expressed in 10 -6 (ppm). NMR was determined by Varian Mercury 300MHz, Bruker Avance III 400MHz machines. The solvents used were deuterated dimethyl sulfoxide (DMSO-d6), deuterated chloroform (CDCl3) and deuterated methanol (CD3OD).
[0207] High performance liquid chromatography (HPLC) was determined using an Agilent 1200DAD high pressure liquid chromatograph (Sunfire C18 150×4.6 mm column) and a Waters 2695-2996 high pressure liquid chromatograph (Gimini C18 150×4.6 mm column). Liquid chromatography mass spectrometry (LCMS) was determined using an Agilent 1200 high pressure liquid chromatograph & mass spectrometer (Sunfire C18 4.6*50 mm 3.5 um column) and an Agilent 19091S-433HP-5 high pressure liquid chromatograph & mass spectrometer (XBridge C18 4.6*50 mm 3.5 um column).
[0208] Chiral high performance liquid chromatography (HPLC) was performed using SFC Thar 80&150&200 (Waters).
[0209] The thin layer silica gel plates used for thin layer chromatography were Yantai Xinnuo silica gel plates. The plate size used in TLC was 0.15 mm to 0.2 mm, and the plate size for thin layer chromatography used for product purification was 0.4 mm to 0.5 mm.
[0210] Column chromatography usually uses Qingdao Haiyang 200 to 300 mesh silica gel as the carrier.
[0211] The known starting materials of the present invention can be prepared by conventional synthetic methods in the prior art, or can be purchased from ABCR GmbH & Co. KG, Acros Organics, Aldrich Chemical Company, Accela ChemBio Inc, or Dari Chemical Company, etc.
[0212] Unless otherwise specified in the examples, the following reactions were carried out under an argon atmosphere or a nitrogen atmosphere.
[0213] The term "argon atmosphere" or "nitrogen atmosphere" means that the reaction flask is equipped with a balloon containing 1 L of argon or nitrogen.
[0214] The term "hydrogen atmosphere" means that the reaction flask was equipped with a balloon containing 1 L of hydrogen.
[0215] MS is mass spectrometry, where (+) refers to the positive mode, typically producing an M+1 (or M+H) absorption, where M = molecular mass.
[0216] Example 1
[0217]
[0218] Compound 1-2:
[0219] Compound 1-1 (5 g, 12.84 mmol) in anhydrous 1,2-dichloroethane (30 mL) was stirred at 0 ° C, TMSOTf (3.43 g, 15.41 mmol, 2.78 mL) was added dropwise over 10 min under continuous stirring, and stirring was continued at room temperature overnight. The reaction mixture was quenched with cold saturated NaHCO solution (200 mL), and the organic layer was separated. The product was extracted with dichloromethane (60 mL x 2); the combined organic layer was washed with water and brine, dried over anhydrous Na2SO4, and evaporated to dryness under reduced pressure to obtain compound 1-2 (4.23 g, 99% yield) as a yellow oil, which was used without further purification.
[0220] C 14 H 19 Calculated mass value of NO8: 329.1; Measured value: 330.1 [M+H] + ,ESI.
[0221] Compound 1-3:
[0222] Compound 1-2 (4.23 g, 12.85 mmol) in anhydrous 1,2-dichloroethane (20 mL) was used Molecular sieve (4.7g) is stirred at room temperature for 5min. 5-hexene-1-ol (1.42g, 14.13mmol) is added, and stirring is continued for 30min. TMSOTf (1.43g, 6.42mmol, 1.16mL) is added dropwise at 0°C, and stirring is continued for 2h at room temperature. The reaction mixture is quenched with cold saturated NaHCO solution (100mL), and the organic layer is separated. The product is extracted with dichloromethane (60mLx2); the combined organic layer is washed with water, dried over anhydrous Na2SO4, and evaporated to dryness under reduced pressure to obtain compound 1-3 (5.5g, 99% yield) as a yellow oil, which is used without further purification.
[0223] C 20 H 31 Calculated mass of NO9: 429.2; Measured value: 430.2 [M+H] + ,ESI.
[0224] Compound 1-4:
[0225] To the solution of compound 1-3 (5.5g, 12.81mmol) in DCM (35mL) and MeCN (35mL), 4.0mol equivalent of (meta) sodium periodate (10.96g, 51.24mmol) in water (45.5mL) is added. The mixture is cooled to 0 ° C in an ice bath and stirred for 15min. Ruthenium chloride trihydrate (110.5mg, 423μmol) is added to the cold reaction mixture. The reaction mixture is stirred at room temperature for 4h. The reaction mixture is diluted with water (90mL), and the pH is adjusted to 7.5 by adding solid NaHCO3. The DCM layer is removed, the water layer is washed with DCM (30mLx2), and the organic extract is discarded. The pH of the water layer is adjusted to 3 by adding citric acid, and the carboxylic acid 1-4 is extracted into DCM (50mLx3). The organic layer was stirred with saturated brine (50 mL x 1), followed by the addition of Na2S2O3 solution (50 mL x 1) until the dark green organic phase turned light yellow. The layers were separated, and the organic layer was dried over anhydrous Na2SO4 and evaporated under reduced pressure to give compound 1-4 (2.3 g, 40% yield) as a white solid, which was used without further purification.
[0226] C 19 H 29 NO 11 Calculated mass: 447.2; Found: 448.2 [M+H] + ,ESI.
[0227] 1 H NMR(400MHz, DMSO-d6)δ7.81(d,J=9.2Hz,1H),5.84-5.73(m,1H),5.21(d,J=3.3Hz,1H),4.98-4.93(m,3H),4.48(d,J=8.5Hz,1H),4.04-4.00(m,3H) ,3.88-3.83(m,1H),3.73-3.68(m,1H),3.40-3.36(m,1H),2.10(s,3H),2. 03-2.02(m,2H),2.00(s,3H),1.89(s,3H),1.76(s,3H),1.43-1.32(m,4H).
[0228] Compounds 1-6:
[0229] HBTU (2.92g, 7.71mmol) and DIPEA (1.99g, 15.42mmol, 2.69mL) are added to a solution of compound 1-5 (1.16g, 6.17mmol) and acid 1-4 (2.3g, 5.14mmol) in DMF (30mL). The reaction is stirred at room temperature for 43h and diluted with water (150mL). The mixture is extracted with ethyl acetate (60mLx3). The combined organic layers are washed with water (100mLx3) and brine (100mL) successively. After drying over anhydrous Na2SO4, the solvent is evaporated under reduced pressure to obtain compound 1-6 (4.3g, crude product) in a yellow oil, which is used without further purification.
[0230] C 29 H 48 N2O 12 Calculated mass: 616.3; Found: 617.4 [M+H] + ,ESI.
[0231] Compound 1-7:
[0232] Compound 1-6 (4.23 g, assuming 6.86 mmol) was added to formic acid (30 mL), and the mixture was stirred at room temperature overnight. LC-MS determined that the reaction was complete. The mixture was then evaporated under reduced pressure and purified by silica gel chromatography (DCM: MeOH = 10: 1) to obtain compound 1-7 (2.88 g, 75% yield over 2 steps) as a yellow oil.
[0233] C 25 H 40 N2O 12 Calculated mass: 560.3; Found: 561.3 [M+H] + ,ESI.
[0234] 1H NMR (400MHz, DMSO-d6) δ12.02(s,1H),7.83(d,J=9.2Hz,1H),7.25(t,J=5.6Hz,1H),5.21(d,J=3. 2Hz,1H),4.96(dd,J=11.2,3.6Hz,1H),4.47(d,J=8.4Hz,1H),4.04-4.00(m,3H),3.90-3.83(m,1H ),3.73-3.68(m,1H),3.42-3.36(m,1H),3.02-2.97(m,1H),2.18(t,J=7.2Hz,2H),2.10(s,3H),2. 02(t,J=7.2Hz,2H),1.99(s,3H),1.89(s,3H),1.77(s,3H),1.54-1.41(m,7H),1.27-1.21(m,3H).
[0235] Example 2
[0236] Method 1:
[0237]
[0238] Compound 2-1:
[0239] A mixture of 2,2-bis(bromomethyl)propane-1,3-diol (270 g, 1.03 mol), benzaldehyde (114.86 g, 1.08 mol), TsOH (17.74 g, 340.55 mmol) in toluene (1 L) was refluxed for 6 h. The mixture was cooled and extracted with EA (1 L), washed with NaHCO3 solution, then washed with brine, and dried over Na2SO4. The solvent was removed under reduced pressure, and the residue was recrystallized from MeOH to give the desired product 2-1 (247 g, 68% yield).
[0240] 1 H NMR (400MHz, DMSO-d6) δ7.47-7.41(m,2H),7.40-7.36(m,3H),5.48(s,1H),4.09-3.93(m,6H),3.46(s,2H).
[0241] Compound 2-2:
[0242] To a suspension of t-BuOK (137.27 g, 1.43 mol) in dry DMF (700 mL), diisopropyl malonate (268.85 g, 1.43 mol) was added dropwise (temperature maintained below 70 ° C), followed by addition of compound 2-1 (250 g, 714.19 mmol). The resulting reaction mixture was heated at 140 ° C for 6 h. After cooling, saturated NH4Cl solution (1.5 L) was added, and the mixture was extracted with hexane (500 mL x 3). The combined organic extracts were dried over sodium sulfate and concentrated in vacuo. The solid product was separated from the liquid residue by filtration, washed with hexane (100 mL x 2) and dried to produce the pure product 2-2 (194 g, 68% yield) as a white solid.
[0243] C 21 H 28 Calculated mass of O6: 376.2; Found: 377.2 [M+H] + ,ESI.
[0244] 1 H NMR(400MHz,DMSO-d6)δ7.45-7.31(m,5H),5.45(s,1H),5.02-4.93(m,2H),3.96(d,J =11.2Hz,2H),3.77(d,J=11.1Hz,2H),2.55(s,2H),2.13(s,2H),1.23-1.15(m,12H).
[0245] Compound 2-3:
[0246] To a solution of compound 2-2 (155 g, 411.7 mmol) in MeOH (750 mL) was added 10% Pd / C (31 g), and the resulting suspension was hydrogenated under 5 atm H2 at ambient temperature with stirring for 48 h. The catalyst was filtered and the solvent was removed in vacuo to give compound 2-3 (118 g, 99% yield) as a colorless oil, which was used in the next step without further purification.
[0247] C 21 H 28 Calculated mass of O6: 288.2; Found: 289.4 [M+H] + ,ESI.
[0248] Compound 2-4:
[0249] Methanesulfonyl chloride (155.7 g, 1.36 mol) was added to a solution of compound 2-3 (140 g, 485.5 mmol) in dichloromethane (840 mL). The resulting mixture was cooled to -30 °C and triethylamine (323.9 g, 3.2 mol) was then added dropwise. After the addition was complete, the reaction mixture was warmed to ambient temperature and stirred for 12 h, then washed with water (1000 mL), 10% aqueous citric acid (1000 mL) and brine (1000 mL). The organic phase was dried over sodium sulfate and evaporated under reduced pressure to give compound 2-4 (125 g, 58% yield).
[0250] C 21 H 28 Calculated mass of O6: 444.1; Found: 445.2 [M+H] + ,ESI.
[0251] 1 H NMR (400MHz, DMSO-d6) δ5.02-4.93(m,2H),4.20(s,4H),3.23(s,6H),2.45(s,4H),1.22-1.14(m,12H).
[0252] Compound 2-5:
[0253] A solution of compound 2-4 (63 g, 141.73 mmol), potassium carbonate (100.88 g, 729.89 mmol), and p-toluenesulfonamide (25.48 g, 148.81 mmol) in DMSO (300 mL) was heated at 85 ° C for 12 h. After cooling, water (300 mL) was added, and the mixture was extracted with EtOAc (600 mL). The combined organic phase was washed with 10% aqueous citric acid (600 mL) and brine (600 mL), dried over sodium sulfate and evaporated in vacuo, and then recrystallized from isopropyl ether to produce compound 2-5 (48 g, 80% yield).
[0254] C 21 H 28 Calculated mass of O6: 423.2; Found: 424.2 [M+H] + ,ESI.
[0255] 1 H NMR (400MHz, DMSO-d6) δ7.67(d,J=8.2Hz,2H),7.45(d,J=8.0Hz,2H),4.45(t ,J=5.4Hz,2H),3.60(s,4H),3.14(d,J=5.7Hz,4H),2.43(s,3H),1.67(s,4H).
[0256] Compound 2-6:
[0257] To a solution of compound 2-5 (58.7 g, 138.60 mmol) in THF (100 mL) was added a solution of lithium borohydride (2 M) in THF (263.82 mL) at -20 ° C. The resulting mixture was stirred at room temperature for 16 h. The mixture was slowly added to ice water (1 L). The pH was adjusted to 7 with aqueous citric acid. The mixture was extracted with EA (500 mL), dried over anhydrous sodium sulfate and evaporated under reduced pressure to give compound 2-6 (40 g, 93% yield).
[0258] C 21 H 28 Calculated mass of O6: 311.1; Found: 312.1 [M+H] + ,ESI.
[0259] 1 H NMR (400MHz, DMSO-D6) δ7.67(d,J=8.2Hz,2H),7.45(d,J=8.0Hz,2H),4.45(t ,J=5.4Hz,2H),3.60(s,4H),3.14(d,J=5.7Hz,4H),2.43(s,3H),1.67(s,4H).
[0260] Compound 2-7:
[0261] Compound 2-6 (5 g, 16.1 mmol) and Mg (powder, 3.47 g, 144.6 mmol) were mixed in MeOH (anhydrous, 60 mL) and stirred at room temperature overnight. LC-MS showed complete conversion, and water (30 mL) was added. A white precipitate was formed. The mixture was filtered, and the filtrate was adjusted to pH 6 with HCl (aqueous 4 M) and concentrated to dryness to give compound 2-7 (2.55 g crude) as a yellow solid. The crude product was used without further purification.
[0262] 8H 15 Calculated value of NO2 mass: 157.1; Measured value: 158.1 [M+H] + ,ESI.
[0263] Compound 2-8:
[0264] Compound 2-7 (2.55 g, assuming 16.2 mmol) was dissolved in dioxane (20 mL), and FmocCl (4.60 g, 17.8 mmol) was slowly added at 0 ° C., followed by Na2CO3 (saturated, 20 mL). The reaction was stirred at 30 ° C. for 3 h. LC-MS showed complete conversion. The reaction mixture was extracted with EA (20 mLx3). The organic phase was concentrated and purified by flash silica gel column chromatography (DCM: MeOH = 97: 3) to give a white solid 2-8 (2.75 g, 44.7% yield over 2 steps).
[0265] C 23 H 25 Calculated mass value of NO4: 379.2; Measured value: 380.2 [M+H] + ,ESI.
[0266] Compound 2-9:
[0267] Compound 2-8 (2.7 g, 7.1 mmol) and pyridine (20 mL) were mixed in a flask, and DMTr-Cl (2.4 g, 7.1 mmol) was added in batches. The reaction was stirred at room temperature for 4 h. LC-MS showed complete conversion. The reaction mixture was extracted with EA (20 mLx3). The organic phase was concentrated and purified by flash silica gel column chromatography (DCM: MeOH = 97: 3) to give a yellow solid 2-9 (2.8 g, 58% yield).
[0268] C 44 H 43 Calculated mass of NO6: 681.3; Measured value: 682.3 [M+H] + ,ESI.
[0269] Compound 2-10:
[0270] Compound 2-9 (2.3 g, 6.8 mmol), piperidine (5 mL) and MeOH (anhydrous, 45 mL) were mixed in a flask and stirred at 30 ° C for 3 h. LC-MS showed complete conversion. The reaction mixture was concentrated and purified by flash silica gel column chromatography (DCM: MeOH = 95: 5) to give a yellow solid 2-10 (0.5 g, 33% yield).
[0271] C 29 H 33 Calculated mass value of NO4: 459.2; Measured value: 460.2 [M+H] + ,ESI.
[0272] Compound 2-11:
[0273] Compound 1-7 (325mg, 0.58mmol), HOBT (105mg, 0.77mmol) and EDCI (150mg, 0.78mmol) are dissolved in DCM (6mL) and stirred at room temperature for 15min, then cooled to 0°C. DIPEA (211mg, 1.6mmol) is added, followed by compound 2-9 (300mg, 0.65mmol), and stirred at room temperature for 4h. LC-MS shows complete conversion. NaHCO3 (saturated, 10mL) is added. The reaction mixture is extracted with DCM (5mLx3). The organic phase is concentrated and purified by silica gel flash column chromatography (DCM: MeOH = 95: 5) to give a crude compound 2-11 (350mg, 88% purity at 210nm, 46% yield) as a white solid. Purification by preparative HPLC: Crude compound 2-7 (1.8 g, 88% purity at 210 nm) was purified by preparative HPLC (C-18 column, water / ACN, 10%-80% ACN) to give compound 2-11 (650 mg, 42% recovery). 54 H 71 N3O 15 Calculated value of mass: 1001.5; Measured value: 1024.5 [M+Na] + ,ESI.
[0274] 1 H NMR (400MHz, DMSO) δ7.82 (d, J = 9.2Hz, 1H), 7.75-7.69 (br, 1H), 7.40-7.35 (m, 2H), 7.37-7.21 (m, 7H), 6 .95-6.88(m,4H),5.21(d,J=3.3Hz,1H),5.00-4.90(m,1H),4.66-4.63(m,1H),4.48(d,J=8.4Hz,1H),4 .08-4.00(br,4H),3.91-3.83(m,1H),3.73(s,6H),3.72-3.66(m,3H),3.51(s,1H),3.43-3.37(m,3H), 3.03-2.96(m,2H),2.91(s,2H),2.10(s,3H),2.00-1.76(m,17H),1.49-1.30(m,8H),1.23-1.19(m,2H).
[0275]
[0276] Compound 2-12:
[0277] 4,5-dicyanoimidazole (32.0 mg, 0.27 mmol) and 2-cyanoethyl N, N, N', N'-tetraisopropylphosphoramidite (108 mg, 0.36 mmol) were added to a solution of compound 2-11 (300.0 mg, 0.30 mmol) in anhydrous DCM (3.0 mL) at room temperature, and stirred for 1 h. LCMS showed that the starting material was completely consumed. The solution was quenched with water (100 mL), washed with brine (300 mLx3) and dried over Na2SO4. The solution was then concentrated under reduced pressure, and the residue was purified by rapid preparative HPLC under the following conditions (column: C18 silica gel; mobile phase: CH3CN / H2O=1 / 1 increased to CH3CN / H2O=1 / 0 in 20 min; detector: UV 254 nm). This resulted in compound 2-12 (177 mg, 49% yield) as a white solid.
[0278] C 63 H 88 N5O 16 Calculated mass of P: 1201.60; Found: 1202.6 [M+H] + ,ESI.
[0279] 1 HNMR(600MHz,CD3CN)δ7.37-7.34(m,2H),7.24-7.20(m,6H),7.14-7.12(m,1H),6.79 -6.77(m,4H),6.57-6.54(m,1H),6.44-6.43(m,1H),5.20(d,J=6.0Hz,1H),4.93-4.9 1(m,1H),4.44(d,J=6.0Hz,1H),4.04-3.83(m,5H),3.73-3.39(m,16H),3.04-2.91(m ,4H),2.52-2.50(m,2H),2.03-1.75(m,24H),1.53-1.33(m,9H),1.21-1.04(m,15H).
[0280] 31 PNMR(242MHz,CD3CN)δ147.37,147.30.
[0281] Compound 2-13:
[0282] To the solution of compound 2-11 (80mg, 0.080mmol) in anhydrous DCM (1.0mL), DMAP (5mg, 0.04mmol) and TEA (24mg, 0.24mmol) were added, followed by succinic anhydride (20mg, 0.2mmol). The reaction mixture was stirred at room temperature for 3h, and LCMS showed that the starting material was completely consumed. The reaction mixture was diluted with DCM (10mL), and washed with H o (3mLx4), then washed with saline (3mLx4), and the organic layer was concentrated to give compound 2-13 (85mg, 97% yield) as a white solid.
[0283] C 58 H 75 N3O 18 Calculated value of mass: 1101.50; Found: 1100.4[MH] - ,ESI.
[0284] 1 HNMR(600MHz,DMSO-d6)δ12.22(s,1H),7.84-7.81(m,1H),7.71-7.69(m,1H),7.37-7.1 6(m,9H),6.92-6.89(m,4H),5.21(d,J=6.0Hz,1H),4.97-4.95(m,1H),4.48(d,J=12.0H z,1H),4.07-4.01(m,6H),3.89-3.84(m,1H),3.73-3.65(m,9H),3.49(s,1H),3.41-3.3 8(m,1H),3.01-2.95(m,4H),2.45-2.44(m,4H),2.09-1.76(m,20H),1.48-1.19(m,10H).
[0285] Solid support 2-14:
[0286] Natural amino-LCAA-CPG (loading value: 75umol / g, ) was washed with ACN (100 mLx2), DMF (100 mLx2) and DCM (100 mLx2), then dried under high vacuum overnight.
[0287] To the solution of succinate 2-13 (85mg, 0.077mmol) and HBTU (53mg, 0.14mmol) in anhydrous DMF (1.5mL), add DIPEA (30mg, 0.23mmol), by reaction mixture vibrated at room temperature 10min, then add natural amino-LCAA-CPG (250mg, load 75umol / g).Suspension is vibrated at room temperature 20h, then filtered, washed with DMF (20mLx5), ACN (20mLx5), DCM (20mLx5) until TLC shows that eluent is spotless at 254nm.Solid support is dried under vacuum for 2h, to provide solid support (260mg). The unreacted amine on the solid support was capped by stirring with Ac2O / pyridine / N-methylimidazole (90μL / 1.0mL / 80μL) at room temperature for 1h, and washed with DMF (20mLx5), CAN (20mLx5), and DCM (20mLx5) until TLC showed that the eluent had no spots at 254nm. The solid support was dried under vacuum for 15h to give solid support 2-14 (260mg). For load calculation, 6.5mg of dry loaded CPG was taken and 3% DCA in 25mL DCM was added. The solution was shaken and the UV absorbance at 500nm was measured. Make sure that the absorbance value is less than 1.0 unit to ensure that there is no signal saturation. Then apply the following equation: Load (μmol / g) = (total amount of DCA added (mL)) * (absorbance value at 500nm) * 1000) / (76 * (mg of CPG taken))
[0288] Total amount of DCA added (mL) = 25 mL
[0289] Absorbance at 500nm = 0.7721
[0290] mg of CPG taken = 6.5 mg
[0291] Loading (μmol / g) = ((25)*(0.7721)*1000) / (76*(6.5)) = 39 μmol / g.
[0292] Method 2:
[0293]
[0294] Compound 2-2:
[0295] Compound 2-1 (11 g, 26.0 mmol) was dissolved in THF (anhydrous, 100 mL) in a 250 mL flask. LiAlH4 (1.97 g, 52 mmol) was added in batches at 0 ° C over 15 min. The reaction was then stirred at room temperature for 4 h. LC-MS showed complete conversion. The reaction was cooled to 0 ° C, and water (2 mL) was slowly added, followed by NaOH (10%, 2 mL), and then water (6 mL). The mixture was filtered, and the filtrate was concentrated to dryness to give compound 2-2 (6.5 g, 80% yield) as a white solid. The crude product was used without further purification.
[0296] C 15 H 21 NO4S: 311.1; Measured value: 312.1 [M+H] + ,ESI.
[0297] 1 H NMR (400MHz, DMSO) δ7.67 (d, J = 8.0 Hz, 2H), 7.48 (d, J = 8.0 Hz, 2H), 4.46 (t, J = 5.4 Hz, 2H), 3.60 (s, 4H), 3.31 (d, J = 5.6 Hz, 4H), 2.43 (s, 3H), 1.67 (s, 4H).
[0298] Compound 2-3:
[0299] Compound 2-2 (5 g, 16.1 mmol) and Mg (powder, 3.47 g, 144.6 mmol) were mixed in MeOH (anhydrous, 60 mL) and stirred at room temperature overnight. LC-MS showed complete conversion, and water (30 mL) was added. A white precipitate was formed. The mixture was filtered, and the filtrate was adjusted to pH 6 with HCl (aqueous 4 M) and concentrated to dryness to give compound 2-3 (2.55 g crude product) as a yellow solid. The crude product was used without further purification.
[0300] 8H 15 Calculated value of NO2 mass: 157.1; Measured value: 158.1 [M+H] + ,ESI.
[0301] Compound 2-4:
[0302] Compound 2-3 (2.55 g, assuming 16.2 mmol) was dissolved in dioxane (20 mL), and FmocCl (4.60 g, 17.8 mmol) was slowly added at 0 ° C., followed by Na2CO3 (saturated, 20 mL). The reaction was stirred at 30 ° C. for 3 h. LC-MS showed complete conversion. The reaction mixture was extracted with EA (20 mLx3). The organic phase was concentrated and purified by flash silica gel column chromatography (DCM: MeOH = 97: 3) to give a white solid 2-4 (2.75 g, 2 step yield 44.7%).
[0303] C 23 H 25 Calculated mass value of NO4: 379.2; Measured value: 380.2 [M+H] + ,ESI.
[0304] Compound 2-5:
[0305] Compound 2-4 (2.7 g, 7.1 mmol) and pyridine (20 mL) were mixed in a flask, and DMTr-Cl (2.4 g, 7.1 mmol) was added in batches. The reaction was stirred at room temperature for 4 h. LC-MS showed complete conversion. The reaction mixture was extracted with EA (20 mLx3). The organic phase was concentrated and purified by flash silica gel column chromatography (DCM: MeOH = 97: 3) to give a yellow solid 2-5 (2.8 g, 58% yield).
[0306] C 44 H 43 Calculated mass of NO6: 681.3; Measured value: 682.3 [M+H] + ,ESI.
[0307] Compound 2-6:
[0308] Compound 2-5 (2.3 g, 6.8 mmol), piperidine (5 mL) and MeOH (anhydrous, 45 mL) were mixed in a flask and stirred at 30 ° C for 3 h. LC-MS showed complete conversion. The reaction mixture was concentrated and purified by flash silica gel column chromatography (DCM: MeOH = 95: 5) to give a yellow solid 2-6 (0.5 g, 33% yield).
[0309] C 29 H 33 Calculated mass value of NO4: 459.2; Measured value: 460.2 [M+H] + ,ESI.
[0310] Compound 2-7:
[0311] Compound 1-7 (325mg, 0.58mmol), HOBT (105mg, 0.77mmol) and EDCI (150mg, 0.78mmol) are dissolved in DCM (6mL) and stirred at room temperature for 15min, then cooled to 0°C. DIPEA (211mg, 1.6mmol) is added, followed by compound 2-6 (300mg, 0.65mmol), and stirred at room temperature for 4h. LC-MS shows complete conversion. NaHCO3 (saturated, 10mL) is added. The reaction mixture is extracted with DCM (5mLx3). The organic phase is concentrated and purified by silica gel flash column chromatography (DCM: MeOH = 95: 5) to give a crude compound 2-7 (350mg, 88% purity at 210nm, 46% yield) as a white solid. Purification by preparative HPLC: Crude compound 2-7 (1.8 g, 88% purity at 210 nm) was purified by preparative HPLC (C-18 column, water / ACN, 10%-80% ACN) to give compound 2-7 (650 mg, 96% purity at 210 nm, 42% recovery). 54 H 71 N3O 15 Calculated value of mass: 1001.5; Measured value: 1024.5 [M+Na] + ,ESI.
[0312] 1 H NMR (400MHz, DMSO) δ7.82 (d, J = 9.2Hz, 1H), 7.75-7.69 (br, 1H), 7.40-7.35 (m, 2H), 7.37-7.21 (m, 7H), 6 .95-6.88(m,4H),5.21(d,J=3.3Hz,1H),5.00-4.90(m,1H),4.66-4.63(m,1H),4.48(d,J=8.4Hz,1H),4 .08-4.00(br,4H),3.91-3.83(m,1H),3.73(s,6H),3.72-3.66(m,3H),3.51(s,1H),3.43-3.37(m,3H), 3.03-2.96(m,2H),2.91(s,2H),2.10(s,3H),2.00-1.76(m,17H),1.49-1.30(m,8H),1.23-1.19(m,2H).
[0313] Compound 2-8:
[0314] At room temperature, DCI (32.0 mg, 0.27 mmol) and CEP [N (iPr) 2] 2 (108 mg, 0.36 mmol) were added to a solution of compound 2-7 (300.0 mg, 0.30 mmol) in anhydrous DCM (3.0 mL) and stirred for 1 h, LCMS showed that the starting material was completely consumed. The solution was quenched with water (100 mL), washed with brine (300 mL x 3) and dried over Na2SO4. The solution was then concentrated under reduced pressure, and the residue was purified by MPLC under the following conditions (column: C18 silica gel; mobile phase: CH3CN / H2O=1 / 1 increased to CH3CN / H2O=1 / 0 in 20 min, eluted product was collected at CH3CN / H2O=3 / 2; detector: UV 254 nm). This resulted in compound 2-8 (177 mg, 0.15 mmol, 97.0% purity, 49% yield) as a white solid.
[0315] C 63 H 88 N5O 16 Calculated mass of P: 1201.60; Found: 1202.6 [M+H] + ,ESI.
[0316] 1 H-NMR (600MHz, CD3CN): δ=7.37-7.34(m,2H),7.24-7.20(m,6H),7.14-7.12(m,1H),6.79 -6.77(m,4H),6.57-6.54(m,1H),6.44-6.43(m,1H),5.20-5.19(d,J=6.0Hz,1H),4.93-4 .91(m,1H),4.44-4.43(d,J=6.0Hz,1H),4.04-3.83(m,5H),3.73-3.39(m,16H),3.04-2. 91(m,4H),2.52-2.50(m,2H),2.03-1.75(m,24H),1.53-1.33(m,9H),1.21-1.04(m,15H);
[0317] 31 PNMR(242MHz,CD3CN)δ147.37,147.29.
[0318] Compound 2-9:
[0319] DMAP (5mg, 0.04mmol) and TEA (24mg, 0.24mmol) were added to a solution of compound 2-7 (80mg, 0.080mmol) in anhydrous DCM (1.0mL), followed by succinic anhydride (20mg, 0.2mmol). The reaction mixture was stirred at room temperature for 3h, and LCMS showed that the starting material was completely consumed. The reaction mixture was diluted with DCM (10mL) and washed with H2O (3mLx4), then washed with brine (3mLx4), and the organic layer was concentrated to give compound 2-9 (85mg, 0.077mmol, 97% purity, 97% yield) as a white solid. 58 H 75 N3O 18 Calculated value of mass: 1101.50; Found: 1100.4[MH] - ,ESI.
[0320] 1 H-NMR (600MHz, DMSO-d6): δ = 12.22 (s, 1H), 7.84-7.81 (m, 1H), 7.71-7.69 (m, 1H), 7.37-7.1 6(m,9H),6.92-6.89(m,4H),5.21-5.20(d,J=6.0Hz,1H),4.97-4.95(m,1H),4.49-4.47(d,J =12.0Hz,1H),4.07-4.01(m,6H),3.89-3.84(m,1H),3.73-3.65(m,9H),3.49(s,1H),3.41- 3.38(m,1H),3.01-2.95(m,4H),2.45-2.44(m,4H),2.09-1.76(m,20H),1.48-1.19(m,10H).
[0321] Solid support 2-10:
[0322] Natural amino-LCAA-CPG (loading value: 75umol / g, ) was washed with ACN (100 mLx2), DMF (100 mLx2) and DCM (100 mLx2), then dried under high vacuum overnight.
[0323] To the solution of succinate 2-9 (85mg, 0.077mmol) and HBTU (53mg, 0.14mmol) in anhydrous DMF (1.5mL), add DIPEA (30mg, 0.23mmol), by reaction mixture vibrated at room temperature 10min, then add natural amino-LCAA-CPG (250mg, load 75umol / g).Suspension is vibrated at room temperature 20h, then filtered, washed with DMF (20mLx5), ACN (20mLx5), DCM (20mLx5) until TLC shows that eluent is spotless at 254nm.Solid support is dried under vacuum for 2h, to provide solid support (260mg). The unreacted amine on the solid support was capped by stirring with Ac2O / pyridine / N-methylimidazole (90μL / 1.0mL / 80μL) at room temperature for 1h, and washed with DMF (20mLx5), CAN (20mLx5), and DCM (20mLx5) until TLC showed that the eluent had no spots at 254nm. The solid support was dried under vacuum for 15h to give solid support 2-10 (260mg). For load calculation, 6.5mg of dry loaded CPG was taken and 3% DCA in 25mL DCM was added. The solution was shaken and the UV absorbance at 500nm was measured. Make sure that the absorbance value is less than 1.0 units to ensure that there is no signal saturation. Then apply the following equation: Load (μmol / g) = (total amount of DCA added (mL)) * (absorbance value at 500nm) * 1000) / (76 * (mg of CPG taken))
[0324] Total amount of DCA added (mL) = 25 mL
[0325] Absorbance at 500nm = 0.7721
[0326] mg of CPG taken = 6.5 mg
[0327] Loading (μmol / g) = ((25)*(0.7721)*1000) / (76*(6.5)) = 39 μmol / g.
[0328] Example 3
[0329]
[0330] Compound 3-2:
[0331] To compound 3-1 (40g, 211.36mmol) in NH3 / MeOH (7M, 192mL) solution was added 2-cyanoacetic acid ethyl ester (47.82g, 422.71mmol), and the mixture was stirred overnight. LC-MS showed complete conversion, and the reaction was filtered. The filter cake was ground and filtered in PE (100mL). The filter cake was dried to obtain compound 3-2 (41g, 44% yield) as a solid.
[0332] C 18 H 18 Calculated value of N4O2 mass: 322.1; Found: 323.1 [M+H] + ,ESI.
[0333] Compound 3-3:
[0334] Compound 3-2 (80 g, 248.17 mmol) was dissolved in sulfuric acid solution (concentrated H2SO4 / water=1:1, v / v, 160 mL) and stirred at 120 ° C for 5 h. LC-MS showed complete conversion, and the reaction mixture was adjusted to pH 9-10 by adding NaOH (30% aqueous) and readjusted to pH 4-5 by adding 1M HCl solution. The reaction was then filtered, and the filtrate was concentrated to dryness to obtain crude compound 3-3 (72 g, 95% yield). The crude product was used directly without further purification.
[0335] C 16 H 21 Calculated mass of NO4: 291.2; Measured value: 292.3 [M+H] + ,ESI.
[0336] Compound 3-4:
[0337] Compound 3-3 (72.3 g, crude) in MeOH (1600 mL) and H2SO4 (160 mL, concentrated H2SO4 / water = 1: 1, v / v) was stirred at 85 ° C for 4 h. LC-MS showed complete conversion. The reaction mixture was filtered and concentrated to dryness and purified by silica gel column (0%-25% EA in PE) to obtain compound 3-4 (62.5 g, 78% yield over 2 steps).
[0338] C 18 H 25 Calculated value of NO4 mass: 319.2; Measured value: 320.3 [M+H] + ,ESI.
[0339] Compound 3-5:
[0340] At 0 ° C, LiAlH4 (14.3 g, 375.1 mmol) was added in batches to a solution of compound 3-4 (40 g, 125.2 mmol) in THF (295 mL) and stirred for 1 h. LC-MS showed complete conversion, and ethyl acetate (100 mL) was added to the reaction mixture, and adjusted to pH 9-10 by adding 10% NaOH (aqueous). The mixture was then filtered and washed with ethyl acetate (50 mL × 2). The combined filtrate was concentrated to dryness to obtain crude compound 3-5 (23 g, 83% yield). The crude product was used in the next step without further purification.
[0341] Calculated mass of C16H25NO2: 263.2; Found: 264.3 [M+H] + ,ESI.
[0342] Compound 3-6:
[0343] Compound 3-5 (20 g, 75.94 mmol), Boc2O (16.57 g, 75.94 mmol) and Pd / C (10% Pd on carbon, wet, about 55% water) in MeOH (150 mL) were stirred overnight at room temperature under 1 atm H2. LC-MS showed complete conversion, and the reaction mixture was filtered and concentrated to give compound 3-6 (20 g, 96% yield) as an oil, which was used without further purification.
[0344] C 14 H 27 Calculated mass of NO4: 273.2; Measured value: 274.1 [M+H] + ,ESI.
[0345] Compound 3-7:
[0346] MsCl (72.91 g, 636.51 mmol) was added to a solution of compound 3-6 (58 g, 212.17 mmol) in triethylamine (85.88 g, 848.67 mmol, 118.37 mL) and DCM (1.16 L). The reaction was stirred at room temperature overnight. LC-MS showed complete conversion (quenched by EtOH and detected by diether). The reaction mixture was diluted with DCM (1 L) and washed with 10% citric acid, then NaHCO (saturated aqueous), and dried to obtain compound 3-7 (87 g, 95% yield) in an oily state, which was used directly in the next step without further purification.
[0347] C 16 H 31 Calculated mass of NO8S2: 429.2; Found: 430.3 [M+H]+ ,ESI.
[0348] Compound 3-8:
[0349] Under nitrogen, NaH (60%, 3.72 g, 93.12 mmol in mineral oil) is suspended in anhydrous DMF (60 mL), diisopropyl malonate (8.76 g, 46.56 mmol) is added. The reaction mixture is stirred at room temperature for 30 min to form a clear solution. KI (1.55 g, 9.31 mmol) is added, followed by compound 3-7 (20 g, 46.56 mmol). The reaction mixture is stirred at 70 ° C for 30 min and stirred for another 30 min at 140 ° C. LC-MS shows complete conversion. The reaction is cooled to room temperature, diluted with ethyl acetate (300 mL), and washed with citric acid (10% aqueous, 200 mL x 2) and NaHCO (saturated aqueous, 200 mL). The organic phase is concentrated and purified by silica gel column (0%-10% EA in PE) to obtain compound 3-8 (3.55 g, 18% yield) as a colorless oil.
[0350] C 23 H 39 Calculated mass of NO6: 425.3; Found: 426.2 [M+H] + ,ESI.
[0351] 1 H NMR (400MHz, DMSO-d6) δ4.96-4.90 (m, 2H), 3.27 (br, 4H), 1.86 (t, J = 10.8Hz, 4H), 1.38 (br, 13H), 1.28 (s, 4H), 1.17-1.16 (m, 12H).
[0352] Compound 3-9:
[0353] LiBH4 (172 mL, 1 M in THF) was added to compound 3-8 (7.5 g, 17.62 mmol) at 0 ° C, and the mixture was stirred overnight. LC-MS showed complete conversion. Ethyl acetate (10 mL) was added to the reaction mixture, followed by NaOH (10% aqueous, 20 mL) and filtered. The filtrate was diluted with water (200 mL) and extracted with ethyl acetate (50 mL X3), and concentrated to give compound 3-9 (6.35 g, 98% yield) as a colorless oil, which was used directly in the next step without further purification.
[0354] C 17 H 31 Calculated mass of NO4: 313.2; Measured value: 314.2 [M+H]+ ,ESI.
[0355] Compound 3-10:
[0356] Compound 3-9 (6.35 g, 20.26 mmol) was mixed with HCl (63.5 mL, 4 M in dioxane), and the mixture was stirred at room temperature for 3 h. LC-MS showed complete conversion. The reaction mixture was concentrated to dryness and azeotropically dried with toluene to give compound 3-10 (7 g, 99% yield), which was used directly in the next step without further purification.
[0357] C 12 H 23 Calculated value of mass of NO2 (free base): 213.2; Found: 214.2 [M+H] + ,ESI.
[0358] 1 H NMR (400MHz, D2O) δ3.39 (br, 4H), 3.18 (t, J = 11.6Hz, 4H), 1.59 (t, J = 12.0Hz, 4H), 1.36-1.33 (m, 4H), 1.25 (t, J = 12.4Hz, 4H).
[0359] Compound 3-11:
[0360] A solution of compound 3-10 (5 g, 20.02 mmol), DIEA (6.47 g, 50.04 mmol, 8.72 mL), HOBT (3.25 g, 24.02 mmol), EDCI (4.60 g, 24.02 mmol) in DCM (150 mL) was stirred at 0° C. for 30 min, then Fmoc-6-aminohexanoic acid (5.66 g, 16.01 mmol) was added, and the mixture was stirred at room temperature for 1 h. LC-MS showed complete conversion. The reaction mixture was diluted with additional DCM (100 mL), washed with citric acid (10% aqueous, 200 mL), NaHCO3 (saturated aqueous, 200 mL), and water (200 mL), dried over Na2SO4, and concentrated to give the crude product, which was purified by silica gel column (0%-10% EA in PE) to give compound 3-11 (3.65 g, LC-MS purity 92%, 33% yield) as a gum.
[0361] C 33 H 44 Calculated value of N2O5 mass: 548.3; Found: 549.3 [M+H] + ,ESI.
[0362] 1H NMR (400MHz, DMSO-d6) δ7.88(d,J=7.5Hz,2H),7.84(d,J=7.5Hz,2H),7.41(t,J=7.3Hz,2H),7.34(t,J=7.3Hz,2H),6.65(t,J=5.3Hz,1H), 6.28(s,2H),4.36-4.18(m,3H),3.36(dt,J=19.9,5.2Hz,4H),3.24(s,4H),2.92-2.87(m,2H),2.24(t,J=7.4Hz,2H),1.49-1.26(m,18H).
[0363] Compound 3-12:
[0364] A solution of compound 3-11 (2.55 g, 4.65 mmol), 4,4'-(chloro(phenyl)methylene)bis(methoxybenzene) (1.57 g, 4.65 mmol), DIEA (600.6 mg, 4.65 mmol), DMAP (56.8 mg, 0.47 mmol) in DCM (51 mL) was stirred overnight at room temperature. LC-MS showed partial conversion. The reaction mixture was then concentrated and purified by a silica gel column (10%-40% EA in PE to elute impurities, then 5%-10% MeOH in DCM (containing 0.1% NH3·H2O)) to give compound 3-12 (2.75 g, 69% yield).
[0365] 1 H NMR(400MHz,DMSO-d6)δ7.88-7.87(m,2H),7.69-7.68(m,2H),7.41-7.37(m ,4H),7.33-7.25(m,9H),6.89-6.80(m,5H),4.41(t,J=5.0Hz,1H),4.28(d,J =6.8Hz,2H),4.20(t,J=6.8Hz,1H),3.72(s,8H),3.40-3.39(m,2H),3.32-3. 27(m,4H),2.96(q,J=6.3Hz,2H),2.22(t,J=7.9Hz,2H),1.48-0.86(m,18H).
[0366] Compound 3-13:
[0367] To a solution of compound 3-12 (1.7 g, 2.00 mmol) in MeOH (51 mL) was added piperidine (5.1 mL), and the mixture was stirred at room temperature for 3 h. LC-MS showed complete conversion. The reaction mixture was concentrated and azeotropically dried with xylene. The residue was purified by silica gel column (0%-10% MeOH in DCM, containing 0.1% NH3·H2O) to give compound 3-13 (1.1 g, 87% yield) as a jelly.
[0368] C 39 H 52 Calculated value of N2O5 mass: 628.4; Found: 629.4 [M+H] + ,ESI.
[0369] Compound 3-14:
[0370] A solution of compound 3-13 (0.94 g, 1.49 mmol), DIEA (482.98 mg, 3.74 mmol), HOBT (242.38 mg, 1.79 mmol), EDCI (343.87 mg, 1.79 mmol) in DCM (29 mL) was stirred at 0 ° C, then compound 1-4 (936.36 mg, 2.09 mmol) was added, and the mixture was stirred at room temperature for 1 h. LC-MS showed complete conversion. The reaction mixture was diluted with additional DCM (20 mL), washed with NaHCO (saturated aqueous, 50 mL) and water (50 mL), concentrated and purified by preparative HPLC (C18 column, ACN / water) to obtain compound 3-14 (700 mg, 44% yield).
[0371] C 58 H 79 N3O 15 Calculated value of mass: 1057.6; Found: 1080.5 [M+Na] + ,ESI.
[0372] 1H NMR(400MHz, DMSO-d6)δ7.82(d,J=9.2Hz,1H),7.69(t,J=5.5Hz,1H),7.40-7.38(m,2H),7.32-7.19(m,7H),6.89-6.87(m, 4H),5.21(d,J=3.3Hz,1H),4.97(dd,J=11.2,3.4Hz,1H),4.48(d,J=8.5Hz,1H),4.40(t,J=5.0Hz,1H),4.02(s,3H),3.91- 3.83(m,1H),3.73-3.68(m,7H),3.43-3.39(m,3H),3.32-3.27(m,2H),2.99(q,J=6.6Hz,2H),2.87(s,2H),2.22(t,J=7.3H z,2H),2.10(s,3H),2.03(t,J=7.0Hz,2H),1.99(s,3H),1.89(s,3H),1.77(s,3H),1.53-1.03(m,20H),0.90-0.83(m,2H).
[0373] Compound 3-15:
[0374] To a solution of compound 3-14 (670.0 mg, 0.61 mmol) in anhydrous DCM (3.0 mL) was added 4,5-dicyanoimidazole (96.0 mg, 0.81 mmol) and 2-cyanoethyl N, N, N', N'-tetraisopropylphosphoramidite (324 mg, 1.08 mmol) at room temperature, and stirred for 1 h. LCMS showed that the starting material was completely consumed. The solution was quenched with water (100 mL), washed with brine (300 mLx3) and dried over Na2SO4. The solution was then concentrated under reduced pressure, and the residue was purified by rapid preparative HPLC under the following conditions (column: C18 silica gel; mobile phase: CH3CN / H2O=1 / 1 increased to CH3CN / H2O=1 / 0 in 20 min; detector: UV 254 nm). This resulted in compound 3-15 (600 mg, 83% yield) as a white solid.
[0375] C 67 H 96 N5O 16 Calculated mass of P: 1257.66; Found: 1204.5 [M-CH2CH2CN] - ,ESI.
[0376] 1HNMR (600MHz, DMSO-d6) δ7.81-7.67(m,2H),7.40-7.19(m,9H),6.88-6.86(m,4H),5.21(d,J=6.0Hz,1H),4.98-4.94(m,1H),4.49(d,J=6.0Hz, 1H),4.04-3.83(m,4H),3.73-3.32(m,15H),3.01-2.89(m,4H),2.73-2 .70(m,2H),2.24-2.20(m,2H),2.11-1.76(m,15H),1.49-0.91(m,34H).
[0377] 31 PNMR(242MHz,DMSO-d6)δ146.21,146.19.
[0378] Example 4
[0379]
[0380] Compound 4-2:
[0381] Potassium carbonate (8.10 g, 58.61 mmol) was added to a solution of MeOH (80 mL), H2O (60 mL), formaldehyde (3.52 g, 117.22 mmol) and compound 4-1 (25 g, 117.22 mmol) at 0°C. The reaction mixture was stirred overnight at 0°C. The reaction mixture was concentrated to 70% of its volume, and the residue was extracted three times with ethyl acetate. The organic phase was washed with water, brine, dried over anhydrous sodium sulfate, and then concentrated to give a crude product 4-2 (27 g, 95% yield), which was used in the next step without further purification.
[0382] C 12 H 21 Calculated mass of NO4: 243.2; Measured value: 244.1 [M+H] + ,ESI.
[0383] Compound 4-3:
[0384] At 0°C, sodium borohydride (11.97 g, 316.48 mmol) was added to a solution of compound 4-2 (35 g, 143.86 mmol) in methanol (28 ml) in about five minutes. The reaction mixture was stirred at 0°C, then warmed to room temperature and stirred for 5 h. The reaction was quenched with saturated ammonium chloride solution, then concentrated, extracted three times with ethyl acetate (EA) and washed with brine, then recrystallized with EA: PE = 1: 3 to give compound 4-3 (19.6 g, 54% yield).
[0385] C 12 H 23 Calculated mass of NO4: 245.2; Measured value: 146.1 [M+H-Boc] + ,ESI.
[0386] Compound 4-4:
[0387] Compound 4-3 (30 g, 122.29 mmol), triethylamine (30.94 g, 305.73 mmol, 42.64 mL) and DCM (300 mL) were mixed, and the mixture was then cooled to -30 ° C, and then MsCl (35.02 g, 305.73 mmol) was slowly added. After stirring at room temperature for 1.5 h, the reaction mixture was extracted with 400 mL of water, washed with 100 mL of 10% citric acid aqueous solution, and dried over anhydrous sodium sulfate. After concentration, the residue was purified by silica gel column to obtain compound 4-4 (40 g, 81% yield) as a light yellow oily liquid.
[0388] C 14 H 27 Calculated mass of NO8S2: 401.1; Found: 302.1 [M+H-Boc] + ,ESI.
[0389] Compound 4-5:
[0390] Under nitrogen, diisopropyl malonate (14.06 g, 74.72 mmol) was slowly added to a mixture of t-BuONa (9.57 g, 99.63 mmol) in DMA (50 mL). After stirring for 20 min, compound 4-4 (20 g, 49.81 mmol) and KI (4.13 g, 24.91 mmol) were added. The reaction mixture was heated to 140 ° C and stirred overnight. The reaction was quenched by adding saturated ammonium chloride and extracted with ethyl acetate. After concentration, the residue was purified by silica gel column (PE: EA) to obtain compound 4-5 (6 g, 30% yield).
[0391] C 21 H 35 Calculated mass of NO6: 397.3; Found: 398.2 [M+H] + ,ESI.
[0392] 1 H NMR (400MHz, DMSO) δ 4.98-4.90 (m, 2H), 3.22-3.20 (m, 4H), 2.25 (s, 4H), 1.42 (t, J = 5.6Hz, 4H), 1.38 (s, 9H), 1.17 (d, J = 6.0Hz, 12H).
[0393] Compounds 4-6:
[0394] At 0 ° C, lithium borohydride (10.69 g, 490.56 mmol) was added to a solution of compound 4-5 (9.75 g, 24.53 mmol) in anhydrous THF (200 mL). The reaction mixture was slowly heated to room temperature and stirred overnight. Ethyl acetate (200 mL) was then added to the reaction mixture and extracted with water (150 mL x3), then washed with saturated sodium chloride, dried over anhydrous sodium sulfate, concentrated to obtain a crude product 4-6 (6.52 g, 93% yield), which was used in the next step without further purification.
[0395] C 15 H 27 Calculated mass of NO4: 285.2; Measured value: 186.2 [M+H-Boc] + ,ESI.
[0396] Compound 4-7:
[0397] To a solution of product 4-6 (7.52 g, 26.35 mmol) in DCM (100 mL) was added HCl (4 M in 1,4-dioxane, 21.52 mL) at 0 °C over 15 min. The reaction mixture was warmed to room temperature and stirred for 3 h. The reaction mixture was filtered and the filter cake was washed with dichloromethane (x3) to give the crude product 4-7 (3.7 g, 76% yield).
[0398] C 10 H 19 Calculated mass of NO2 (free base): 185.1 m / z; Found: 186.2 [M+H] + ,ESI.
[0399] Compound 4-8:
[0400] A mixture of Fmoc-6-aminocaproic acid (1.91 g, 5.41 mmol), 1-hydroxybenzotriazole (HOBT, 609.41 mg, 4.51 mmol), EDCI (864.59 mg, 4.51 mmol), DIEA (582.89 mg, 4.51 mmol, 785.56 μL) in DCM (10 mL) was stirred at room temperature for 30 min, then added to a solution of compound 4-7 (1 g, 4.51 mmol) in DCM, and the mixture was stirred for 4 hours. The reaction mixture was washed with saturated sodium bicarbonate solution, brine, and dried over anhydrous sodium sulfate. After concentration, the residue was purified by silica gel column to obtain compound 4-8 (1.35 g, 58% yield).
[0401] C 31 H 40 Calculated value of N2O5 mass: 520.3; Found: 521.2 [M+H] + ,ESI.
[0402] 1 H NMR (400MHz, DMSO) δ7.88(d,J=7.5Hz,2H),7.68(d,J=7.4Hz,2H),7.39(d,J=7.5Hz,4H),7.3 4-7.18(m,10H),6.89(d,J=8.8Hz,4H),4.64(t,J=4.7Hz,1H),4.28(d,J=6.8Hz,2H),4.20(t, J=6.8Hz,1H),3.73(s,6H),3.44(d,J=5.0Hz,2H),3.30-3.10(m,4H),3.01(s,2H),3.00-2.90 (m,2H),2.21(t,J=7.2Hz,2H),1.56(d,J=11.9Hz,2H),1.46-1.30(m,8H),1.21-1.00(m,4H).
[0403] Compound 4-9:
[0404] A mixture of DMTr-Cl (488.07 mg, 1.44 mmol) and compound 4-8 (0.75 g, 1.44 mmol) in pyridine (6 ml) was stirred at room temperature overnight. The reaction mixture was concentrated under vacuum. The residue was redissolved in ethyl acetate (containing 1% pyridine) and dried with alumina and purified by alumina column chromatography (0%-10% MeOH, 0.1% TEA in DCM) to obtain compound 4-9 (0.39 g, 32.9% yield).
[0405] 1 H NMR (400MHz, DMSO) δ7.39(d,J=7.3Hz,2H),7.34-7.18(m,7H),6.89(d,J=8.8Hz,4H),4.63(s,1H),3.73(s,6H), 3.43(s,2H),3.30-3.18(m,6H),3.05(s,2H),2.22(t,J=7.4Hz,2H),1.57(d,J=12.1Hz,2H),1.47-1.08(m,12H).
[0406] Compound 4-10:
[0407] Compound 4-9 (1.4 g, 1.70 mmol) was dissolved in MeOH (40 mL), and piperidine (4 ml) was then added. The mixture was stirred at room temperature overnight. The reaction mixture was concentrated under vacuum. The piperidine residue was further removed by azeotropic drying with xylene. The residue was then purified by silica gel column (DCM: MeOH = 10: 1, methanol containing 10% ammonia) to obtain compound 4-10 (1 g, 97% yield).
[0408] C 37 H 48 Calculated value of N2O5 mass: 600.4; Found: 601.4 [M+H] + ,ESI.
[0409] 1 H NMR (400MHz, DMSO-d6) δ7.40-7.39(m,2H),7.33-7.21(m,7H),6.89(d,J=8.8Hz,4H),4.63(s,1H),3.73(s,6H),3.44-3.16 (m,8H),3.01-3.00(m,2H),2.24-2.21(m,2H),1.57(d,J=12.2Hz,2H),1.45-1.33(m,7H),1.27-1.21(m,4H),1.09(s,1H).
[0410] Compound 4-11:
[0411] The mixture of compound 1-4 (959.23 mg, 2.14 mmol), HOBt (289.68 mg, 2.14 mmol), EDCI (410.98 mg, 2.14 mmol), DIEA (395.82 mg, 3.06 mmol, 533.45 μ L) in DCM (10 mL) was stirred for 20 min, then added to a solution of compound 4-10 (920 mg, 1.53 mmol) in DCM (5 mL) and stirred at room temperature overnight. Water was added to quench the reaction, and the organic layer was separated and concentrated. The residue was purified by preparative HPLC to give compound 4-11 (1 g, 63% yield).
[0412] C 56 H 75 N3O 15 Calculated value of mass: 1029.5; Found: 1052.3 [M+Na] + ,ESI.
[0413] 1H NMR(400MHz, DMSO-d6)δ7.82(d,J=9.2Hz,1H),7.79(t,J=5.0Hz,1H),7.40-7.19(m,9H),6.90-6.88(m,2H) ,5.21(d,J=3.2Hz,1H),4.97(dd,J=11.2,3.3Hz,1H),4.62(t,J=4.9Hz,1H),4.48(d,J=8.4Hz,1H),4.02(s ,3H),3.87(dd,J=20.4,9.6Hz,1H),3.97-3.67(m,7H),3.45-3.38(m,3H),3.30-3.13(m,4H),3.05-2.96(m ,4H),2.22(t,J=7.3Hz,2H),2.10(s,3H),2.04-1.99(m,5H),1.89(s,3H),1.77(s,3H),1.59-1.21(m,18H).
[0414]
[0415] Compound 4-12:
[0416] To a solution of compound 4-11 (750.0 mg, 0.75 mmol) in anhydrous DCM (7.0 mL) was added 4,5-dicyanoimidazole (80.0 mg, 0.67 mmol) and 2-cyanoethyl N, N, N', N'-tetraisopropylphosphoramidite (270 mg, 0.90 mmol) at room temperature, and stirred for 1 h, LCMS showed that the starting material was completely consumed. The solution was quenched with water (100 mL), washed with saline (300 mLx3) and dried over Na2SO4. The solution was then concentrated under reduced pressure, and the residue was purified by rapid preparative HPLC, and the conditions were as follows (C18 silica gel column; mobile phase: CH3CN / H2O=1 / 1 increased to CH3CN / H2O=1 / 0 in 20 min; detector: UV 254 nm). This resulted in 4-12 (500 mg, 53% yield) being given as a white solid.
[0417] C 65 H 92 N5O 16 Calculated mass of P: 1229.63; Found: 1129.0 [MN(CH(CH3)2)2] + ,ESI.
[0418] 1HNMR (600MHz, DMSO-d6): δ7.44-7.18(m,9H),6.85-6.83(m,4H),6.52-6.44(m,2H),5.26(d,J=6.0Hz,1H),4.99-4.96(m,1H),4.49(d,J=6.0Hz ,1H),4.13-3.89(m,4H),3.79-3.55(m,13H),3.44-3.48(m,1H),3.35-3 .07(m,8H),2.58-2.56(m,2H),2.24-1.89(m,16H),1.62-1.11(m,31H).
[0419] 31 PNMR(242MHz,DMSO-d6)δ147.17,147.16.
[0420] Compound 4-13:
[0421] To a solution of compound 4-11 (80 mg, 0.080 mmol) in anhydrous DCM (1.0 mL) was added DMAP (5 mg, 0.04 mmol) and TEA (24 mg, 0.24 mmol), followed by succinic anhydride (20 mg, 0.2 mmol), the reaction mixture was stirred at room temperature for 3 h, LCMS showed that the starting material was completely consumed, then the reaction mixture was diluted with DCM and washed with water (3 mL x 4), then with brine (3 mL x 4), the organic layer was concentrated to give compound 4-13 (85 mg, 97% yield) as a white solid.
[0422] C 60 H 79 N3O 18 Calculated mass: 1129.54; Found: 1128.6 [MH] - ,ESI.
[0423] 1HNMR(600MHz,DMSO-d6)δ12.22(s,1H),7.84-7.81(m,1H),7.71-7.69(m,1H),7.37-7.16(m,9H),6 .92-6.89(m,4H),5.21(d,J=6.0Hz,1H),4.97-4.95(m,1H),4.48(d,J=12.0Hz,1H),4.12-4.01(m,3 H),3.89-3.84(m,1H),3.73-3.65(m,7H),3.41-3.38(m,2H),3.28-3.15(m,4H),3.15-2.98(m,4H) ,2.46-2.44(m,4H),2.22-2.20(m,2H),2.09-1.76(m,14H),1.65-1.60(m,2H),1.48-1.06(m,19H).
[0424] Compound 4-14:
[0425] To compound 4-13 (85mg, 0.077mmol) and HBTU (53mg, 0.14mmol) in anhydrous DMF (1.5mL) solution, add DIPEA (30mg, 0.23mmol).Reactant mixture is vibrated at room temperature for 10min, then natural amino-lcaa-CPG (250mg, load 75umol / g) is added.Suspension is vibrated at room temperature for 20h, then filtered, washed with DMF (20mLx5), ACN (20mL x5), DCM (20mLx5) until TLC shows that eluent is spotless at 254nm.Solid support is dried under vacuum for 2h, to provide solid support (260mg). The unreacted amine on the support is capped by stirring 1h with Ac2O / pyridine / N-methylimidazole (90 μL / 1.0mL / 80 μL) at room temperature, washed with DMF (20mLx5), ACN (20mLx5) and DCM (20mLx5) until TLC shows that the eluent is spotless at 254nm. The solid support is dried under vacuum for 15h to give solid support 4-14 (260mg). For load calculation, 5.97mg of CPG dried load is taken and 25mL of 3% DCA is added on DCM. The oscillation solution is also measured for UV absorbance at 500nm. Ensure that the absorbance value is less than 1.0 unit to ensure that there is no signal saturation. Then apply the following equation:
[0426] Load (umol / g) = (total amount of DCA added (mL)) * (absorbance at 500nm) * 1000) / 76 * (mg of CPG taken)
[0427] Total amount of DCA added (mL) = 25 mL
[0428] Absorbance at 500nm = 0.6689
[0429] mg of CPG taken = 5.97 mg
[0430] Loading (umol / g) = ((25)*(0.6689)*1000) / 76*(5.97) = 36.85 umol / g.
[0431] Example 5
[0432]
[0433] Compound 5-2:
[0434] Under nitrogen at 0 ° C, compound 5-1 (10 g, 41.78 mmol) was added to a solution of methoxymethyl (triphenyl) phosphine chloride (12.89 g, 37.61 mmol) and KOtBu (4.69 g, 41.79 mmol) in THF (150 mL). The reaction mixture was stirred overnight at 25 ° C. TLC showed complete conversion. The reaction was then adjusted to pH 6 by adding citric acid (10% aqueous) and extracted with ethyl acetate (EA). The organic phase was concentrated and purified by flash column chromatography (0%-10% EA in PE) to obtain compound 5-2 (2.92 g, 37% yield) as an oil.
[0435] C 15 H 25 Calculated value of NO3 mass: 267.2; Measured value: 268.2 [M+H] + ,ESI.
[0436] Compound 5-3:
[0437] 2,2,2-trichloroacetic acid (6.31 g, 38.64 mmol) in water (70 mL) was added to a mixture of compound 5-2 (8.2 g, 30.67 mmol) in MeCN (220 mL), and the mixture was stirred overnight. TLC showed complete conversion. The reaction was then quenched by adjusting pH to 7-8 by NaHCO (aqueous, saturated), and extracted with ethyl acetate. The organic phase was concentrated to obtain compound 5-3 (7.8 g) in an oily state. The crude product was used directly in the next step without purification.
[0438] C 14 H 23 Calculated mass of NO3: 253.2; Measured value: 154.2 [M+H-Boc] + ,ESI.
[0439] Compound 5-4:
[0440] To a mixture of compound 5-3 (1.35 g, 5.33 mmol) and NaOH (21.32 mg, 532.89 μmol, 29.38 μL) in MeOH (30 mL) was added formaldehyde solution (454.47 mg, 15.13 mmol, 37% aqueous, 0.91 g). The reaction mixture was stirred at 25 ° C for 36 h. The reaction mixture was concentrated to remove most of the methanol and extracted with ethyl acetate. The organic phase was concentrated and purified by column (0%-5% MeOH in DCM) to obtain compound 5-4 (1.5 g, 96% yield over 2 steps) as a solid.
[0441] C 15 H 25 Calculated mass of NO4: 283.2; Measured value: 184.2 [M+H-Boc] + ,ESI.
[0442] Compound 5-5:
[0443] Sodium borohydride (866.50 mg, 22.90 mmol) was added to a solution of compound 5-4 (2.95 g, 10.41 mmol) in MeOH (90 mL). The reaction mixture was stirred for 1 h. LC-MS showed complete conversion. The reaction mixture was adjusted to pH 6 with citric acid (10% aqueous), then concentrated to dryness, and the residue was extracted and filtered with DCM. The filtrate was concentrated to obtain compound 5-5 (2.95 g, 73% yield), which was used directly in the next step without purification.
[0444] C 15 H 27 Calculated value of NO4 mass: 285.2; Measured value: 271.2 [M+ACN+H-tBu] + ,ESI.
[0445] Compound 5-6:
[0446] To compound 5-5 (4 g, 14.02 mmol) was added HCl (4 M in dioxane, 63.5 mL). The reaction mixture was stirred for 3 h. LC-MS showed complete conversion. The reaction mixture was concentrated to give compound 5-6 (3.5 g), which was used directly in the next step without purification.
[0447] C 10 H 19 Calculated value of mass of NO2 (free base): 185.1; Found: 186.1 [M+H] + ,ESI.
[0448] Compound 5-7:
[0449] A solution of Fmoc-6-aminocaproic acid (3.19 g, 9.02 mmol), DIEA (2.91 g, 22.55 mmol, 3.93 mL), HOBT (1.46 g, 10.82 mmol), EDCI (2.08 g, 10.82 mmol) in DCM (12 mL) was stirred at 0 ° C for 30 min, and then compound 5-6 (2 g, 9.02 mmol) was added. The reaction mixture was stirred at room temperature overnight. LC-MS showed complete conversion. The reaction mixture was diluted with DCM (12 mL) and washed with citric acid (10% aqueous, 20 mL) and water. The organic phase was concentrated and purified by silica gel column (0%-5% MeOH in DCM) to obtain compound 5-7 (3.5 g, 34% yield).
[0450] C 31 H 40 Calculated value of N2O5 mass: 520.3; Found: 521.2 [M+H] + ,ESI.
[0451] 1 H NMR (400MHz, DMSO-d6) δ7.91-7.68(m,4H),7.44-7.28(m,5H),4.32-4.28(m,4H),4.20(t,J=6.6Hz,1H),3.69(s,2H),3. 43(s,2H),3.22(t,J=5.6Hz,4H),2.02-1.98(m,3H),1.55-1.52(t,J=6.6Hz,4H),2.26-2.23(m,4H),1.24-1.16(m,8H).
[0452] Compound 5-8:
[0453] To compound 5-7 (2.2g, 4.23mmol), DMAP (51.6mg, 0.423mmol) and DIEA (1.09g, 8.46mmol) in DCM (66mL) solution, add DMTrCl (1.43g, 4.23mmol). The reaction mixture was stirred at room temperature overnight. LC-MS showed partial conversion. The reaction mixture was filtered through an alumina pad and washed with DCM (50mL). The filtrate was concentrated and purified by silica gel column (10%-40% EA (containing 0.1% ammonia) in PE, then 0%-10% MeOH (containing 0.1% ammonia) in DCM) to obtain compound 5-8 (3.0g, 86% yield).
[0454] C 52 H 58 Calculated value of N2O7 mass: 822.4; Measured value: 845.3 [M+Na] + ,ESI.
[0455] 1H NMR (400MHz, DMSO-d6) δ7.90-7.67(m,4H),7.42-7.39(m,4H),7.41-7.24(m,14H),6.89-6.87(m,4H),4.44(t,J=7.6Hz,1H),4.24-4.19(m,1H),4. 06-4.01(m,1H),3.74-3.73(m,6H),3.65-3.59(m,2H),3.42-3.39(m,3H) ,3.32(br,1H),3.00-2.83(m,4H),1.99-1.96(m,4H),1.45-1.16(m,16H).
[0456] Compound 5-9:
[0457] To a solution of compound 5-8 (3g, 3.65mmol) in MeOH (90mL), piperidine (9mL) was added. The reaction mixture was stirred at room temperature overnight. LC-MS showed complete conversion. The reaction mixture was concentrated and then further azeotropically distilled with dimethylbenzene. The residue was purified by silica gel column chromatography (0%-10% MeOH in DCM, containing 1% TEA) to obtain compound 5-9 (1.1g, 91% yield).
[0458] C 37 H 48 Calculated value of N2O5 mass: 600.4; Found: 601.3 [M+H] + ,ESI.
[0459] 1 H NMR(400MHz,DMSO-d6)δ7.40-7.21(m,9H),6.89(d,J=7.2Hz,4H),3.74(s,6H),3.67-3.61 (m,2H),3.39-3.33(m,2H),2.86-2.62(m,4H),1.99(t,J=7.4Hz,2H),1.51-1.21(m,16H).
[0460] Compound 5-10:
[0461] A solution of compound 1-4 (2.09 g, 4.66 mmol), DIEA (1.08 g, 8.32 mmol, 1.45 mL), HOBT (539.77 mg, 3.99 mmol) and EDCI (765.80 mg, 3.99 mmol) in DCM (60 mL) was stirred at 0 ° C for 30 min, and then compound 5-9 (2 g, 3.33 mmol) was added. The reaction mixture was stirred overnight. The reaction mixture was concentrated, and the residue was purified by preparative HPLC (C18, water / ACN), to obtain compound 5-10 (1.0 g, 15% yield).
[0462] C 56 H 75 N3O 15 Calculated value of mass: 1029.5; Found: 1052.3 [M+Na] + ,ESI.
[0463] 1 H NMR (400MHz, DMSO-d6) δ7.83 (d, J = 9.2Hz, 1H), 7.71 (t, J = 5.2Hz, 1H), 7.40-7.38 (m, 2H), 7.32-7.19 (m, 5H), 6. 90-9.87(m,2H),5.22(d,J=3.4Hz,1H),4.97(dd,J=11.2,3.4Hz,1H),4.49(d,J=8.5Hz,1H),4.42(t,J=5.0Hz, 1H),4.03(s,2H),3.91-3.84(m,2H),3.74(s,6H),3.67-3.61(m,1H),3.44-3.37(m,4H),3.00(dd,J=12.7,6.6 Hz,2H),2.85(d,J=9.6Hz,2H),2.11(s,3H),2.05-1.96(m,7H),1.90(s,3H),1.78(s,3H),1.52-1.18(m,18H).
[0464] Compound 5-11:
[0465] To a solution of compound 5-10 (690.0 mg, 0.66 mmol) in anhydrous DCM (3.0 mL) was added 4,5-dicyanoimidazole (96.0 mg, 0.81 mmol) and 2-cyanoethyl N, N, N', N'-tetraisopropylphosphoramidite (324 mg, 1.08 mmol) at room temperature and stirred for 1 h, LCMS showed that the starting material was completely consumed. The solution was quenched with water (100 mL), washed with saline (300 mLx3) and dried over Na2SO4. The solution was then concentrated under reduced pressure, and the residue was purified by rapid preparative HPLC under the following conditions (C18 silica gel column; mobile phase: CH3CN / H2O=1 / 1 increased to CH3CN / H2O=1 / 0 in 20 min; detector: UV 254 nm). This resulted in 5-11 (460 mg, 56% yield) as a white solid.
[0466] C 65 H 92 N5O 16 Calculated mass of P: 1229.63; Found: 1230.3 [M+H] + ,ESI.
[0467] 1 HNMR(600MHz,DMSO-d6)δ7.81-7.67(m,2H),7.40-7.19(m,9H),6.88-6.86(m,4H),5.21(d,J=6.0Hz,1H),4.98-4.94(m,1H),4.49(d, J=6.0Hz,1H),4.04-3.83(m,4H),3.73-3.32(m,18H),3.01-2.83(m,4H),2.72-2.69(m,2H),2.10-1.76(m,16H),1.52-1.04(m,30H).
[0468] 31 PNMR(242MHz,DMSO-d6)δ146.33,146.26.
[0469] Example 6
[0470]
[0471] Compound 6-2:
[0472] Compound 6-1 (20g, 99.88mmol) is dissolved in THF (200mL). At 0 ° C, NaH (4.79g, 119.86mmol, 60% purity) is added to the reaction mixture and stirred for 30min. 2,3-dibromopropylene (20.96g, 104.88mmol) is slowly added to the reaction mixture. And the reaction is stirred at room temperature for 2h. The reaction mixture is quenched with saturated NH4Cl solution (100mL), extracted with EA (200mLX3), washed with brine (100mL), dried over Na2SO4, concentrated under vacuum and purified by flash silica gel column chromatography to give compound 6-2 (31g, 97% yield) as a colorless oil.
[0473] C 13 H 19 Calculated mass of BrO4: 318.0; Found: 319.0 [M+H] + ,ESI.
[0474] 1 H NMR (400MHz, CDCl3) δ5.71-5.58(m,3H),5.14-5.10(m,2H),4.25-4.13(m,4H),3.14(s,2H),2.7(d,J=7.2Hz,2H),1.26(t,J=6.8Hz,6H).
[0475] Compound 6-3:
[0476] Compound 6-2 (31 g, 97.12 mmol), Pd(OAc)2 (2.18 g, 9.71 mmol), PPh3 (5.09 g, 19.42 mmol) and AgOAc (19.45 g, 116.54 mmol) were dissolved in ACN (600 mL). The reaction mixture was stirred at 85 °C under N2 atmosphere for 3 h. The reaction was cooled to room temperature and filtered, concentrated under vacuum and purified by flash silica gel column chromatography to give compound 6-3 (21 g, 91% yield) as a colorless oil. 13 H 18 Calculated mass of O4: 238.1; Found: 239.2 [M+H] + ,ESI.
[0477] 1 H NMR (400MHz, CDCl3) δ5.39 (t, J = 2Hz, 2H), 4.95 (t, J = 1.6Hz, 2H), 4.18 (q, J = 7.2Hz, 4H), 3.03 (t, J = 7.2Hz, 4H), 1.24 (t, J = 7.2Hz, 6H).
[0478] Compound 6-4:
[0479] Compound 6-3 (21 g, 88.13 mmol) was dissolved in DCM (300 mL) and cooled to -78 ° C. Br (14.08 g, 88.13 mmol, 4.51 mL) was dissolved in DCM (100 mL) and added to the reaction mixture over 1 h. The mixture was stirred at -78 ° C for 1 h. The reaction mixture was quenched with saturated Na2SO3 solution (100 mL), extracted with DCM (200 mL × 3), washed with brine (100 mL), dried over Na2SO4, concentrated under vacuum and purified by flash silica gel column chromatography to give compound 6-4 (28 g, 80% yield) as a light yellow oil.
[0480] C 13 H 18 Calculated mass of Br2O4: 396.0; Found: 397.0 [M+H] + ,ESI.
[0481] 1 H NMR (400MHz, CDCl3) δ: 4.21 (q, J = 7.2Hz, 4H), 4.00 (s, 4H), 3.19 (s, 4H), 1.26 (t, J = 7.2Hz, 6H).
[0482] Compound 6-5:
[0483] 4-methylbenzenesulfonamide (12.05g, 70.35mmol) is dissolved in DMF (260mL). At 0 DEG C, NaH (6.19g, 154.77mmol) is added to the reaction mixture, and the reaction mixture is stirred at 0 DEG C for 30min. The compound 6-4 (28g, 70.35mmol) in DMF (50mL) is slowly added to the reaction mixture. The mixture is stirred at room temperature for 1h. The reaction mixture is quenched with saturated NH4Cl solution (500mL), extracted with EA (200mLx3), washed with water (500mLx3), brine (300mL), through Na2SO4, concentrated under vacuum and purified by flash silica gel column chromatography, to give compound 6-5 (22g, 76% yield) as a colorless solid.
[0484] C 20 H 25 Calculated mass of NO6S: 407.1; Found: 408.2 [M+H] + ,ESI.
[0485] 1H NMR (400MHz, CDCl3) δ7.70-7.68(m,2H),7.32-7.30(m,2H),4.17(q,J=7.2Hz,4H),3.96(s,4H),2.89(s,4H),2.42(s,3H),1.22(t,J=7.2Hz,6H).
[0486] Compound 6-6:
[0487] Compound 6-5 (22g, 54.05mmol) is dissolved in THF (300mL). LiBH4 (11.8g, 540.5mmol) is added to the reaction mixture at 0°C. The reaction is stirred at room temperature for 1h. The reaction mixture is quenched with water (100mL), extracted with EA (200mLx3), washed with brine (100mL), dried over Na2SO4, concentrated under vacuum and purified by flash silica gel column chromatography to give compound 6-6 (14.8g, 89% yield) as a white solid.
[0488] C 16 H 21 Calculated mass of NO4S: 323.1; Measured value: 324.1 [M+H] + ,ESI.
[0489] 1 H NMR (400MHz, DMSO-d6) δ7.70-7.68(m,2H),7.43-7.41(m,2H),4.56(t,J=5.2Hz,2H),3.26(d,J=4.8Hz,4H),2.84(s,4H),2.39(s,3H),1.95(s,4H).
[0490] Compound 6-7:
[0491] Compound 6-6 (4.1g, 12.68mmol) and DIEA (4.92g, 3.83mmol) are dissolved in DCM (20mL).DMTrCl (4.30g, 12.68mmol) in DCM (80mL) is slowly added to the reaction mixture at 0°C.The reaction is stirred at room temperature for 1h.Reaction mixture is quenched with saturated NaHCO solution (20mL), extracted with DCM (50mLx2), washed with brine (50mL), through NaSO drying, concentrated under vacuum and passed through fast AlO column chromatography purification (0%-3% MeOH), to give compound 6-7 (6.39g, 80% yield) as white foam solid.
[0492] C 37 H 39Calculated mass value of NO6S: 625.25; Measured value: 648.25 [M+Na] + ,ESI.
[0493] 1 H NMR (400MHz, DMSO-d6) δ7.68(d,J=8.0Hz,2H),7.41(d,J=8.0Hz,2H),7.33(d,J=4.0Hz,2H),7.31-7.18(m,7H),6.85(d,J=8.0Hz,4H),4 .68(t,J=4.8Hz,1H),3.83(s,4H),3.72(s,6H),3.37(d,J=2.0Hz,2H),2.94(s,2H),2.39(s,3H),2.07-2.03(m,2H),1.92-1.89(m,2H).
[0494] Compound 6-8:
[0495] Compound 6-7 (6.0 g, 9.59 mmol) was dissolved in MeOH (300 mL), and then Mg (18 g) was added to the reaction mixture at 0°C. The mixture was stirred at room temperature overnight. The reaction mixture was quenched with H2O, extracted with DCM, washed with brine (50 mL), dried over Na2SO4, concentrated under vacuum and purified by flash Al2O3 column chromatography (0%-15% MeOH) to give compound 6-8 (1.2 g, 26.6% yield) as a white foamy solid.
[0496] C 30 H 33 Calculated mass value of NO4: 471.24; Measured value: 472.20 [M+H] + ,ESI.
[0497] 1 H NMR (400MHz, DMSO-d6) δ7.37(d,J=8.0Hz,2H),7.32-7.28(m,2H),7.25-7.19(m,5H),6.89-6.87(m,4H),4.76( s,1H),3.83(s,1H),3.73(s,6H),3.47(s,3H),3.45(s,3H),3.00(s,2H),2.13-2.09(m,2H),1.97-1.93(m,2H).
[0498] Compound 6-9:
[0499] Compound 6-8 (2.4g.5.09mmol) and Fmoc-6-aminocaproic acid (1.80g, 5.09mmol) are dissolved in DCM (60mL), then DIEA (1.97g, 15.27mmol), EDCI (1.95g, 10.18mmol) and HOBT (1.38g, 10.18mmol) are added to the mixture. The reaction is stirred at room temperature for 2h. By saturated NaHCO for reaction mixture solution (200mL) quenching, DCM (60mLx3) extraction, washing with salt solution (60mL), through NaSODrying, concentrated under vacuum and passed through fast AlOColumn chromatography purification (0%-10%MeOH), to give compound 6-9 (3.1g, 75% yield) in white foam solid.
[0500] 1 H NMR (400MHz, DMSO-d6) δ7.88(d,J=7.4Hz,2H),7.68(d,J=7.4Hz,2H),7.43-7.37(m,4H),7.34-7.28( m,5H),7.26-7.21(m,5H),6.88(d,J=8.9Hz,4H),4.75(t,J=4.8Hz,1H),4.30-4.28(m,2H),4.22-4.19 (m,1H),4.11-3.91(m,2H),3.91-3.85(m,2H),3.73(s,6H),3.49-3.48(d,J=4.6Hz,2H),3.02-2.95(m ,4H),2.20-2.14(m,4H),2.00-1.97(m,2H),1.52-1.46(m,2H),1.44-1.36(m,2H),1.24-1.29(m,2H).
[0501] Compound 6-10:
[0502] Compound 6-9 (3.1g, 3.84mmol) is dissolved in MeOH (60mL), and then piperidine (6mL) is added to the mixture.The reaction is stirred at room temperature for 8h.The reaction mixture is quenched with water and extracted with DCM (100mLx3), washed with salt solution (60mL), through Na2SO4, concentrated under vacuum and passed through fast Al2O3 column chromatography purification (0%-20%MeOH), to give compound 6-10 (1.45g, 64% yield) as white foam solid.
[0503] C 36 H 44 Calculated value of N2O5 mass: 584.33; Found: 585.4 [M+H] +,ESI.
[0504] 1 H NMR (400MHz, DMSO-d6) δ7.39-7.39(m,2H),7.37-7.28(m,2H),7.25-7.19(m,5H),6.88(d,J=8.8Hz,2H),4.76(s,1H),4.04(m,2H),3.86( m,2H),3.78(s,6H),3.49(s,2H),3.02(s,2H),2.55(m,2H),2.22-2.14(m,4H),2.01-1.97(m,2H),1.53-1.46(m,2H),1.37-1.25(m,5H).
[0505] Compound 6-11:
[0506] Compound 6-10 (1.5g, 2.57mmol) and compound 1-4 (1.15g, 2.57mmol) are dissolved in DCM (60mL), then DIEA (1.66g, 12.83mmol), EDCI (1.10g, 6.41mmol) and HOBT (519.92mg, 3.85mmol) are added in mixture.Reaction is stirred at room temperature for 2h.Saturated NaHCO for reaction mixture solution (200mL) is quenched, extracted with DCM (60mLx3), washed with salt solution (60mL), through NaSODry, concentrated under vacuum and passed through fast AlOColumn chromatography purification (0%-10%MeOH), to give compound 6-11 (2g, 76% yield) in white foam solid.
[0507] C 55 H 71 N3O 15 Calculated mass: 1013.49; Found: 1014.4 [M+H] + ,ESI.
[0508] 1H NMR(400MHz, DMSO-d6)δ7.82(d,J=9.2Hz,1H),7.72(t,J=5.6Hz,1H),7.39-7.37(m,2H),7.32-7.28(m,2H),7.26 -7.19(m,5H),6.90-6.87(m,4H),5.22(d,J=3.4Hz,1H),4.97(dd,J=11.2,3.4Hz,1H),4.50-4.48(m,1H),4.03-4. 00(m,5H),3.91-3.84(m,3H),3.74(s,7H),3.49(d,J=4.6Hz,1H),3.43-3.38(m,1H),3.02-2.98(m,4H),2.21-2. 15(m,4H),2.10-2.08(m,3H),2.05-2.00(m,7H),1.89(s,3H),1.78(s,3H),1.52-1.35(m,9H),1.27-1.24(m,3H).
[0509] Compound 6-12:
[0510] To a solution of compound 6-11 (790.0 mg, 0.78 mmol) in anhydrous DCM (3.0 mL) was added 4,5-dicyanoimidazole (96.0 mg, 0.81 mmol) and 2-cyanoethyl N, N, N', N'-tetraisopropylphosphoramidite (324 mg, 1.08 mmol) at room temperature and stirred for 1 h, LCMS showed that the starting material was completely consumed. The solution was quenched with water (100 mL), washed with saline (300 mLx3) and dried over Na2SO4. The solution was then concentrated under reduced pressure, and the residue was purified by rapid preparative HPLC under the following conditions (C18 silica gel column; mobile phase: CH3CN / H2O=1 / 1 increased to CH3CN / H2O=1 / 0 in 20 min; detector: UV 254 nm). This resulted in 6-12 (680 mg, 71% yield) as a white solid.
[0511] C 64 H 88 N5O 16 Calculated mass of P: 1213.60; Found: 1159.5 [M-CH2CH2CN] - ,ESI.
[0512] 1HNMR(600MHz,DMSO-d6)δ7.82-7.68(m,2H),7.38-7.19(m,9H),6.90-6.86(m,4H),5.21(d,J=6.0Hz,1H),4.98-4.94(m,1H),4.48(d, J=12.0Hz,1H),4.04-3.99(m,4H),3.90-3.37(m,16H),3.09-2.87(m,4H),2.71-2.68(m,2H),2.19-1.76(m,20H),1.52-1.05(m,22H).
[0513] 31 PNMR(242MHz,DMSO-d6)δ146.51,146.47.
[0514] Example 7
[0515]
[0516] Compound 7-2:
[0517] To a solution of methoxymethyl (triphenyl) phosphine chloride (54.78 g, 159.80 mmol) in THF (600 mL) was added KOtBu (19.92 g, 177.55 mmol) at 0 ° C and stirred for 0.5 h. Compound 7-1 (20 g, 88.78 mmol) was then added at 0 ° C and stirred overnight, and the reaction was allowed to warm to room temperature. LC-MS showed complete conversion. The reaction mixture was adjusted to pH 6 with citric acid (10% aqueous), filtered and concentrated to dryness. The residue was purified by silica gel column (0%-5% EA in PE) to obtain compound 7-2 (15.5 g, 68% yield) as an oil.
[0518] C 14 H 23 Calculated value of NO3 mass: 253.2; Measured value: 239.1 [M-tBu+ACN+H] + ,ESI.
[0519] 1 H NMR (400 MHz, DMSO-d6) δ 5.99 (quintet, J = 2.1 Hz, 1H), 3.48 (s, 3H), 3.44-3.36 (m, 2H), 2.99-2.91 (m, 2H), 2.59 (br, 2H), 2.44-2.36 (m, 2H), 2.04-1.97 (m, 2H), 1.38 (s, 9H).
[0520] Compound 7-3:
[0521] 2,2,2-trichloroacetic acid (4.06 g, 24.87 mmol, in 50 mL water) was added to a solution of compound 7-2 (5 g, 19.74 mmol) in MeCN (150 mL). The reaction mixture was stirred at room temperature overnight. TLC showed complete conversion. The reaction mixture was adjusted to pH 7 with NaHCO (aqueous, saturated) and extracted with EA. The organic phase was concentrated to give crude compound 7-3 (4.7 g, 99% yield) in an oily state, which was used directly in the next step without further purification.
[0522] C 13 H 21 Calculated value of NO3 mass: 239.2; Measured value: 225.1 [M-tBu+ACN+H] + ,ESI.
[0523] Compound 7-4:
[0524] To a mixture of compound 7-3 (4.7 g, 19.64 mmol) and K2CO3 (542.87 mg, 3.93 mmol) in MeOH (150 mL), formalin (15.9 g, 37% aqueous formaldehyde, 55.78 mmol) was added. The reaction mixture was stirred at room temperature overnight. TLC showed complete conversion. The reaction mixture was adjusted to pH 6 with citric acid (10% aqueous) and extracted with EA. The organic phase was concentrated and purified by silica gel column (0%-3% MeOH in DCM) to obtain compound 7-4 (5.2 g, 98% yield) in an oily state.
[0525] C 14 H 23 Calculated mass value of NO4: 269.2; Measured value: 170.1 [M-Boc+H] + ,ESI.
[0526] Compound 7-5:
[0527] To a solution of compound 7-4 (17 g, 63.12 mmol) in MeOH (190 mL) was added NaBH4 (5.25 g, 138.86 mmol). The reaction mixture was stirred at room temperature for 1 h. LC-MS showed complete conversion. The reaction mixture was adjusted to pH 6 with citric acid (10% aqueous), filtered and extracted with DCM. The organic phase was concentrated and purified by a silica gel column (0%-5% MeOH in DCM) to obtain compound 7-5 (14.5 g, 84% yield).
[0528] C 14 H 25Calculated mass value of NO4: 271.2; Measured value: 172.1 [M-Boc+H] + ,ESI.
[0529] 1 H NMR (400MHz, DMSO-d6) δ4.53(t,J=5.3Hz),3.37-3.32(m,2H),3.27(d,J=5.3Hz,2H),3.19(d,J=5.3Hz,2H ), 3.07 (dd, J = 10.78, 3.5 Hz, 2H), 1.60 ( dd, J = 13.4, 7.9 Hz, 2H) 1.39 ( s, 9H), 1.27 ( dd, J = 13.5, 6.3 Hz, 2H).
[0530] Compound 7-6:
[0531] HCl (4M, 140 mL) in dioxane was added to a reaction vial containing compound 7-5 (14.5 g, 53.44 mmol). The reaction mixture was stirred at room temperature for 1.5 h. LC-MS showed complete conversion. The reaction mixture was concentrated to obtain crude compound 7-6 (11 g), which was used directly in the next step without further purification.
[0532] C9H 17 Calculated value of mass of NO2 (free base): 171.1; Measured value: 172.1 [M-Boc+H] + ,ESI.
[0533] Compound 7-7:
[0534] A mixture of Fmoc-6-aminocaproic acid (18.38 g, 52.00 mmol), DIEA (16.80 g, 130.00 mmol, 22.64 mL), HOBT (8.43 g, 62.40 mmol) and EDCI (11.96 g, 62.40 mmol) in DCM (300 mL) was stirred at 0 ° C for 30 min, and then compound 7-6 (10.8 g, 52.00 mmol) was added. The reaction mixture was stirred overnight and allowed to warm to room temperature. LC-MS showed complete conversion. The reaction mixture was diluted with DCM (300 mL) and washed with NaHCO (aqueous, saturated) and water. The organic phase was concentrated and purified by silica gel column (0%-10% MeOH in DCM) to obtain compound 7-7 (19.6 g, 74% yield) as a jelly.
[0535] C 30 H 38 Calculated value of N2O5 mass: 506.3; Found: 507.3 [M+H]+ ,ESI.
[0536] 1 H NMR (400MHz, DMSO-d6) δ7.90-7.68(m,4H),7.44-7.33(m,5H),4.55(s,2H),4.29(d,J=6.8Hz,2H),4.23-4.18 (m,1H),3.28-3.21(m,6H),2.97-2.96(m,2H),2.61-2.53(m,2H),2.17(t,J=7.6Hz,2H),1.63-1.23(m,12H).
[0537] Compound 7-8:
[0538] At 0 ° C, DMTrCl (13.98 g, 41.25 mmol) was added in batches to a solution of compound 7-7 (19 g, 37.50 mmol), N, N-dimethylpyridine-4-amine (458.17 mg, 3.75 mmol) and DIEA (7.27 g, 56.25 mmol, 9.80 mL) in DCM (590 mL). The reaction mixture was stirred overnight. LC-MS showed partial conversion to form 2 isomers and di-DMTr by-products. The reaction mixture was concentrated and purified by a silica gel column (20%-100% EA in PE, containing 0.2% TEA) to obtain compounds 7-8a and 7-8b (17.9 g, 47% yield) as a mixture of endo-isomers and exo-isomers.
[0539] The isomers were separated by preparative HPLC (C18 column, water / ACN) to give compound 7-8a (endo isomer, 7.5 g) and compound 7-8b (exo isomer, 5.7 g).
[0540] 7-8a:
[0541] C 51 H 56 Calculated value of N2O7 mass: 808.4; Measured value: 832.3 [M+Na] + ,ESI.
[0542] 1H NMR(400MHz,DMSO-d6)δ7.90-7.88(m,2H),7.69-7.67(m,2H),7.43-8.18(m,13H),6.8 8-6.85(m,4H),4.62(br,1H),4.37-4.28(m,2H),4.20(t,J=6.7Hz,1H),3.73(s,6H),3. 47 (dd, J = 9.9, 8.2 Hz, 1H), 3.28 (br, 2H), 3.11 (td, J = 12.0, 4.3 Hz, 2H), 2.99-2.91 (m, 4H), 2.66-2.54 (m, 2H), 2.19-2.06 (m, 2H), 1.67 (quintet, J = 6.8 Hz, 2H), 1.51-1.17 (m, 10H).
[0543] 7-8b:
[0544] C 51 H 56 Calculated value of N2O7 mass: 808.4; Measured value: 832.3 [M+Na] + ,ESI.
[0545] 1 H NMR(400MHz,DMSO-d6)δ7.90-7.84(m,4H),7.44-7.20(m,13H),6.91-6.89(m,4H),6.66(br,1H),6.29(s,2H),3.74(s,6H),3.36-3.3 1(m,3H),3.22-3.12(m,3H),2.90(dd,J=12.7,6.5Hz,2H),2.86(s,2H),2.44-2.29(m,2H),2.15(t,J=7.1Hz,2H),1.64-1.18(m,12H).
[0546]
[0547] Compound 7-9a:
[0548] A solution of compound 7-8a (6.5 g, 8.03 mmol) in MeOH (200 mL) and piperidine (20 mL) was stirred at room temperature overnight. LC-MS showed complete conversion. The reaction mixture was concentrated, and the residue was purified by silica gel column (20%-30% MeOH in DCM, containing 1% TEA), to obtain compound 7-9a (4.4 g, 94% yield).
[0549] C 36 H 46Calculated value of N2O5 mass: 586.3; Found: 587.3 [M+H] + ,ESI.
[0550] Compound 7-10a:
[0551] A solution of compound 1-4 (4.70 g, 10.50 mmol), DIEA (2.42 g, 18.75 mmol, 3.27 mL), HOBT (1.22 g, 9.00 mmol) and EDCI (1.73 g, 9.00 mmol) in DCM (132 mL) was stirred at 0 ° C for 30 min, and then compound 7-9a (4.4 g, 7.50 mmol) was added. The reaction mixture was stirred overnight. LC-MS showed complete conversion. The reaction mixture was diluted with DCM (150 mL) and washed with water. The organic phase was concentrated and purified by silica gel column (0%-10% MeOH in DCM, containing 1% TEA) to obtain compound 7-10a (3.8 g, 51% yield).
[0552] C 55 H 73 N3O 15 Calculated value of mass: 1015.5; Found: 1039.1 [M+Na] + ,ESI.
[0553] 1H NMR(400MHz,DMSO-d6)δ7.85(d,J=9.2Hz,1H),7.74(t,J=5.3Hz,1H),7.38 -7.36(m,2H),7.31-7.27(m,2H),7.24-7.19(m,5H),6.88-6.86(m,4H),5. 22(d,J=2.8Hz,1H),4.97(dd,J=11.2,2.8Hz,1H),4.65(t,J=4.8Hz,1H),4 .49(d,J=8.4Hz,1H),4.03(s,3H),3.88(dd,J=19.5,9.1Hz,1H),3.73-3.7 0(m,7H),3.50-3.39(m,2H),3.34-3.31(m,1H),3.27(d,J=4.5Hz,2H),3.1 7(d,J=5.2Hz,1H),3.15-3.09(m,2H),3.00(dd,J=12.4,6.3Hz,2H),2.94( br,1H),2.67-2.53(m,2H),2.19-2.08(m,5H),2.04(t,J=6.9Hz,2H),2.00 (s,3H),1.89(s,3H),1.78(s,3H),1.70-1.63(m,2H),1.53-1.16(m,14H).
[0554] Compound 7-11a:
[0555] To a solution of compound 7-10a (680.0 mg, 0.67 mmol) in anhydrous DCM (3.0 mL) was added 4,5-dicyanoimidazole (96.0 mg, 0.81 mmol) and 2-cyanoethyl N, N, N', N'-tetraisopropylphosphoramidite (324 mg, 1.08 mmol) at room temperature and stirred for 1 h, LCMS showed that the starting material was completely consumed. The solution was quenched with water (100 mL), washed with saline (300 mLx3) and dried over Na2SO4. The solution was then concentrated under reduced pressure, and the residue was purified by rapid preparative HPLC, under the following conditions (C18 silica gel column; mobile phase: CH3CN / H2O=1 / 1 increased to CH3CN / H2O=1 / 0 in 20 min; detector: UV 254 nm). This resulted in 7-11a (390 mg, 47% yield) as a white solid.
[0556] C 64 H 90 N5O16 P Calculated mass: 1215.61; Found: 1161.3 [M-CH2CH2CN] - ,ESI.
[0557] 1 HNMR(600MHz,DMSO-d6)δ7.81-7.69(m,2H),7.40-7.19(m,9H),6.88-6.86(m,4H),5.21(d,J=6.0Hz,1H),4.98-4.94(m,1H),4.49(d, J=6.0Hz,1H),4.02-3.83(m,4H),3.73-3.32(m,18H),3.01-2.97(m,6H),2.71-2.68(m,4H),2.12-1.99(m,18H),1.49-1.04(m,24H).
[0558] 31 PNMR(242MHz,DMSO-d6)δ146.70.
[0559]
[0560] Compound 7-9b:
[0561] A solution of compound 7-8b (5.70 g, 7.05 mmol) in MeOH (200 mL) and piperidine (20 mL) was stirred at room temperature overnight. LC-MS showed complete conversion. The reaction mixture was concentrated and purified by silica gel column (10%-20% MeOH in DCM, containing 1% TEA) to obtain compound 7-9b (4.1 g, 99% yield).
[0562] C 36 H 46 Calculated value of N2O5 mass: 586.3; Found: 587.3 [M+H] + ,ESI.
[0563] Compound 7-10b:
[0564] A solution of compound 1-4 (4.38 g, 9.78 mmol), DIEA (2.26 g, 17.47 mmol, 3.04 mL), HOBT (1.13 g, 8.39 mmol), EDCI (1.61 g, 8.39 mmol) in DCM (120 ml) was stirred at 0 ° C for 30 min, and then compound 7-9b (4.10 g, 6.99 mmol) was added. The reaction mixture was stirred overnight. LC-MS showed complete conversion. The reaction mixture was diluted with DCM (150 mL) and washed with water. The organic phase was concentrated and purified by a silica gel column (0%-10% MeOH in DCM, containing 1% TEA) to give a crude product 4.4 g, which was further purified by preparative HPLC (C18, water / ACN) to obtain compound 7-10b (2.0 g, 28% yield).
[0565] C 55 H 73 N3O 15 Calculated value of mass: 1015.5; Found: 1039.1 [M+Na] + ,ESI.
[0566] 1 H NMR(400MHz, DMSO-d6)δ7.84(d,J=9.2Hz,1H),7.72(t,J=5.5Hz,1H),7.40-7.38(m,2H),7.33-7.29(m,2H),7.28-7.20(m,5H),6.91-6.88(m,4H), 5.22(d,J=3.3Hz,1H),4.97(dd,J=11.2,3.3Hz,1H),4.66(t,J=4.9Hz,1H),4.49(d,J=8.5Hz,1H),4.03(s,3H),3.88(dd,J=20.2,8.8Hz,1H),3.74 -3.69(m,7H),3.48-3.38(m,4H),3.34-3.31(m,1H),3.21(dd,J=10.4,4.2Hz,1H),3.14(dd,J=12.0,4.6Hz,1H),3.00(dd,J=12.7,6.6Hz,2H),2.8 6(s,2H),2.46-2.27(m,2H),2.16(t,J=6.7Hz,2H),2.11(s,3H),2.04(t, J=7.0Hz,2H),2.00(s,3H),1.89(s,3H),1.78(s,3H),1.63-1.12(m,14H).
[0567] Compound 7-11b:
[0568] To a solution of compound 7-10b (680.0 mg, 0.67 mmol) in anhydrous DCM (3.0 mL) was added 4,5-dicyanoimidazole (96.0 mg, 0.81 mmol) and 2-cyanoethyl N, N, N', N'-tetraisopropylphosphoramidite (324 mg, 1.08 mmol) at room temperature and stirred for 1 h, LCMS showed that the starting material was completely consumed. The solution was quenched with water (100 mL), washed with saline (300 mLx3) and dried over Na2SO4. The solution was then concentrated under reduced pressure, and the residue was purified by rapid preparative HPLC, and the conditions were as follows (C18 silica gel column; mobile phase: CH3CN / H2O=1 / 1 increased to CH3CN / H2O=1 / 0 in 20 min; detector: UV 254 nm). This resulted in 7-11b (390 mg, 47% yield) being given as a white solid.
[0569] C 64 H 90 N5O 16 Calculated mass of P: 1215.61; Found: 1161.6 [M-CH2CH2CN] - ,ESI.
[0570] 1 HNMR(600MHz,DMSO-d6)δ7.81-7.69(m,2H),7.40-7.19(m,9H),6.88-6.86(m,4H),5.21(d,J=6.0Hz,1H),4.98-4.94(m,1H),4.49(d, J=6.0Hz,1H),4.02-3.83(m,4H),3.73-3.32(m,18H),3.01-2.97(m,6H),2.71-2.68(m,4H),2.12-1.99(m,18H),1.49-1.04(m,24H).
[0571] 31 PNMR(242MHz,DMSO-d6)δ146.22.
[0572] Example 8
[0573]
[0574] Compound 8-2:
[0575] To a solution of methoxymethyl (triphenyl) phosphine chloride (17.71 g, 51.67 mmol) in THF (120 mL) was added KOtBu (9.66 g, 86.12 mmol) at 0 ° C and stirred for 0.5 h. Compound 8-1 (9.7 g, 43.06 mmol) was then added at 0 ° C and stirred overnight, and the reaction was allowed to warm to room temperature. LC-MS showed complete conversion. The reaction mixture was adjusted to pH 6 by adding citric acid (10% aqueous), filtered and concentrated to dryness. The residue was purified by silica gel column (0%-5% EA in PE) to obtain compound 8-2 (6.0 g, 55% yield) as an oil.
[0576] 1 H NMR (400MHz, DMSO-d6) δ6.01(s,1H),3.48(s,3H),3.43-3.33(m,2H),2.82-2.74(m,2H),2.35-2.26(m,2H),1.90-1.79(m,4H),1.38(s,9H).
[0577] Compound 8-3:
[0578] To a solution of compound 8-2 (5.85 g, 23.09 mmol) in THF (50 mL), hydrochloric acid (3.28 g, 90.00 mmol, 2 N, 45 mL) was added. The reaction mixture was stirred at room temperature for 3 h. TLC showed complete conversion. The reaction mixture was adjusted to pH 7 by adding NaHCO (aqueous, saturated) and extracted with EA. The organic phase was concentrated to obtain a crude compound 8-3 (5.5 g) in an oily state, which was used directly in the next step without further purification.
[0579] 1 H NMR (400 MHz, DMSO-d6) δ9.62 (quintet, J=1.2 Hz, 1H), 3.42-3.33 (m, 3H), 2.82-2.72 (m, 2H), 2.03-1.93 (m, 1H), 1.92-1.87 (m, 2H), 1.75-1.62 (m, 1H), 1.51-1.44 (m, 1H), 1.38 (s, 9H).
[0580] Compound 8-4:
[0581] To a mixture of compound 8-3 (5.25 g, 21.94 mmol) and K2CO3 (660.39 mg, 4.39 mmol) in MeOH (30 mL) was added formalin (6.59 g, 37% aqueous, 219.38 mmol). The reaction mixture was stirred at room temperature overnight. TLC showed complete conversion. The reaction mixture was adjusted to pH 6 by adding citric acid (10% aqueous) and extracted with EA. The organic phase was concentrated to give compound 8-4 (6.7 g), which was used directly in the next step without further purification.
[0582] Compound 8-5:
[0583] To a solution of compound 8-4 (6.3 g, 23.39 mmol) in MeOH (50 mL) was added NaBH4 (2.65 g, 70.17 mmol). The reaction mixture was stirred at room temperature for 1 h. LC-MS showed complete conversion. The reaction mixture was adjusted to pH 6 by adding citric acid (10% aqueous), filtered and extracted with DCM. The organic phase was concentrated and purified by a silica gel column (0%-5% MeOH in DCM) to obtain compound 8-5 (1.4 g, 22% yield).
[0584] C 14 H 25 Calculated mass value of NO4: 271.18; Measured value: 257.24 [M-tBu+CH3CN+H] + ,ESI.
[0585] 1 H NMR (400MHz, DMSO-d6) δ7.16-7.55(m,1H),4.52-4.48(m,2H),3.36-3.27(m,5H),2.74-2.50(m,2H),1.98-1.84(m 2H),1.54-1.50(m 2H),1.49(s,9H),1.05-0.97(m,2H).
[0586] Compound 8-6:
[0587] Compound 8-5 (1.35 g, 4.97 mmol) was dissolved in DCM (5 mL), HCl / dioxane (4 M, 10 mL) was added to the mixture at room temperature, and then stirred at room temperature for 2 h. The reaction mixture was concentrated under vacuum to give the crude product 8-6 (1.3 g) as an oil, which was used in the next step without further purification.
[0588] C9H 17 Calculated value of NO2 mass: 171.1; Measured value: 172.2 [M+H] +,ESI.
[0589] Compound 8-7:
[0590] Z-6-aminohexanoic acid (1.99 g, 7.51 mmol), HATU (4.72 g, 12.52 mmol) and DIPEA (2.43 g, 18.78 mmol, 3.27 mL) were dissolved in DCM (20 mL). The reaction was stirred for 20 min, then compound 8-6 (1.3 g, 6.26 mmol) was added and stirred for another 2 hours. The reaction mixture was quenched with H2O (20 mL), washed with aqueous saturated NaHCO3 (30 mL), washed with brine (30 mL), dried over Na2SO4, concentrated under vacuum and purified by flash silica gel column chromatography (DCM: MeOH = 20: 1) to give compound 8-7 (1.5 g, 3.58 mmol, 57% yield) as a white foamy solid. 23 H 34 Calculated value of N2O5 mass: 418.3; Found: 419.3 [M+H] + ,ESI.
[0591] Compound 8-8:
[0592] Compound 8-7 (1.2 g, 2.87 mmol) was dissolved in DCM (20 mL). DMTrCl (971.49 mg, 2.87 mmol) and DIPEA (741.12 mg, 5.73 mmol, 998.81 μL) were added. The reaction mixture was stirred at room temperature for 2 hours. The reaction was then quenched with water, extracted with DCM (50 mLx2), and washed with brine (50 mL). The organic phase was collected, dried, concentrated under vacuum and purified by rapid Al2O3 column chromatography (DCM: MeOH: TEA = 20: 1: 0.5%) to give compound 8-8 (850 mg, 41% yield) as a white foamy solid.
[0593] C 44 H 52 Calculated value of N2O7 mass: 720.4; Found: 721.4 [M+H] + ,ESI.
[0594] 1H NMR (400MHz, DMSO-d6) δ7.41-7.36(m,3H),7.35-7.29(m,6H),7.27-7.20(m,5H),6.89(d,J= 8.9Hz,4H),5.00(s,2H),4.67(t,J=4.9Hz,1H),3.75(s,6H),3.55-3.47(m,2H),3.39(d,J=4 .5Hz,2H),3.00-2.95(m,4H),2.92-2.84(m,1H),2.62(q,J=11Hz,1H),2.16-2.10(m,2H),1. 95-1.70(m,2H),1.62-1.58(m,1H),1.51-1.35(m,5H),1.27-1.23(m,3H),1.12-1.00(m,2H).
[0595] Compounds 8-9:
[0596] Compound 8-8 (0.8 g, 1.11 mmol) was dissolved in MeOH (10 mL). Pd / C (80 mg) was added. The reaction mixture was stirred at room temperature under a hydrogen atmosphere for 3 h. The reaction mixture was filtered and concentrated under vacuum to give a crude product 8-9 (550 mg, 84% yield) as a white foamy solid, which was used in the next step without further purification.
[0597] C 36 H 46 Calculated value of N2O5 mass: 586.3; Found: 587.3 [M+H] + ,ESI.
[0598] 1 H NMR(400MHz,DMSO-d6)δ7.40-7.38(m,2H),7.31(t,J=7.7Hz,2H),7.29-7.18(m,5H),6 .89(d,J=8.9Hz,4H),3.74(s,6H),3.54-3.43(m,2H),3.34-3.21(m,2H),2.96(s,2H), 2.94-2.85(m,2H),2.67-2.55(m,1H),2.17-2.10(m,2H),1.99-1.74(m,2H),1.63-1.5 8(m,1H),1.53-1.42(m,3H),1.36-1.24(m,5H),1.16-1.10(m,1H),1.05-0.98(m,1H).
[0599] Example 9
[0600]
[0601] Compound 9-2:
[0602] Methoxymethyl (triphenyl) phosphine chloride (116.8g, 340.72mmol) is dissolved in THF (1200mL). KOtBu (46.74g, 416.56mmol) is added to the mixture at 0°C. The reaction mixture is stirred for another 30min at 0°C. Compound 9-1 (40g, 189.34mmol) is added to the mixture. The mixture is warmed to room temperature and stirred at room temperature overnight. The reaction is quenched with saturated citric acid, and the pH is adjusted to 6-7. The reaction mixture is extracted with EA (500mL x3), washed with brine (200mL), dried over Na2SO4, concentrated under vacuum and purified by flash silica gel column chromatography (10%-30% EA in PE), to obtain compound 9-2 (24g, 52% yield) in an oily state.
[0603] C 13 H 21 Calculated value of NO3 mass: 239.3; Measured value: 225.1 [M-tBu+ACN+H] + ,ESI.
[0604] 1 H NMR (400MHz, DMSO-d6) δ5.88 (t, J = 2.4Hz, 1H), 3.83 (s, 4H), 3.47 (s, 3H), 2.79-2.74 (m, 4H), 1.41 (s, 9H).
[0605] Compound 9-3:
[0606] Compound 9-2 (15g, 62.68mmol) is dissolved in ACN (450mL). 2,2,2-trichloroacetic acid (12.90g, 78.98mmol) in water (150mL) is added to the reaction mixture. The reaction is stirred at room temperature overnight, then saturated NaHCO is quenched, and pH is adjusted to 7-8. The mixture is extracted with EA (200mLx3), washed with brine (100mL), dried over NaSO, concentrated under vacuum, to give the crude product 9-3 (13g, 92% yield) in an oily state, which is used for the next step without further purification.
[0607] C 12 H 19 Calculated value of NO3 mass: 225.3; Measured value: 211.1 [M-tBu+ACN+H] + ,ESI.
[0608] Compound 9-4:
[0609] Compound 9-3 (13g, 57.71mmol) is dissolved in MeOH (400mL). KCO (1.60g, 11.54mmol) and formaldehyde (4.92g, 163.88mmol, in water) are added to the mixture. The reaction is stirred at room temperature overnight, then quenched with saturated citric acid, and pH is adjusted to 6-7. The mixture is concentrated under vacuum to remove MeOH. Residue is extracted with EA (200mLx3), washed with brine (100mL), dried over NaSO, concentrated under vacuum to give crude product 9-4 (14g, 95% yield).
[0610] C 13 H 21 Calculated value of NO4 mass: 255.3; Measured value: 241.1 [M-tBu+ACN+H] + ,ESI.
[0611] Compound 9-5:
[0612] Compound 9-4 (14g, 54.84mmol) is dissolved in MeOH (420mL). NaBH4 (4.56g, 120.64mmol) is added in batches. The reaction is stirred at room temperature for 1h, and then quenched with water. PH is adjusted to 6-7 with saturated citric acid. The mixture is concentrated under vacuum to remove MeOH, then residue is extracted with DCM (200mLx3), washed with brine (100mL), dried over Na2SO4, concentrated under vacuum and purified by flash silica gel column chromatography (0%-5% MeOH), to give compound 9-5 (7.05g, 50% yield).
[0613] C 13 H 23 Calculated value of NO4 mass: 257.3; Measured value: 243.1 [M-tBu+ACN+H] + ,ESI.
[0614] 1 H NMR (400MHz, DMSO-d6) δ4.51-4.11(m,2H),3.83-3.75(m,4H),3.25-3.17(m,4H),2.01-1.91(m,4H),1.36(s,9H).
[0615] Compound 9-6:
[0616] Compound 9-5 (13.1 g, 50.91 mmol) was dissolved in HCl in 1,4-dioxane (4M, 131 mL). The reaction mixture was stirred at room temperature for 1 h, then it was concentrated under vacuum to give the crude product 9-6 (9.8 g), which was used in the next step without further purification.
[0617] 8H 13 Calculated mass of NO2Cl: 157.2; Found: 158.2 [M+H] + ,ESI.
[0618] Compound 9-7:
[0619] Compound 9-6 (9.8 g, 50.60 mmol) was dissolved in DCM (300 mL). DIEA (22.89 g, 177.10 mmol, 30.85 mL), HOBT (8.20 g, 60.72 mmol), EDCI (11.64 g, 60.72 mmol) and Fmoc-6-hexanoic acid (17.88 g, 50.60 mmol) were added to the reaction mixture. The reaction was stirred overnight at room temperature, then quenched with water, washed with 10% citric acid (50 mL), saturated NaHCO3 solution (50 mL), brine (50 mL), dried over Na2SO4, concentrated under vacuum and purified by flash silica gel column chromatography (0%-10% MeOH) to give compound 9-7 (6.7 g, 25% yield over two steps).
[0620] C 30 H 36 Calculated value of N2O5 mass: 492.3; Found: 493.3 [M+H] + ,ESI.
[0621] 1 H NMR(400MHz,DMSO-d6)δ7.91-7.68(m,4H),7.44-7.28(m,4H),6.76(s,1H),6.68-6.66(m,1H),6.29(s,2H),4 .01(s,2H),3.74(s,2H),3.69(s,2H),3.27(s,4H),2.92-2.87(m,2H),1.98-1.91(m,4H),1.46-1.18(m,6H).
[0622] Compound 9-8:
[0623] Compound 9-7 (6.7g, 13.60mmol), DMAP (166.15mg, 1.36mmol) and DIEA (2.64g, 20.40mmol, 3.18mL) are dissolved in DCM (180mL). At 0 ° C, DMTrCl (5.52g, 14.96mmol) is added to the reaction mixture in batches. The reaction is stirred at room temperature overnight, then quenched with water. The mixture is extracted with DCM (50mLx2), washed with brine (50mL), dried over Na2SO4, concentrated under vacuum and passed through fast Al2O3 column chromatography purification (50%-100%EA), to give compound 9-8 (4.3g, 40% yield).
[0624] C 51 H 56 Calculated value of N2O8 mass: 824.4; Measured value: 848.3 [M+Na] + ,ESI.
[0625] 1 H NMR(400MHz,DMSO-d6)δ7.91-7.68(m,4H),7.44-7.28(m,4H),7.75-7.71(m,6H),6.90-6.88(m,6H),6.67-6.65(m,1H),6.29(s,2H),3 .96(s,1H),3.74(s,9H),3.69-3.67(m,2H),3.53(s,1H),3.39-3.37(m,2H),2.92-2.89(m,4H),2.03-1.79(m,8H),1.46-1.18(m,6H).
[0626] Compound 9-9:
[0627] Compound 9-8 (4.2 g, 5.09 mmol) was dissolved in MeOH (126 mL), and piperidine (12.6 mL) was then added to the mixture. The reaction mixture was stirred at room temperature overnight, then concentrated under vacuum and purified by flash Al2O3 column chromatography (0%-10% MeOH) to give compound 9-9 (3 g, 97% yield) as a white foam.
[0628] C 36 H 46 Calculated value of N2O6: 602.3; Found: 603.4 [M+H] + ,ESI.
[0629] Compounds 9-10:
[0630] Compound 1-4 (3.2g, 7.16mmol) and compound 9-9 (3g, 5.11mmol) are dissolved in DCM (130mL).DIEA (1.65g, 12.78mmol, 2.17mL), HOBT (807.01mg, 6.13mmol) and EDCI (1.18g, 6.13mmol) are added to the mixture.The reaction is stirred at room temperature overnight, then quenched with water (40mL), extracted with DCM (50mLx2), washed with salt water (50mL), through Na2SO4, dried, concentrated under vacuum and purified by HPLC, to give compound 9-10 (610mg, 12% yield).
[0631] C 55 H 73 N3O 16 Calculated value of mass: 1031.5; Found: 1054.5 [M+Na] + ,ESI.
[0632] 1 H NMR (400MHz, DMSO-d6) δ7.82-7.73(m,2H),7.24-6.88(m,12H),5.22(s,1H),4.97(d,J=10.8Hz,1H),4.64-4.48(m,2H),4.05- 3.85(m,4H),3.71-3.69(m,12H),3.52(s,1H),3.39-3.38(m,1H),3.04-2.91(m,4H),2.11-1.78(m,19H),1.46-1.18(m,14H).
[0633]
[0634] Compound 9-11:
[0635] 4,5-dicyanoimidazole (32.0mg, 0.27mmol) and 2-cyanoethyl N,N,N',N'-tetraisopropylphosphoramidite (108mg, 0.36mmol) were added to a solution of compound 9-10 (1.0g, 0.97mmol) in anhydrous DCM (3.0mL) at room temperature, and stirred for 1h. LCMS showed that the starting material was completely consumed. The solution was quenched with water (100mL), washed with brine (300mLx3) and dried over Na2SO4. The solution was then concentrated under reduced pressure, and the residue was purified by rapid preparative HPLC under the following conditions (column: C18 silica gel; mobile phase: CH3CN / H2O=1 / 1 increased to CH3CN / H2O=1 / 0 in 20min; detector: UV 254nm). This resulted in compound 9-11 (680mg, 56% yield) as a white solid.
[0636] C 64 H 90 N5O 17 Calculated mass of P: 1231.61; Found: 1177.1 [M-CH2CH2CN] - ,ESI.
[0637] 1 HNMR (600MHz, DMSO-d6) δ7.81-7.67(m,2H),7.26-7.23(m,6H),6.88-6.86(m,6H),5.22(d,J=6.0Hz,1H),4.98-4.95(m,1H),4.48(d,J=12.0Hz ,1H),4.04-3.96(m,4H),3.89-3.84(m,1H),3.73-3.38(m,20H),3.01-2 .93(m,4H),2.73-2.71(m,2H),2.10-1.75(m,20H),1.51-1.07(m,22H).
[0638] 31 PNMR(242MHz,DMSO-d6)δ146.82,146.70.
[0639] Compounds 9-12:
[0640] To the solution of compound 9-10 (100mg, 0.097mmol) in anhydrous DCM (1.0mL), DMAP (5mg, 0.04mmol) and TEA (24mg, 0.24mmol) were added, followed by succinic anhydride (20mg, 0.2mmol). The reaction mixture was stirred at room temperature for 3h, and LCMS showed that the starting material was completely consumed. The reaction mixture was diluted with DCM (10mL) and washed with H2O (3mLx4), then washed with brine (3mLx4), and the organic layer was concentrated to give compound 9-12 (85mg, 90% yield) as a white solid.
[0641] C 59 H 77 N3O 19 Calculated mass: 1131.52; Found: 1130.2[MH] - ,ESI.
[0642] 1 HNMR(600MHz,DMSO-d6)δ7.87-7.72(m,2H),7.24-7.21(m,6H),6.90-6.87(m,6H),5.21(d,J=6.0Hz,1H),4.98-4.95(m,1H),4.49(d,J=12.0Hz ,1H),4.06-3.98(m,6H),3.90-3.83(m,1H),3.73-3.50(m,13H),3.02-2 .94(m,4H),2.45-2.44(m,4H),2.11-1.76(m,20H),1.48-1.18(m,12H).
[0643] Solid supports 9-13:
[0644] Natural amino-LCAA-CPG (loading value: 75umol / g, ) was washed with ACN (100 mLx2), DMF (100 mLx2) and DCM (100 mLx2), then dried under high vacuum overnight.
[0645] To succinate 9-12 (85mg, 0.075mmol) and HBTU (53mg, 0.14mmol) solution in anhydrous DMF (1.5mL), add DIPEA (30mg, 0.23mmol), by reaction mixture vibrated at room temperature 10min, then add natural amino-LCAA-CPG (300mg, load 75umol / g).Suspension is vibrated at room temperature 20h, then filtered, washed with DMF (20mLx5), ACN (20mLx5), DCM (20mLx5) until TLC shows that eluent is spotless at 254nm.Solid support is dried under vacuum for 2h, to provide solid support (300mg). The unreacted amine on the solid support was capped by stirring with Ac2O / pyridine / N-methylimidazole (90 μL / 1.0mL / 80 μL) at room temperature for 1 h, and washed with DMF (20mLx5), ACN (20mLx5), DCM (20mLx5) until TLC showed that the eluent had no spots at 254nm. The solid support was dried under vacuum for 15h to give solid support 9-13 (300mg). For load calculation, 5.00mg of dry loaded CPG was taken and 25mL of 3% DCA was added on DCM. The solution was shaken and the UV absorbance at 482nm was measured. Ensure that the absorbance value is less than 1.0 unit to ensure that there is no signal saturation. Then the following equation is applied:
[0646] Load (umol / g) = (total amount of DCA added (mL)) * (absorbance at 482nm) * 1000) / 78.3 * (mg of CPG taken)
[0647] Total amount of DCA added (mL) = 25 mL
[0648] Absorbance at 482nm = 0.577
[0649] mg of CPG taken = 5.00 mg
[0650] Loading (umol / g) = ((25)*(0.577)*1000) / 78.3*(5.00) = 36.8 umol / g.
[0651] Example 10
[0652]
[0653] Compound 10-2:
[0654] Compound 10-1 (0.6 g, 0.299 mmol), DIEA (96.63 mg, 0.748 mmol, 130.23 μ L), HOBT (48.49 mg, 0.359 mmol) and EDCI (68.80 mg, 0.359 mmol) were mixed in DCM (18 mL) and stirred at room temperature for 30 min, then compound 2-10 (412.34 mg, 0.897 mmol) was added and stirred at room temperature for 1 h. LC-MS showed complete conversion. The reaction mixture was concentrated and purified by preparative HPLC (C18 column, eluent A: water, eluent B: ACN) to obtain compound 10-2 (580 mg, 79% yield) as a white solid.
[0655] C 120 H 179 N 11 O 42 Calculated mass: 2446.22; Found: 1247.61 [M+2Na] 2+ ,ESI.
[0656] 1 H NMR (400MHz, DMSO-d6) δ7.86-7.82(m,6H),7.75(t,J=5.5Hz,3H),7.39-7.29(m,4H),7.26-7.19(m,5H),7.00(br,1H),6.89(dd,J=8.9,3. 7Hz,4H),5.21(d,J=3.4Hz,3H),4.96(dd,J=11.2,3.4Hz,3H),4.66-4.64(m,1H),4.78(d,J=8.4Hz,3H),4.04-3.96(m,10H),3.90-3.83(m, 3H), 3.73-3.67 (m, 11H), 3.55-3.50 (m, 13H), 3.43-3.37 (m, 5H), 3.02 (quintet, J = 5.8 Hz, 12H), 2.90 (s, 2H), 2.27 (t, J = 6.2 Hz, 6H), 2.10 (s, 9H) 2.07-2.00 (m, 10H), 1.99 (s, 9H), 1.96-1.92 (m, 2H), 1.89 (s, 9H), 1.85-1.80 (m, 2H), 1.77 (s, 9H), 1.54-1.37 (m, 22H), 1.22-1.20 (m, 12H).
[0657] Compound 10-3:
[0658] To a solution of compound 10-2 (150 mg, 0.06 mmol) in anhydrous DCM (1.0 mL) was added DMAP (14 mg, 0.12 mmol) and TEA (24 mg, 0.24 mmol), followed by succinic anhydride (20 mg, 0.2 mmol), the reaction mixture was stirred at room temperature for 3 h, LCMS showed that the starting material was completely consumed, the reaction mixture was diluted with DCM and washed with water (3 mL x 4), then with brine (3 mL x 4), the organic layer was concentrated to give compound 10-3 (130 mg, 97% yield) as a white solid.
[0659] C 124 H 183 N 11 O 45 Calculated mass: 2546.24; Found: 1273.5 [M+2H] 2+ ,ESI.
[0660] 1 HNMR(600MHz,DMSO-d6):7.84-7.73(m,9H),7.37-7.21(m,9H),6.98-6.89(m,5H),5.21(d,J=6.0Hz,3H),4.97-4.94(m,3H),4.48(d,J=12.0Hz,3H ),4.07-3.66(m,26H),3.55-3.37(m,17H),3.04-2.95(m,14H),2.45(d,J =6.0Hz,4H),2.29-2.25(m,6H),2.11-1.72(m,50H),1.51-1.12(m,38H).
[0661] Compound 10-4:
[0662] DIPEA (30 mg, 0.23 mmol) was added to a solution of compound 10-3 (130 mg, 0.05 mmol) and HBTU (53 mg, 0.14 mmol) in anhydrous DMF (1.5 mL). The reaction mixture was vibrated at room temperature for 10 min, then natural amino-lcaa-CPG (300 mg, load 75 μmol / g) was added. The suspension was vibrated at room temperature for 20 h, then filtered, washed with DMF (20 mLx5), ACN (20 mLx5), DCM (20 mLx5) until TLC showed that the eluent was spotless at 254 nm. The solid support was dried under vacuum for 2 h to give a solid support (300 mg). The unreacted amine on the support was capped by stirring with Ac2O / pyridine / N-methylimidazole (90 μL / 1.0mL / 80 μL) for 1 h at room temperature, and washed with DMF (20mLx5), ACN (20mLx5), DCM (20mLx5) until TLC showed that the eluent had no spots at 254nm. The solid support was dried under vacuum for 15h to give solid support 10-4 (300mg). For load calculation, 5.19mg of dry loaded CPG was taken and 20mL of 3% DCA was added on DCM. The solution was shaken and the UV absorbance at 500nm was measured. Ensure that the absorbance value is less than 1.0 unit to ensure that there is no signal saturation. Then the following equation is applied:
[0663] Load (μmol / g) = (total amount of DCA added (mL)) * (absorbance at 500nm) * 1000) / 76 * (mg of CPG taken)
[0664] Total amount of DCA added (mL) = 20 mL
[0665] Absorbance at 500nm = 0.335
[0666] mg of CPG taken = 5.19 mg
[0667] Loading (μmol / g) = ((20)*(0.335)*1000) / 76*(5.19) = 17 μmol / g.
[0668] Example 11
[0669]
[0670]
[0671] Compound 11-1:
[0672] To a solution of compound 2-10 (1.27 g, 3.59 mmol) in DCM (15 mL), TEA (495.41 mg, 4.90 mmol) and HATU (1.35 g, 3.59 mmol) were added. After stirring for 15 min, Fmoc-6-hexanoic acid (1.5 g, 3.26 mmol) was added to the reaction mixture and stirring was continued for 4 h. The mixture was distributed between DCM (50 mL) and water (35 mL), and the DCM extract was washed with brine (100 mL), dried over sodium sulfate and concentrated in vacuo. The residue was purified by column chromatography, eluted with DCM / MeOH=20 / 1, to give 600 mg of compound 11-1 (23.2% yield).
[0673] 1 H NMR (400MHz, DMSO-d6) δ7.87(d,J=7.6Hz,2H),7.68(d,J=7.4Hz,2H),7.44-7.35(m,4H),7.35-7.28(m, 4H),7.27-7.17(m,6H),6.88(d,J=7.6Hz,4H),4.64(td,J=5.04,1.6Hz,1H),4.28(d,J=6.9Hz,2H),4.20 (t,J=6.8Hz,1H),3.96(s,1H),3.73(d,J=3.8Hz,6H),3.66(d,J=10.4Hz,2H),3.50(s,1H),3.39(t,J=5 .9Hz,2H),2.96(t,J=6.6Hz,2H),2.91(s,2H),2.06-1.74(m,6H),1.47-1.31(m,4H),1.26-1.13(m,2H).
[0674] Compound 11-2:
[0675] Piperidine (0.4 mL) was added to a solution of compound 11-1 (600 mg, 0.75 mmol) in MeOH (4 mL). After stirring overnight, the mixture was concentrated in vacuo. The residue was purified by column chromatography, eluting with DCM / MeOH / NH3OH=100 / 10 / 1 to give 360 mg of compound 11-2 (82% yield).
[0676] C 35 H 44 Calculated value of N2O5 mass: 572.3; Found: 573.4 [M+H] + ,ESI.
[0677] 1H NMR(400MHz,DMSO-d6)δ7.27-7.21(m,4H),6.91-6.85(m,9H),3.97(s,1H),3.73(s,6H),3.68(s,2H),3. 47(d,J=6.5Hz,2H),3.16(s,2H),2.90(s,2H),2.66-2.62(m,2H),2.54-2.51(m,2H),1.49-1.17(m,12H).
[0678] Compound 11-4:
[0679] A mixture of compound 11-3 (10 g, 84.65 mmol), 4-bromopyridine (14.71 g, 93.11 mmol), Pd(PPh3)2Cl2 (4 g, 5.70 mmol) and t-BuOK (19.00 g, 169.30 mmol) in 1,4-dioxane (200 mL) was degassed by purging with nitrogen. The mixture was then heated at 60 ° C for 6 hours. The mixture was concentrated. The residue was then purified by column chromatography, eluted with DCM / MeOH / NH4OH=95 / 5 / 1, to give 8 g of compound 11-4 (48% yield) as a yellow solid.
[0680] C 12 Calculated mass of H9N3: 195.1; Measured mass: 196.2 [M+H] + ,ESI.
[0681] Compound 11-5:
[0682] Compound 11-4 (10 g, 51.22 mmol) was dissolved in tert-butyl alcohol and heated to 50 ° C, then KOH (574.84 mg, 10.24 mmol) and MeOH (5 mL) were added. Then tert-butyl acrylate (7.22 g, 56.35 mmol) was slowly added to the reaction mixture and stirred for 5 h. The mixture was concentrated in vacuo. The residue was distributed between ethyl acetate (250 mL) and water (150 mL), and the ethyl acetate extract was washed with brine (100 ml), dried over sodium sulfate and concentrated in vacuo. The residue was purified by column chromatography, eluted with PE / EA=1 / 2, to give 11 g of compound 11-5 (66% yield).
[0683] C 19 H 21 Calculated value of N3O2 mass: 323.2; Found: 324.2 [M+H] + ,ESI.
[0684] 1H NMR (400MHz, DMSO-d6) δ 8.65 (d, J = 5.6 Hz, 4H), 7.50 (d, J = 6.0 Hz, 4H), 2.82 (t, J = 7.8 Hz, 2H), 2.23 (t, J = 7.8 Hz, 2H), 1.35 (s, 9H).
[0685] Compound 11-6:
[0686] Cobalt chloride hexahydrate (1.47 g, 6.18 mmol) is added to a solution of compound 11-5 (1 g, 3.09 mmol) in MeOH (20 mL). Sodium borohydride (1.17 g, 30.92 mmol) is then slowly added to the reaction mixture at -6 °C. The mixture is warmed to room temperature and stirred for 5 h. The mixture is concentrated in vacuo. The residue is dissolved in EA and filtered through a celite layer and washed with MeOH. The filtrate is concentrated to give 0.7 g of compound 11-6 (69% yield).
[0687] C 19 H 25 Calculated value of N3O2 mass: 327.2; Found: 328.3 [M+H] + ,ESI.
[0688] Compound 11-7:
[0689] Compound 11-6 (2.12g, 9.16mmol) is dissolved in DCM (40mL). Then TEA (925.42mg, 9.16mmol) and HATU (3.46g, 9.16mmol) are added to the solution. After stirring for 20min, Boc-6-aminocaproic acid (3g, 9.16mmol) is added to the reaction mixture, and the mixture is stirred for 5h. The mixture is distributed between DCM (50mL) and water (35mL), and the DCM extracts are washed with brine (100mL), dried over sodium sulfate and concentrated in vacuo. The residue is purified by column chromatography, wherein eluted with DCM / MeOH=9 / 1, to give 2.5g compound 11-7 (71% yield) in a yellow oil.
[0690] C 30 H 44 Calculated value of N4O5 mass: 540.3; Found: 541.4 [M+H] + ,ESI.
[0691] 1H NMR (400MHz, DMSO-d6) δ8.48(d,J=5.9Hz,4H),7.45(t,J=6.6Hz,1H),7.14(d,J=6.1Hz,4H),6.73(t,J=5.4Hz,1H),3.88(d,J=6.1Hz,2 H),2.85(q,J=6.6Hz,2H),2.31(t,J=8.0Hz,2H),1.94(q,J=8.0Hz,4H),1.36(s,9H),1.32(s,9H),1.31-1.23(m,4H),1.1-0.9(m,2H).
[0692] Compound 11-8:
[0693] Platinum oxide (2.2g, 9.69mmol) is added to a solution of compound 11-7 (4.5g, 8.32mmol) in AcOH (15ml). The mixture is hydrogenated at about 0.4MPa for 56 hours. The catalyst is filtered through a celite layer and washed with MeOH. The mixture is concentrated in vacuo. The pH is adjusted to 7 by adding concentrated NaHCO3 aqueous solution, and then dried in vacuo. The residue is dissolved in THF, the mixture is then filtered, and the filtrate is evaporated under reduced pressure to give 4g compound 11-8 (87% yield) as a colorless oil.
[0694] C 30 H 56 Calculated value of N4O5 mass: 552.4; Found: 553.4 [M+H] + ,ESI.
[0695] Compound 11-9:
[0696] TEA (402.72mg, 3.98mmol) and HATU (1.50g, 3.98mmol) are added to a solution of Boc-6-aminocaproic acid (920.49mg, 3.98mmol) in DCM (10mL). After the solution is stirred for 20min, compound 11-8 (1g, 1.18mmol) is added to the reaction mixture and continues to stir for 5h. The mixture is distributed between DCM (50mL) and water (35mL), and the DCM extracts are washed with brine (100mL), dried over sodium sulfate and concentrated in vacuo. The residue is purified by column chromatography, eluted with DCM / MeOH=15 / 1, to give 0.4g compound 11-9 (22% yield) as a white solid.
[0697] C 52 H 94 N6O 11Calculated mass: 978.7; Found: 979.8 [M+H] + ,ESI.
[0698] 1 H NMR (400MHz, DMSO-d6) δ7.41(t,J=6.0Hz,1H),6.78-6.70(m,3H),3.88(d,J=11.4Hz,2H),3.02(d,J=6.5Hz,6H),2.92-2.82(m,8H),2.25(t,J=7 .4Hz,4H),2.15(t,J=8.1Hz,2H),2.16(t,J=7.2Hz,2H),1.70-1.50(m,6 H),1.49-1.38(m,10H),1.38(s,9H),1.36(s,27H),1.34-1.15(m,14H).
[0699] Compound 11-10:
[0700] TFA (2 mL) was added to a solution of compound 11-9 (1.4 g, 1.43 mmol) in DCM (6 mL), and the mixture was then stirred at room temperature for 4 h. The mixture was concentrated in vacuo to give 850 mg of compound 11-10 (95% yield) as a colorless oil.
[0701] C 33 H 62 Calculated mass of N6O5: 622.5; Found: 623.6 [M+H] + ,ESI.
[0702] Compound 11-11:
[0703] TEA (584.84 mg, 5.78 mmol) and HATU (1.64 g, 4.33 mmol) were added to a solution of compound 1-4 (2.13 g, 4.77 mmol) in DMF (10 mL). After stirring for 20 min, compound 11-10 (0.9 g, 1.44 mmol) was added to the reaction mixture and continued to stir for 5 h. The mixture was purified by reverse phase column (C18 column) to provide 1.3 g of compound 11-11 (47% yield) as a white solid.
[0704] C 90 H 143 N9O 35 Calculated mass: 1909.9; Found: 956.0 [M+2H] 2+ ,ESI.
[0705] 1H NMR(400MHz,DMSO-d6)δ12.0(br,1H),7.83(d,J=9.2Hz,3H),7.70(t,J=5.5Hz,3H),7.50-7.40(m,1H) ,5.20(d,J=3.4Hz,3H),4.96(dd,J=11.24,3.4Hz,3H),4.50-4.40(m,5H),4.08-3.96(m,9H),3.92-3. 82(m,5H),3.76-3.66(m,3H),3.46-3.36(m,4H),3.15-2.75(m,11H),2.40-2.30(m,2H),2.25(t,J=7. 3Hz,4H),2.10(s,9H),2.08-2.00(m,8H),1.99(s,9H),1.98(s,9H),1.77(s,9H),1.60-1.08(m,42H).
[0706] Compound 11-12:
[0707] Compound 11-11 (1.4g, 0.73mmol) is dissolved in DCM (15mL), then HOBT (148.47mg, 1.10mmol), EDCI (210.10mg, 1.10mmol) and DIEA (236.69mg, 1.83mmol) are added to the solution. After stirring for 15min, compound 11-2 (503.47mg, 0.88mmol) is added to the reaction mixture and continues to stir for 4h. The mixture is distributed between DCM (50mL) and water (35mL), and the DCM extracts are washed with brine (100mL), dried over sodium sulfate and concentrated in vacuo. The residue is purified by reverse phase column (C18 column), to provide 0.8g compound 11-12 (44% yield) as a white powder.
[0708] C 125 H 185 N 11 O 39 Calculated mass value: 2464.3; Found value: 1255.6 [M+2Na] 2+ ,ESI.
[0709] 1H NMR (400MHz, DMSO-d6) δ7.86-7.76(m,4H),7.71(t,J=5.3Hz,3H),7.45(s,1H),7.41-7.35(m,2H),7.34-7.28(m,2H),7.27-7.18(m,5H),6.93- 6.86(m,4H),5.27-5.15(d,J=3.3Hz,3H),5.02-4.90(dd,J=11.2,3.4H z,3H),4.69-4.60(m,1H),4.57-4.33(m,5H),4.11-3.98(m,9H),3.97(s ,1H),3.93-3.81(m,5H),3.73(s,6H),3.72-3.62(m,5H),3.51(s,1H), 3.46-3.36(m,5H),3.14-2.73(m,14H),2.43-2.29(m,2H),2.29-2.19(m ,4H),2.01(s,9H),2.06-1.97(m,19H),1.96-1.91(m,3H),1.87(s,9H), 1.86-1.80(m,2H),1.77(s,9H),1.70-1.55(m,5H),1.54-1.13(m,44H).
[0710]
[0711] Compounds 11-13:
[0712] To a solution of compound 11-12 (2.0 g, 0.8 mmol) in anhydrous DCM (7.0 mL) was added 4,5- dicyanoimidazole (80.0 mg, 0.67 mmol) and 2- cyanoethyl N, N, N', N'-tetraisopropylphosphoramidite (270 mg, 0.90 mmol) at room temperature, and stirred for 1 h, LCMS showed that the starting material was completely consumed. The solution was quenched with water (100 mL), washed with saline (300 mLx3) and dried over Na2SO4. The solution was then concentrated under reduced pressure, and the residue was purified by rapid preparative HPLC, and the conditions were as follows (C18 silica gel column; mobile phase: CH3CN / H2O=1 / 1 increased to CH3CN / H2O=1 / 0 in 20 min; detector: UV 254 nm). This resulted in compound 11-13 (1.0 g, 45% yield) being given as a white solid.
[0713] C 134 H 202 N 13 O 40Calculated mass of P: 2664.39; Found: 1132.5 [M-DMTr-N(CH(CH3)2)2+4H] 2+ ,ESI.
[0714] 1 HNMR(600MHz,DMSO-d6)δ7.82-7.69(m,6H),7.44-7.19(m,9H),6.90-6.87(m,4H),5.21(d,J=6.0Hz,3H),4.98-4 .94(m,3H),4.49-4.44(m,5H),4.04-3.37(m,35H),3.02-2.71(m,15H),2.33-1.75(m,56H),1.64-1.07(m,57H).
[0715] 31 PNMR(242MHz,DMSO-d6)δ146.79,146.67.
[0716]
[0717] Compounds 11-14:
[0718] To a solution of compound 11-12 (150 mg, 0.06 mmol) in anhydrous DCM (1.0 mL) was added DMAP (5 mg, 0.04 mmol) and TEA (24 mg, 0.24 mmol) followed by succinic anhydride (20 mg, 0.2 mmol). The reaction mixture was stirred at room temperature for 3 h. LCMS showed that the starting material was completely consumed. The reaction mixture was diluted with DCM and washed with water (3 mL x 4) and then with brine (3 mL x 4). The organic layer was concentrated to give compound 11-14 (135 mg, 97% yield) as a white solid.
[0719] C 129 H 189 N 11 O 42 Calculated mass: 2564.30; Found: 1132.5 [M-DMTr+2H] 2+ ,ESI.
[0720] 1H NMR(600MHz,DMSO-d6):7.84-7.71(m,6H),7.45-7.21(m,10H),6.92-6.89(m,4H),5.21(d,J=6.0Hz,3H),4.98-4 .94(m,3H),4.49-4.44(m,5H),4.07-3.37(m,36H),3.16-2.84(m,14H),2.44-1.77(m,62H),1.45-1.21(m,50H).
[0721] Compounds 11-15:
[0722] DIPEA (30mg, 0.23mmol) is added to the solution of compound 11-14 (135mg, 0.05mmol) and HBTU (53mg, 0.14mmol) in anhydrous DMF (1.5mL). The reaction mixture is vibrated at room temperature for 10min, then natural amino-lcaa-CPG (300mg, load 75umol / g) is added. The suspension is vibrated at room temperature for 20h, then filtered, washed with DMF (20mLx5), ACN (20mLx5), DCM (20mLx5) until TLC shows that the eluent is spotless at 254nm. The solid support is dried under vacuum for 2h, to give a solid support (300mg). The unreacted amine on the support was capped by stirring with Ac2O / pyridine / N-methylimidazole (90 μL / 1.0mL / 80 μL) at room temperature for 1 h, and washed with DMF (20mLx5), ACN (20mLx5), DCM (20mLx5) until TLC showed that the eluent was spotless at 254nm. The solid support was dried under vacuum for 15h to give solid support 11-15 (300mg). For load calculation, 5.00mg of dry loaded CPG was taken and 20mL of 3% DCA was added on DCM. The solution was shaken and the UV absorbance at 500nm was measured. Ensure that the absorbance value is less than 1.0 unit to ensure that there is no signal saturation. Then the following equation is applied:
[0723] Load (umol / g) = (total amount of DCA added (mL)) * (absorbance at 500nm) * 1000) / 76 * (mg of CPG taken)
[0724] Total amount of DCA added (mL) = 20 mL
[0725] Absorbance at 500nm = 0.464
[0726] mg of CPG taken = 5.0 mg
[0727] Loading (umol / g) = ((20)*(0.464)*1000) / 76*(5.0) = 24 umol / g.
[0728] Example 12
[0729]
[0730] Compound 12-1:
[0731] Compound 3-4 (1.1 g, 5.16 mmol) was dissolved in H2O (10 mL) and THF (20 mL). K2CO3 (1.43 g, 10.31 mmol) and benzyl chloroformate (967 mg, 5.67 mmol) were added. The reaction mixture was stirred at room temperature for 3 h. It was then concentrated under vacuum and purified by flash silica gel column chromatography (PE / EA=5 / 1) to obtain compound 12-1 (1.5 g, 84% yield) as a white foamy solid.
[0732] C 20 H 29 Calculated value of NO4 mass: 347.2; Measured value: 348.3 [M+H] + ,ESI.
[0733] Compound 12-2:
[0734] Compound 12-1 (1.52g, 4.37mmol), DMAP (147.10mg, 1.20mmol) and DIEA (3.11g, 24.08mmol, 4.19mL) are dissolved in DCM (20mL). DMTrCl (1.48g, 4.37mmol) in DCM (20mL) is slowly added to the reaction mixture at 0 ° C. The reaction is stirred at room temperature for 2h. The reaction mixture is quenched with saturated NaHCO solution (40mL), extracted with DCM (50mLx2), washed with brine (50mL), dried over NaSO, concentrated under vacuum and purified by rapid AlO column chromatography (0%-3% MeOH), to give compound 12-4 (1.9g, 67% yield) as a white foam solid.
[0735] C 41 H 47 Calculated mass of NO6: 649.34; Measured value: 650.34 [M+H] + ,ESI.
[0736] 1H NMR(400MHz,DMSO-d6)δ7.41-7.19(m,15H),6.90-6.87(m,3H),5.06-5.05(m,2H),4 .42-4.40(m,1H),3.76(s,6H),3.40-3.38(m,6H),2.88(s,2H),1.39-1.11(m,12H).
[0737] Compound 12-3:
[0738] Compound 12-2 (0.7 g, 1.08 mmol) was dissolved in MeOH (30 mL), and Pd / C (140 mg) was then added to the solution. The reaction mixture was stirred for 3 h at room temperature under a hydrogen atmosphere. The reaction mixture was filtered and concentrated under vacuum to give a crude compound 12-3 (520 mg) as a white foamy solid, which was used in the next step without further purification.
[0739] C 33 H 41 Calculated mass of NO4: 515.30; Measured value: 516.30 [M+H] + ,ESI.
[0740] 1 H NMR(400MHz, DMSO-d6)δ7.38(d,J=8.8Hz,2H),7.32-7.20(m,7H),6.89-6.87(m,4H),4.51-4.49( m,1H),3.73(s,6H),2.89-2.86(m,8H),1.52-1.51(m,2H),1.19-1.12(m,7H),0.91-0.88(m,2H).
[0741] Compound 12-4:
[0742] Compound 10-1 (1.56g, 0.756mmol) is dissolved in DCM (20mL). DIEA (300.74mg, 2.33mmol), EDCI (297.39mg, 1.55mmol) and HOBT (209.62mg, 1.55mmol) are added to the mixture at 0°C. The reaction is stirred for 30min at 0°C. Compound 12-3 (400mg, 0.756mmol) is added to the reaction mixture. The reaction mixture is stirred at room temperature for 2h. The reaction mixture is quenched with saturated NaHCO solution (40mL), extracted with DCM (30mLx2), washed with brine (30mL), dried over NaSO, concentrated under vacuum and purified by rapid AlO column chromatography (0%-8% MeOH), to give compound 12-4 (1g, 51% yield) as a white foam solid.
[0743] C 124 H 187 N 11 O 42 Calculated mass: 2503.28; Found: 1101.6 [M-DMTr+2H + ] 2+ ,ESI.
[0744] 1 H NMR (400MHz, DMSO-d6) δ7.85-7.81(m,6H),7.73(t,J=5.6Hz,3H),7.39(d,J=7.32Hz,2H),7.32-7.19(m,8H),6.99(s,1H),6.88(d,J= 8.9Hz,4H),5.21-5.20(m,3H),4.98-4.94(m,3H),4.48(d,J=8.44Hz,3H),4.42(t,J=5.0Hz,1H),4.05-4.00(m,9H),3.90-3.83(m,3H ),3.73-3.67(m,9H),3.55-3.52(m,11H),3.43-3.38(m,6H),3.22-3.21(m,6H),3.06-3.00(m,11H),2.29-2.24(m,5H),2.22(t,J=7. 4Hz,2H),2.10(s,8H),2.05(t,J=6.96Hz,8H),1.99-1.98(m,9H),1.89(s,8H),1.77(s,8H),1.52-1.44(m,22H),1.30-1.22(m,24H).
[0745] Example 13
[0746]
[0747] Compound 13-1:
[0748] Compound 4-7 (1.3g, 7.01mmol) is dissolved in THF (30mL) and H2O (15mL). K2CO3 (2.91g, 21.05mmol) is added to the solution. And benzyl chloroformate (1.32g, 7.72mmol) is added to the reaction mixture at 0°C. The mixture is stirred at room temperature for 3h. The reaction mixture is extracted with EA (50mL×2), washed with brine (50mL), dried over Na2SO4, concentrated under vacuum and purified by flash silica gel column chromatography (0%-5% MeOH), to obtain compound 13-1 (1.95g, 87% yield) as a white foam solid.
[0749] C 18 H 25 Calculated mass value of NO4: 319.2; Measured value: 320.2 [M+H] + ,ESI.
[0750] Compound 13-2:
[0751] Compound 13-1 (2 g, 6.26 mmol) and DIEA (2.43 g, 18.79 mmol, 4.19 mL) were dissolved in DCM (60 mL). DMTrCl (2.02 g, 5.95 mmol) was added to the reaction mixture at 0 ° C. The reaction was stirred for 1 h at 0 ° C. The reaction mixture was quenched with saturated NaHCO solution (40 mL), extracted with DCM (50 mL × 2), washed with brine (50 mL), dried over NaSO, concentrated under vacuum and purified by rapid AlO column chromatography (PE / EA = 0% -40%) to give compound 13-2 (2.6 g, 66% yield) as a white foamy solid.
[0752] Compound 13-3:
[0753] Compound 13-2 (600 mg, 0.96 mmol) was dissolved in MeOH (20 mL), and Pd / C was then added to the reaction mixture. The reaction mixture was stirred for 3 h at room temperature under a hydrogen atmosphere. The reaction mixture was filtered and concentrated under vacuum to give a crude product 13-3 (470 mg, crude product) as a white foamy solid, which was used in the next step without further purification.
[0754] C 31 H 37 Calculated value of NO4 mass: 487.3; Measured value: 488.3 [M+H]+ ,ESI.
[0755] Compound 13-4:
[0756] Compound 10-1 (1.23g, 0.61mmol) is dissolved in DCM (20mL). DIEA (239mg, 1.85mmol, 0.32mL), EDCI (236mg, 1.23mmol) and HOBT (166mg, 1.23mmol) are added to the mixture at 0°C. The reaction is stirred for 30min at 0°C. Compound 13-3 (300mg, 0.61mmol) is added to the reaction mixture. The reaction mixture is stirred at room temperature for 2h. The reaction mixture is quenched with saturated NaHCO solution (40mL), extracted with DCM (30mLx2), washed with brine (30mL), dried over NaSO, concentrated under vacuum and purified by rapid AlO column chromatography (0%-8%MeOH), to obtain compound 13-4 (1g, 66% yield) as a white foam solid.
[0757] 1 H NMR (400MHz, DMSO-d6) δ7.85-7.82(m,6H),7.75-7.73(m,3H),7.40-7.38(m,2H),733-7.29(m,2H),7.27-7.25(m,4H),7.23-7.19(m,1H),6.98( s,1H),6.90-6.88(m,4H),5.21(d,J=3.2Hz,3H),4.97(dd,J=3.2,11.2H z,3H),4.63-4.61(m,1H),4.48(d,J=8.4Hz,3H),4.04-4.00(m,9H),3.91 -3.83(m,3H),3.73(s,6H),3.71-3.67(m,3H),3.55-3.52(m,12H),3.44 -3.37(m,5H),3.27-3.15(m,5H),3.06-3.01(m,14H),2.27(t,J=12.8Hz, 6H),2.21(d,J=14.8Hz,2H),2.10(s,9H),2.04(t,J=6.8Hz,8H),1.99(s ,9H),1.89(s,9H),1.77(s,9H),1.58-1.33(m,30H),1.29-1.23(m,12H).
[0758] Example 14
[0759]
[0760] Compound 14-1:
[0761] Compound 5-6 (3.6 g, 19.27 mmol) is dissolved in THF (30 mL) and H2O (15 mL). K2CO3 (5.33 g, 38.54 mmol) is added to the solution. And benzyl chloroformate (3.62 g, 21.20 mmol) is added to the reaction mixture at 0 ° C. The mixture is stirred at room temperature for 2 h. The reaction mixture is extracted with EA (50 mLx2), washed with brine (50 mL), dried over Na2SO4, concentrated under vacuum and purified by flash silica gel column chromatography (0%-2% MeOH), to obtain compound 14-1 (5 g, 81% yield) as a white foam solid.
[0762] C 18 H 25 Calculated mass value of NO4: 319.2; Measured value: 320.2 [M+H] + ,ESI.
[0763] 1 H NMR (400MHz, DMSO) δ7.39-7.28 (m, 5H), 5.01 (s, 2H), 4.27 (t, J = 5.4Hz, 2H), 3.6 1-3.50(m,4H),3.22(d,J=5.3Hz,4H),1.55(t,J=6.1Hz,4H),1.25-1.22(m,8H).
[0764] Compound 14-2:
[0765] Compound 14-1 (3.5 g, 10.96 mmol) and DIEA (2.12 g, 16.44 mmol) were dissolved in DCM (60 mL). DMTrCl (3.34 g, 9.86 mmol) was added to the reaction mixture at 0 ° C. The reaction was stirred for 3 h at 0 ° C. The reaction mixture was quenched with saturated NaHCO solution (40 mL), extracted with DCM (50 mL × 2), washed with brine (50 mL), dried over NaSO, concentrated under vacuum and purified by rapid AlO column chromatography (PE / EA = 0% -60%) to obtain compound 14-2 (5.5 g, 81% yield) as a white foamy solid.
[0766] 1H NMR(400MHz,DMSO-d6)δ7.39-7.18(m,14H),6.88(d,J=8.8Hz,4H),5.00(s,2H),4.3 9(t,J=4.9Hz,1H),3.73(s,6H),3.58-3.35(m,6H),2.83(s,2H),1.29-1.15(m,8H).
[0767] Compound 14-3:
[0768] Compound 14-2 (254 mg, 408.52 μmol) was dissolved in MeOH (10 mL), and Pd / C was then added to the reaction mixture. The reaction mixture was stirred for 2 h at room temperature under a hydrogen atmosphere. The reaction mixture was filtered and concentrated under vacuum to give a crude product 14-3 (199 mg, crude product) as a white foamy solid, which was used in the next step without further purification.
[0769] C 31 H 37 Calculated value of NO4 mass: 487.3; Measured value: 488.3 [M+H] + ,ESI.
[0770] Compound 14-4:
[0771] Compound 10-1 (820mg, 408.51 μmol) is dissolved in DCM (20mL). DIEA (158mg, 1.23mmol), EDCI (157mg, 817 μmol) and HOBT (110mg, 817 μmol) are added to the mixture at 0 ° C. The reaction is stirred for 30min at 0 ° C. Compound 14-3 (199mg, 408.51 μmol) is added to the reaction mixture. The reaction mixture is stirred at room temperature for 2h. The reaction mixture is quenched with saturated NaHCO solution (40mL), extracted with DCM (30mLx2), washed with brine (30mL), dried over NaSO, concentrated under vacuum and purified by rapid AlO column chromatography (0%-6% MeOH), to obtain compound 14-4 (540mg, 53% yield) as a white foamy solid.
[0772] 1H NMR (400MHz, DMSO-d6) δ7.89-7.80(m,6H),7.75(t,J=5.5Hz,3H),7.37(d,J=7.3Hz,2H),7.30(t,J=7.7Hz,2H),7.23-7.17(m,5H),6.99 (s,1H),6.87(d,J=8.4Hz,4H),5.21(d,J=3.4Hz,3H),4.96(dd,J=10.8,3.4Hz,3H),4.47(d,J=8.5Hz,3H),4.41(t,J=4.9Hz,1H),4.04-3 .98(m,9H),3.91-3.82(m,3H),3.74-3.48(m,23H),3.43-3.36(m,6H),3.06-2.98(m,12H),2.83(d,J=9.4Hz,2H),2.27(t,J=6.3Hz,6H), 2.09(s,9H),2.03(t,J=7.0Hz,8H),2.00-1.95(m,12H),2.01(s,9H),1.89(s,9H),1.77(s,9H),1.54-1.37(m,22H),1.31-1.14(m,20H).
[0773] Example 15
[0774]
[0775] Compound 15-1:
[0776] Compound 7-6 (3.8 g, 18.30 mmol) is dissolved in THF (30 mL) and H2O (15 mL). K2CO3 (5.06 g, 36.59 mmol) is added to the reaction mixture. And benzyl chloroformate (3.43 g, 20.13 mmol) is added to the reaction mixture at 0 ° C. The mixture is stirred at room temperature for 2 h. The reaction mixture is extracted with EA (50 mL x2), washed with brine (50 mL), dried over Na2SO4, concentrated under vacuum, to give the crude product 15-1 (3.46 g, crude product) in a white foamy shape.
[0777] C 17 H 23 Calculated mass value of NO4: 305.2; Measured value: 306.2 [M+H] + ,ESI.
[0778] Compound 15-2:
[0779] Compound 15-1 (3.07g, 10.06mmol) and DIEA (1.95g, 15.09mmol) are dissolved in DCM (60mL).DMTrCl (3.41g, 10.06mmol) is added to the reaction mixture at 0°C.The reaction is stirred for 3h at 0°C.The reaction mixture is quenched with saturated NaHCO solution (40mL), extracted with DCM (50mLx2), washed with brine (50mL), dried over NaSO, concentrated under vacuum and purified by rapid AlO column chromatography (PE / EA=0%-60%) and preparative HPLC to give compound 15-2a (1.04g, 34% yield) and compound 15-2b (1.78g, 58% yield) as a white foam solid.
[0780] 15-2a:
[0781] 1 H NMR(400MHz,DMSO-d6)δ7.38-7.36(m,1H),7.36-7.31(m,5H),7.31-7.20(m,7H), 7.20-7.15(m,1H),6.85(d,J=8.9Hz,4H),5.02(d,J=6.1Hz,2H),6.98(s,1H),4.6 1(t,J=5.0Hz,1H),3.71(s,6H),3.46-3.35(m,2H),3.27(d,J=5.0Hz,2H),3.13-3 .05(m,2H),2.93(s,2H),2.64-2.55(m,2H),1.72-1.62(m,2H),1.30-1.21(m,2H).
[0782] 15-2b:
[0783] 1 H NMR (400MHz, DMSO-d6) δ7.40-7.27(m,9H),7.27-7.22(m,4H),7.22-7.16(m,1H),6.89(d,J=8.9Hz,4H),5.03(s,2H),6.98(s,1H),4.64(t,J=5.1Hz ,1H),3.73(s,6H),3.43-3.34(m,4H),3.19-3.09(m,2H),3.13-3.05(m,2 H),2.84(s,2H),2.41-2.31(m,2H),1.62-1.54(m,2H),1.38-1.30(m,2H).
[0784] Compound 15-3:
[0785] Compound 15-2a (210 mg, 350.48 μmol) was dissolved in MeOH (10 mL), and Pd / C was then added to the solution. The reaction mixture was stirred for 2 h at room temperature under a hydrogen atmosphere. The reaction mixture was filtered and concentrated under vacuum to give a crude product 15-3a (166 mg, crude product) as a white foamy solid, which was used in the next step without further purification.
[0786] C 30 H 35 Calculated value of NO4 mass: 473.3; Measured value: 474.3 [M+H] + ,ESI.
[0787] Compound 15-2b (610 mg, 1.00 mmol) was dissolved in MeOH (10 mL), and Pd / C was then added to the solution. The reaction mixture was stirred for 2 h at room temperature under a hydrogen atmosphere. The reaction mixture was filtered and concentrated under vacuum to give the crude product 15-3b (475 mg, crude product) as a white foamy solid, which was used in the next step without further purification.
[0788] Compound 15-4:
[0789] Compound 10-1 (700mg, 348.92 μmol) is dissolved in DCM (20mL). DIEA (135mg, 1.05mmol), EDCI (134mg, 698 μmol) and HOBT (94mg, 698 μmol) are added to the mixture at 0 ° C. The reaction is stirred for 30min at 0 ° C. Compound 15-3a (199mg, 408.51 μmol) is added to the reaction mixture. The reaction mixture is stirred at room temperature for 2h. The reaction mixture is quenched with saturated NaHCO solution (40mL), extracted with DCM (30mLx2), washed with brine (30mL), dried over NaSO, concentrated under vacuum and purified by rapid AlO column chromatography (0%-6% MeOH), to obtain compound 15-4a (550mg, 64% yield) as a white foamy solid.
[0790] 1H NMR(400MHz, DMSO-d6)δ7.88-7.80(m,6H),7.75(t,J=5.4Hz,3H),7.38-7.34(m,2H),7.28(t,J=7.6Hz,2H),7.24-7.17(m,5H),7.00(s,1H),6.87 (d,J=8.9Hz,4H),5.21(d,J=3.4Hz,3H),4.96(dd,J=11.3,3.4Hz,3H),4. 64-4.60(m,1H),4.47(d,J=8.5Hz,3H),4.05-3.98(m,9H),3.92-3.83(m, 3H),3.76-3.65(m,9H),3.62-3.45(m,13H),3.45-3.37(m,6H),3.28-3. 23(m,2H),3.17-3.09(m,2H),3.07-2.98(m,12H),2.97-2.89(m,2H),2.6 9-2.53(m,2H),2.27(t,J=6.2Hz,6H),2.16-2.07(m,11H),2.06-1.96(m, 17H),1.88(s,9H),1.78(s,9H),1.57-1.36(m,22H),1.26-1.15(m,14H).
[0791] Compound 10-1 (1g, 500.29 μmol) is dissolved in DCM (20mL). DIEA (194mg, 1.50mmol), EDCI (192mg, 1.00mmol) and HOBT (135mg, 1.00mmol) are added to the mixture at 0 ° C. The reaction is stirred for 30min at 0 ° C. Compound 15-3b (238mg, 502.53 μmol) is added to the reaction mixture. The reaction mixture is stirred at room temperature for 2h. The reaction mixture is quenched with saturated NaHCO solution (40mL), extracted with DCM (30mLx2), washed with brine (30mL), dried over NaSO, concentrated under vacuum and purified by rapid AlO column chromatography (0%-6% MeOH), to obtain compound 15-4b (550mg, 44% yield) as a white foamy solid.
[0792] 1H NMR (400MHz, DMSO-d6) δ7.87-7.80(m,4H),7.74(t,J=5.6Hz,3H),7.40-7.36(m,2H),7.31(t,J=7.7Hz,2H),7.27-7.18(m,5H),6.99(s,1H),6.91-6 .87(m,4H),5.22(d,J=3.4Hz,3H),4.96(dd,J=11.3,3.4Hz,3H),4.66-4.6 2(m,1H),4.48(d,J=8.4Hz,3H),4.05-3.98(m,9H),3.92-3.83(m,3H),3.7 5-3.67(m,9H),3.57-3.47(m,11H),3.46-3.36(m,6H),3.34-3.27(m,4H), 3.23-3.09(m,2H),3.07-2.98(m,12H),2.85(s,2H),2.46-2.31(m,2H),2. 30-2.24(m,6H),2.18-2.12(m,2H),2.09(s,9H),2.06-2.01(m,8H),1.99( s,9H),1.88(s,9H),1.77(s,9H),1.55-1.37(m,22H),1.33-1.14(m,14H).
[0793] Example 16
[0794]
[0795] Compound 16-1:
[0796] Compound 6-8 (190mg, 0.403mmol) and compound 10-1 (809mg, 0.403mmol) are dissolved in DCM (10mL), then DIEA (156.35mg, 1.21mmol), EDCI (154.61mg, 0.81mmol) and HOBT (108.97mg, 0.81mmol) are added to the mixture. The reaction is stirred at room temperature for 2h. Reactant mixture is saturated with NaHCO solution (40mL) is quenched, extracted with DCM (30mLx2), washed with salt water (30mL), through Na sO dried, concentrated under vacuum and passed through fast Al o column chromatography purification (0%-10% MeOH), to obtain compound 16-1 (772mg, 77% yield) as white foam solid.
[0797] C 121 H 179 N 11 O 42Calculated mass: 2458.22; Found: 1079.2 [M-DMTr+2H] 2+ ,ESI.
[0798] 1 H NMR (400MHz, DMSO-d6) δ7.85-7.82(m,6H),7.75-7.72(m,3H),7.38-7.36(m,2H),7.29-7.27(m,2H),7.25-7.22(m,5H),6.98(s,1 H),6.87(d,J=8.0Hz,4H),5.21(d,J=4.0Hz,3H),4.97(dd,J=3.2,8.0Hz,3H),4.80-4.70(m,1H),4.48(d,J=8.4Hz,3H),4.02-4.0 1(m,11H),3.88-3.86(m,5H),3.73-3.69(m,9H),3.55-3.52(m,12H),3.46-3.36(m,5H),3.17(d,J=5.2Hz,1H),3.04-3.00(m,14H ),2.29-2.26(m,10H),2.10-2.07(m,8H),2.06-2.02(m,19H),1.99(s,9H),1.77(s,9H),1.52-1.46(m,22H),1.45-1.22(m,12H).
[0799] Example 17
[0800]
[0801] Compound 17-1:
[0802] Compound 11-11 (1.5 g, 0.78 mmol), DIEA (302.32 mg, 2.35 mmol), HOBT (212.11 mg, 1.57 mmol) and EDCI (300.92 mg, 1.57 mmol) were dissolved in DCM (15 mL) at 0 ° C, then compound 3-12 (493.56 mg, 0.78 mmol) was added, and the mixture was stirred at room temperature for 1 h. LC-MS showed complete conversion. The reaction mixture was diluted by adding DCM (20 mL), washed with NaHCO (saturated aqueous, 50 mL) and water (50 mL), concentrated and purified by preparative HPLC (C18 column, ACN / water) to obtain compound 17-1 (1.14 g, 58% yield).
[0803] C 129 H 193 N 11 O39 Calculated mass: 2520.35, found: 1109.35 (M-DMTr+2H) 2+ ,ESI.
[0804] 1 H NMR (400MHz, DMSO-d6) δ7.83(d,J=9.2Hz,4H),7.73(t,J=9.2Hz,3H),7.47-7.39(m,3H),7.33-7.19(m,7H),6.88( d,J=8.92Hz,4H),5.21(d,J=3.3Hz,3H),4.98-4.94(m,3H),4.49-4.42(m,5H),4.02(s,9H),3.91-3.86(m,5H),3.7 3-3.68(m,9H),3.43-3.39(m,5H),3.34-3.30(m,3H),3.02-2.99(m,10H),2.87(s,4H),2.34-2.33(m,2H),2.25-2. 21(m,6H),2.10(s,9H),2.10-2.08(m,8H),2.0(s,9H),1.99(s,3H),1.89(s,9H),1.77(s,9H),1.45-1.24(m,64H).
[0805] Example 18
[0806]
[0807] Compound 18-1:
[0808] DIEA (193.61mg, 1.85mmol, 0.32mL), EDCI (191.45mg, 0.99mmol) and HOBT (134.95mg, 0.99mmol) are added to a solution of compound 11-11 (1.01g, 0.45mmol) in DCM (20mL) at 0°C. The reaction is stirred for 30min at 0°C. Compound 4-10 (300mg, 0.49mmol) is added to the reaction mixture. The reaction mixture is stirred at room temperature for 2h. The reaction mixture is quenched with saturated NaHCO solution (40mL), extracted with DCM (30mLx2), washed with brine (30mL), dried over NaSO, concentrated under vacuum and purified by rapid AlO column chromatography (0%-8%MeOH), to give compound 18-1 (500mg, 46% yield) as a white foam solid.
[0809] C 127 H 189 N 11O 39 Calculated mass: 2493.31; Found: 1096.7 [M-DMTr+2H] 2+ ,ESI.
[0810] 1 H NMR (400MHz, DMSO-d6) δ7.84-7.78(m,2H),7.72(t,J=5.4Hz,3H),7.45(br,1H),7.40-7.39(m,2H),7.33-7.30(m,2H),7.28-7.20(m ,5H),5.22(d,J=3.4Hz,3H),4.99-4.95(m,3H),4.64-4.62(m,3H),4.49(d,J=8.4Hz,2H),4.03(s,9H),3.91-3.84(m,5H),3.74(s,6 H),3.72-3.68(m,3H),3.45-3.41(m,2H),3.40-3.34(m,4H),3.28-3.16(m,4H),3.01-2.99(m,11H),2.85-2.67(m,4H),2.34-2.32( m,2H),2.27-2.22(m,6H),2.07-2.00(m,17H),1.89(s,9H),1.78(s,9H),1.64-1.56(m,4H),1.55-1.34(m,36H),1.28-1.21(m,16H).
[0811] Example 19
[0812]
[0813] Compound 19-1:
[0814] Compound 11-11 (1.59g, 832.24 μmol) (3.2g, 7.16mmol) and compound 5-9 (500mg, 832.24 μmol) are dissolved in DCM (50mL).DIEA (215.12mg, 1.66mmol, 289.92 μL), EDCI (239.31mg, 1.25mmol) and HOBT (112.45mg, 832.24 μmol) are added to the mixture.The reaction is stirred at room temperature overnight.Reaction mixture is quenched with water (40mL), extracted with DCM (50mLx2), washed with salt water (50mL), through Na2SO4, dried, concentrated under vacuum, and purified by HPLC, to give compound 19-1 (840mg, 36% yield).
[0815] C 127 H189 N 11 O 39 Calculated mass value: 2492.3; Found value: 1258.4 [M+2Na] 2+ ,ESI.
[0816] 1 H NMR (400MHz, DMSO-d6) δ7.85-7.71(m,7H),7.49(s,1H),7.37-7.20(m,9H),6.82-6. 87(m,J=8.8Hz,4H),5.22(d,J=3.2Hz,3H),4.97(d,J=11.6Hz,3H),4.49-4.46(m,6H ),4.05(s,9H),3.91-3.85(m,5H),3.77-3.62(m,11H),3.41(s,6H),3.01-2.71(m,1 4H),2.32-2.25(m,6H),2.11-1.78(m,48H),1.62-1.34(m,37H),1.26-1.21(m,20H).
[0817] Example 20
[0818]
[0819]
[0820] Compound 20-1a:
[0821] Compound 11-11 (554mg, 289.73 μmol) is dissolved in DCM (20mL). DIEA (112mg, 869.18 μmol), EDCI (222mg, 1.16mmol) and HOBT (157mg, 1.16mmol) are added to the mixture at 0 ° C. The reaction is stirred for 30min at 0 ° C. Compound 7-9a (170mg, 289.73 μmol) is added to the reaction mixture, and the mixture is stirred at room temperature for 2h. The reaction is saturated with NaHCO solution (40mL) quenched, extracted with DCM (30mLx2), washed with brine (30mL), through Na sO dried, concentrated and purified by preparative HPLC (C18 posts, ACN / water), to obtain compound 20-1a (640mg, 89% yield) as a white foam solid.
[0822] 1H NMR (400MHz, DMSO-d6) δ7.86-7.76(m,4H),7.72(t,J=5.4Hz,3H),7.49-7.42(m,1H),7.38(d,J=8.6Hz,2H),7.31(t,J=7.7Hz ,2H),7.27-7.19(m,5H),6.88(d,J=8.9Hz,4H),5.21(d,J=3.4Hz,3H),4.96(dd,J=11.2,3.4Hz,3H),4.65(t,J=5.0Hz,1H),4. 50-4.41(m,5H),4.05-3.99(m,9H),3.91-3.82(m,5H),3.76-3.66(m,9H),3.49-3.36(m,6H),3.32-3.28(m,1H),3.23-3.09(m ,2H),3.08-2.91(m,10H),2.84(s,2H),2.44-2.21(m,8H),2.20-1.92(m,30H),1.88(s,9H),1.77(s,9H),1.70-1.08(m,54H).
[0823] Compound 20-1b:
[0824] Compound 11-11 (1.3 g, 681.71 μmol) was dissolved in DCM (20 mL). DIEA (176 mg, 1.36 mmol), EDCI (261 mg, 1.36 mmol) and HOBT (138 mg, 1.02 mmol) were added to the mixture at 0 °C. The reaction was stirred at 0 °C for 30 min. Compound 7-9b (400 mg, 681.71 μmol) was added to the reaction mixture. The reaction mixture was stirred at room temperature for 2 h.
[0825] The reaction mixture was quenched with saturated NaHCO3 solution (40 mL), extracted with DCM (30 mL×2), washed with brine (30 mL), dried over Na2SO4, concentrated and purified by preparative HPLC (C18 column, ACN / water) to give compound 20-1b (610 mg, 36% yield) as a white foamy solid.
[0826] 1H NMR (400MHz, DMSO-d6) δ: 7.87-7.76 (m, 4H), 7.72 (t, J = 5.3Hz, 3H), 7.46 (s ,1H),7.35(d,J=7.4Hz,2H),7.28(t,J=7.6Hz,2H),7.25-7.18(m,5H),6.86 (d,J=8.9Hz,4H),5.21(d,J=3.4Hz,3H),4.96(dd,J=11.2,3.4Hz,3H),4.6 2(t,J=5.0Hz,1H),4.50-4.38(m,5H),4.07-3.98(m,9H),3.92-3.82(m,5H) ,3.75-3.66(m,9H),3.51-3.36(m,6H),3.29-3.23(m,2H),3.15-3.07(m,2 H),3.01-2.94(m,10H),2.93-2.88(m,2H),2.87-2.78(m,2H),2.68-2.60(m ,1H),2.37-2.23(m,2H),2.29-2.19(m,4H),2.13-2.08(m,10H),2.07-1.98 (m,18H),1.88(s,9H),1.77(s,9H),1.71-1.58(m,6H),1.53-1.13(m,48H).
[0827] Example 21
[0828]
[0829] Compound 21-1:
[0830] Compound 11-11 (1.76 g, 920.31 μmol), HOBt (248.70 mg, 1.84 mmol), EDCI (529.27 mg, 2.76 mmol) were dissolved in DCM (20 mL). The mixture was stirred for 30 min, and then compound 8-9 (540 mg, 920.31 μmol) was added. The reaction mixture was stirred for another 2 hours, and then concentrated and purified by preparative HPLC to give compound 21-1 (1.2 g, 53% yield).
[0831] C 126 H 187 N 11 O 39 Calculated mass: 2478.3; Found: 1089.6 [M-DMTr+2H] 2+ ,ESI.
[0832] 1H NMR (400MHz, DMSO-d6) δ7.84-7.80(m,4H),7.72(t,J=5.4Hz,3H),7.39(s,1H),7.40-7.37(m,2H),7.31(t,J=7.7Hz,2H),7.27-7.20(m,5H),6.9 8(d,J=8.9Hz,4H),5.22(d,J=3.4Hz,3H),4.97(dd,J=3.4,7.8Hz,3H),4.67(t,J=4.8Hz,1H),4.48(d,J=8.5Hz,3H),4.47-4.42(m,2H),4.05-3.9 8(m,9H),3.92-3.83(m,5H),3.73(s,6H),3.72-3.67(m,3H),3.55-3.45 (m,2H),3.44-3.35(m,5H),3.05-2.93(m,11H),2.91-2.80(m,3H),2.65 -2.55(m,2H),2.38-2.20(m,9H),2.10(s,9H),2.08-2.01(m,9H),2.00( s,9H),1.89(s,9H),1.78(s,9H),1.69-1.52(m,6H),1.47-0.98(m,48H).
[0833] Example 22
[0834]
[0835] Compound 22-1:
[0836] Compound 6-10 (410mg.0.71mmol) and compound 11-11 (1.34g, 0.71mmol) are dissolved in DCM (60mL), then DIEA (453.09mg, 3.51mmol), EDCI (299.57mg, 1.75mmol) and HOBT (236.85mg, 1.75mmol) are added in solution. Reactant mixture is stirred at room temperature for 2h.Saturated NaHCO for reaction is quenched by solution (100mL), extracted with DCM (60mLx3), washed with salt water (60mL), through NaSODry, concentrated under vacuum and passed through fast AlOColumn chromatography purification (0%-20% MeOH) to give compound 22-1 (1.2g, 69% yield) in white foam solid.
[0837] C 126 H 185 N 11 O 39Calculated mass: 2476.28; Found: 1088.2 [M-DMTr+2H] 2+ ,ESI.
[0838] 1 H NMR (400MHz, DMSO-d6) δ7.85-7.81(m,3H),7.75-7.72(m,3H),7.47(s,H),7.39-7.37(m,2H),7.32-7.25(m,2H),7.24-7.19(m,5 H),6.88(d,J=8.84Hz,4H),5.22(d,J=3.4Hz,2H),4.97(d,J=11.2Hz,3H),4.75(t,J=4.4Hz,1H),4.50-4.48(m,5H),4.03(s,11H ),3.94-3.80(m,7H),3.77-3.66(m,9H),3.50-3.41(m,6H),3.02-3.00(m,12H),2.92-2.79(m,2H),2.43-2.30(m,2H),2.29-2.2 2(m,2H),2.21-2.19(m,3H),2.11-2.08(m,11H),2.05-2.02(m,8H),2.00(s,9H),1.90(s,9H),1.78(s,9H),1.62-1.23(m,48H).
[0839] Example 23
[0840]
[0841] Compound 23-1:
[0842] A solution of N-Boc-4-piperidone (5 g, 25.09 mmol), malononitrile (2.49 g, 37.64 mmol), AcNH2 (3.87 g, 50.19 mmol) and AcOH (4.52 g, 75.28 mmol) in toluene (50 mL) was stirred at 110 ° C. for 2 h. LC-MS showed complete conversion. The reaction mixture was washed with water (50 mL), dried over Na2SO4, concentrated and purified by silica gel column (0%-10% EA in PE) to give compound 23-1 (6.18 g, 98% yield) as a gum.
[0843] C 13 H 17 Calculated value of O2N3 mass: 247.1; Measured value: 246.2 [MH] - ,ESI.
[0844] 1 H NMR (400MHz, DMSO-d6) δ3.53 (t, J = 11.6 Hz, 4H), 2.69 (d, J = 11.6 Hz, 4H), 7.41 (t, J = 7.3 Hz, 2H), 1.427 (s, 9H).
[0845] Compound 23-2:
[0846] A solution of compound 23-1 (7.6 g, 30.73 mmol) in MeOH (76 mL) was stirred at 0 ° C. NaBH4 (1.16 g, 30.73 mmol) was added to the stirred solution in batches and stirred for 20 min. The mixture was concentrated in vacuo. The residue was distributed between ethyl acetate (250 mL) and water (150 mL), and the ethyl acetate extract was washed with brine (100 mL), dried over sodium sulfate and concentrated in vacuo. The residue was purified by column chromatography, eluted with PE / EA=1 / 5, to obtain compound 23-2 (4.6 g, 60% yield) in a jelly-like state.
[0847] C 13 H 19 Calculated value of O2N3 mass: 249.2; Measured value: 248.3 [MH] - ,ESI.
[0848] 1 H NMR (400MHz, DMSO-d6) δ4.04-4.01(m,2H),2.75(s,2H),2.31-2.27(m,1H),1.82-1.78(m,2H),1.04(s,9H),1.27-1.16(m,3H).
[0849] Compound 23-3:
[0850] A mixture of compound 23-2 (25 g, 100.28 mmol), tert-butyl 3-bromopropionate (41.93 g, 200.56 mmol), t-BuOK (22.50 g, 200.56 mmol) and KI (33.29 g, 200.56 mmol) in DMSO (250 mL) was stirred at 60 ° C overnight. LC-MS showed complete conversion. The mixture was concentrated in vacuo. The residue was distributed between ethyl acetate (100 mL × 3) and water (150 mL × 3), and the ethyl acetate extract was washed with brine (100 mL), dried over sodium sulfate and concentrated in vacuo. The residue was purified by column chromatography, eluted with PE / EA=10 / 1, to obtain compound 23-3 (32.87 g, 87% yield) as a jelly.
[0851] C20 H 31 Calculated mass of O4N3: 377.2; Found: 319.4 [M-Boc+MeCN+H] + ,ESI.
[0852] 1 H NMR(400MHz,DMSO-d6)δ4.06(d,J=11.2Hz,2H),2.75(s,2H),2.55-2.53(m,1H),2.3 5-2.31(m,3H),1.89(d,J=12.4Hz,2H),1.43(s,9H),1.41(s,9H),1.27-1.19(m,3H).
[0853] Compound 23-4:
[0854] Cobalt chloride hexahydrate (40.34 g, 169.55 mmol) was added to a solution of compound 23-3 (16 g, 42.39 mmol) in MeOH (400 mL), and then sodium borohydride (32.07 g, 847.73 mmol) was slowly added to the reaction mixture at -20 ° C and stirred for 1 h. The mixture was then stirred at room temperature for 1 h. The reaction mixture was concentrated to dryness and azeotropically dried with DMF to give crude compound 23-4, which was used directly in the next step without further purification.
[0855] C 20 H 39 Calculated mass of O4N3: 385.5; Found: 386.5 [M+H] + ,ESI.
[0856] Compound 23-5:
[0857] A solution of Z-6-aminocaproic acid (27.53 g, 103.75 mmol), TEA (12.6 g, 124.50 mmol), HATU (46.97 g, 124.50 mmol) in DMF (240 mL) was stirred at room temperature for 30 min, compound 23-4 (16 g, 41.50 mmol) was added and stirred at room temperature overnight. LC-MS showed complete conversion. Water (50 mL) and EA (50 mL) were added to the reaction mixture. The mixture was filtered, and the filtrate was distributed between ethyl acetate (100 mL × 3) and water (150 mL × 3), and the ethyl acetate extract was washed with brine (100 mL), dried over sodium sulfate and concentrated in vacuo. The residue was purified by preparative HPLC (C18 column, ACN / water) to obtain compound 23-5 (8.3 g, 23% yield) as a jelly.
[0858] C 48 H 72 O 11 Calculated mass of N4: 879.5; Found: 880.1 [M+H] + ,ESI.
[0859] 1 H NMR (400MHz, DMSO-d6) δ7.73(t,J=12.4Hz,2H),7.38-7.30(m,10H),7.23(t,J=10.8Hz,2H),5.00(s,4H),4.06-3.60( m,4H),3.00-2.97(m,8H),2.23-2.19(m,4H),1.99(s,2H),1.58-1.48(m,6H),1.42-1.38(m,25H),1.25-1.23(m,4H).
[0860] Compound 23-6:
[0861] A mixture of compound 23-5 (3.8 g, 4.31 mmol), NH .H O (3.5 mL) and Pd / C (760 mg) in MeOH (38 mL) was stirred at room temperature under a hydrogen atmosphere for 2 h. LC-MS showed complete conversion. The mixture was filtered and the filtrate was concentrated in vacuo to give crude compound 23-6, which was used directly in the next step without further purification.
[0862] C 32 H 60 Calculated value of N4O7 mass: 611.8; Found: 612.8 [M+H] + ,ESI.
[0863] Compound 23-7:
[0864] A mixture of compound 1-4 (2.46 g, 5.49 mmol), TEA (757.89 mg, 7.49 mmol) and HATU (2.35 mg, 6.24 mmol) in DCM (15 mL) was stirred at room temperature for 30 min. Compound 23-6 (1.53 g, 2.5 mmol) was added, and the mixture was stirred at room temperature overnight. LC-MS showed complete conversion. The reaction mixture was diluted by adding DCM (20 mL), then washed with water (50 mL), concentrated and purified by preparative HPLC (C18 column, ACN / water) to obtain compound 23-7 (3.14 g, 85% yield).
[0865] 1H NMR(400MHz,DMSO-d6)δ7.82(d,J=9.2Hz,2H),7.71(s,4H),5.52(d,J=0.4Hz,2H),4.99-4 .95(m,2H),4.48(d,J=8.8Hz,2H),4.03(s,8H),3.95-3.84(m,2H),3.72-3.70(m,2H),3.4 4-3.38(m,2H),3.01-2.99(m,8H),2.23-2.19(m,2H),2.11-2.07(m,10H),2.05-2.00(m,1 0H),1.90(s,6H),1.78(s,6H),1.58-1.49(m,14H),1.39-1.38(m,25H),1.24-1.23(m,8H).
[0866] Compound 23-8:
[0867] A solution of compound 23-7 (3.0 g, 2.04 mmol) and TFA (12 mL) in DCM (30 mL) was stirred at room temperature for 4 h. LC-MS showed complete conversion. The solution was concentrated in vacuo and then basified by adding TEA. Compound 23-8 was used directly in the next step without further purification.
[0868] C 61 H 99 O 24 Calculated mass of N7: 1313.4; Found: 1314.4 [M+H] + ,ESI.
[0869] Compound 23-9:
[0870] Compound 1-7 (2.68 g, 2.04 mmol), TEA (412.62.89 mg, 4.08 mmol) and HATU (769.19 mg, 2.04 mmol) in DCM (30 mL) were stirred at room temperature for 4 h. The solution was then added to compound 23-8 (2.68 g, 2.04 mmol) and stirred at room temperature overnight. LC-MS showed complete conversion. The reaction mixture was diluted by adding DCM (20 mL), washed with water (50 mL), concentrated and purified by preparative HPLC (C18 column, ACN / water) to obtain compound 23-9 (1.76 g, 47% yield).
[0871] C 86 H 137 O 35 Calculated mass of N9: 1857.0; Found: 929.0 [M+2H] 2+ ,ESI.
[0872] 1 H NMR(400MHz, DMSO-d6)δ7.94(d,J=9.2Hz,2H),7.88-7.79(m,6H),5.21(d,J=3.2Hz,3H),4. 99-4.95(m,3H),4.51-4.48(m,4H),4.05-4.00(m,9H),3.92-3.84(m,4H),3.73-3.37(m,3H) ,2.99(s,10H),2.81(t,J=23.2Hz,1H),2.48-2.44(m,2H),2.34-2.16(m,6H),2.11-2.09(m, 13H),2.05-2.00(m,16H),1.89(s,9H),1.78(s,9H),1.49-1.35(m,31H),1.24-1.23(m,6H).
[0873] Compound 23-10:
[0874] A mixture of compound 23-9 (1.76 g, 0.94 mmol), DIEA (367.47 mg, 2.84 mmol), HOBT (256.12 mg, 1.90 mmol) and EDCI (363.37 mg, 1.90 mmol) in DCM (20 mL) was stirred at 0 ° C for 1 h, and then compound 11-2 (542.80 mg, 0.94 mmol) was added. The mixture was stirred at room temperature overnight. LC-MS showed complete conversion. The reaction mixture was diluted by adding DCM (20 mL), washed with NaHCO (saturated aqueous, 50 mL) and water (50 mL), concentrated and purified by preparative HPLC (C18 column, ACN / water) to obtain compound 23-10 (1.07 g, 47% yield).
[0875] 1H NMR(400MHz,DMSO-d6)δ7.83(d,J=9.2Hz,3H),7.76-7.65(m,6H),7.40-7.30(m,4 H),7.26-7.22(m,5H),6.92-6.89(m,4H),5.22(d,J=0.8Hz,3H),4.99-4.95(m,3H) ,4.65(d,J=10.4Hz,1H),4.49(d,J=8.4Hz,4H),4.03-3.98(m,10H),3.91-3.89(m, 4H),3.74-3.67(m,11H),3.51(s,1H),3.41-3.39(m,5H),3.01-2.92(m,14H),2.27 -2.25(m,14H),2.05-2.02(m,7H),2.00-1.94(m,12H),1.78(s,9H),1.49-1.37(m,33H),1.24-1.22(m,11H).
[0876] Example 24
[0877]
[0878] Compound 24-1:
[0879] 4-pyridylacetonitrile (5g, 42.32mmol), N-Cbz-4-iodopiperidine (21.91g, 63.49mmol) and KOH (4.75g, 84.64mmol) were dissolved in DMF (50mL). The reaction mixture was stirred at room temperature overnight. LC-MS showed complete conversion. The residue was distributed between ethyl acetate (100mL×2) and water (80mL×3), and the ethyl acetate extract was washed with brine (100mL), dried over sodium sulfate and concentrated in vacuo. The residue was purified by column chromatography, eluted with DCM / MeOH=20 / 1, to obtain compound 24-1 (11.3g, 80% yield) as a light brown oil.
[0880] C 20 H 21 Calculated value of N3O2 mass: 335.4; Found: 336.2 [M+H] + ,ESI.
[0881] 1H NMR (400MHz, DMSO-d6) δ8.62-8.61(m,2H),7.40-7.31(m,7H),5.06(s,2H),4.35(d,J=7.2Hz, 1H),4.34-4.00(m,2H),2.75(s,2H),2.12-2.06(m,1H),1.64-1.53(m,2H),1.24-1.14(m,2H).
[0882] Compound 24-2:
[0883] KI (2.97 g, 17.89 mmol) and NaH (858.6 mg, 35.78 mmol) in anhydrous THF (10 mL) are cooled at 0 ° C under N2 atmosphere for 10 min. Compound 24-1 (3 g, 8.94 mmol) added in anhydrous THF (15 mL) is stirred for 30 min. Then N- (chloromethyl) benzyl carbamate (2.14 g, 10.73 mmol) is added in anhydrous THF (5 mL) and stirred overnight at room temperature under N2 atmosphere. The mixture is quenched with water and extracted with ethyl acetate (50 mLx3). The combined organic layer is washed with brine (60 mL), dried over anhydrous MgSO4, and concentrated in vacuo. The residue is purified by column chromatography, eluted with dichloromethane / methanol 4: 1, to obtain compound 24-2 (1.8 g, 40% yield) as a yellow oil.
[0884] C 29 H 30 Calculated value of N4O4 mass: 498.2; Found: 499.2 [M+H] + ,ESI.
[0885] 1 H NMR (400MHz, DMSO) δ8.61 (d, J = 5.2Hz, 2H), 7.52-7.57 (m, 1H), 7.44-7.22 (m, 12H),5.06(s,2H),5.03-4.91(m,2H),4.14(d,J=13.6Hz,1H),3.97-3.89(m, 2H),3.73-3.68(m,1H),2.89-2.68(m,2H),2.39-2.34(t,J=11.6Hz,1H),2.0 7(d,J=11.8Hz,2H),1.31-1.21(m,1H),1.18-1.12(m,1H),1.04-0.94(m,1H).
[0886] Compound 24-3:
[0887] CoCl2.6H2O (2.97 g, 17.89 mmol) and compound 24-2 (5 g, 10.03 mmol) in anhydrous MeOH (50 mL) were cooled at -50 ° C for 20 min under N2 atmosphere. LiBH4 (50 mmol, 2M, 25 mL) in THF was added dropwise at -50 ° C and stirred for 3 h, then anhydrous MeOH (50 mL) was added dropwise at -50 ° C. The mixture was warmed to room temperature and stirred overnight under N2 atmosphere. The mixture was concentrated in vacuo. The residue was distributed between dichloromethane (250 mL) and water (150 mL), and the dichloromethane extract was washed with brine (100 mL), dried over sodium sulfate and concentrated in vacuo. The residue was purified by column chromatography, eluted with DCM / MeOH=15 / 1, to obtain compound 24-3 (1.8 g, 40% yield) as a light yellow solid.
[0888] C 29 H 34 Calculated value of N4O4 mass: 502.2; Found: 503.2 [M+H] + ,ESI.
[0889] 1 H NMR (400MHz, DMSO-d6) δ8.48(d,J=5.2Hz,2H),7.50-7.47(m,1H),7.37-7.25(m,12H),5.02(s,2H),4.99(s,2H),3.96(d,J=12.4Hz,2H),3.69-3 .58(m,2H),3.16(d,J=14Hz,1H),2.94(d,J=13.2Hz,1H),2.63(s,2H),1 .93(s,2H),1.77-1.68(m,2H),1.26(d,J=8.8Hz,1H),0.86-0.77(m,2H).
[0890] Compound 24-4:
[0891] Compound 24-3 (2.1 g, 4.18 mmol), 5-(tert-butoxy)-5-oxopentanoic acid (943.7 mg, 5.01 mmol), HATU (3.15 g, 8.36 mmol) and Et3N (1.27 g, 12.53 mmol) were dissolved in DCM (20 mL). The reaction mixture was stirred at room temperature for 2 h. The reaction mixture was then diluted with CH2Cl2 (50 mL). The organic layer was washed with water (50 mLx2), dried over sodium sulfate, and concentrated in vacuo. The residue was purified by column chromatography, eluted with DCM / MeOH=20 / 1 to obtain compound 24-4 (2.23 g, 81% yield) as a light yellow solid.
[0892] C 38 H 48 Calculated mass of N4O7: 672.3; Found: 673.3 [M+H] + ,ESI.
[0893] 1 H NMR (400MHz, DMSO-d6) δ8.48(d,J=5.2Hz,2H),7.83-7.79(m,1H),7.36-7.21(m,13H),5.01(s,2H),4.98(s,2H),3.96(d,J =12.4Hz,2H),3.65-3.52(m,4H),2.68-2.62(m,2H),2.12-2.09(m,4H),1.77-1.69(m,5H),1.35(s,9H),0.76-0.64(m,2H).
[0894] Compound 24-5:
[0895] PtO2 (1.21 g, 5.36 mmol) and compound 24-4 (1.8 g, 2.67 mmol) in HOAc (10 mL) were stirred at room temperature overnight under H2 atmosphere. The mixture was then filtered and the solvent was evaporated in vacuo to give the crude product 24-5, which was used directly in the next step.
[0896] C 22 H 42 Calculated value of N4O3 mass: 410.3; Found: 411.3 [M+H] + ,ESI.
[0897] Compound 24-6:
[0898] A mixture of compound 1-7 (4.76 g, 8.52 mmol), TEA (1.48 g, 14.6 mmol), HATU (2.94 g, 7.8 mmol) in DCM (15 mL) was stirred at room temperature for 30 min, then compound 24-5 (1 g, 2.44 mmol) was added and stirred at room temperature for 2 h. LC-MS showed complete conversion. The reaction mixture was diluted with additional DCM (20 mL), washed with water (50 mL), concentrated and purified by preparative HPLC (C18 column, ACN / water) to obtain compound 24-6 (1 g, 20% yield) as a white solid.
[0899] C 97 H 156 N 10 O 36Calculated mass: 2037.07; Found: 1019.1 [M+2H] 2+ ,ESI.
[0900] 1 H NMR (400MHz, DMSO-d6) δ7.80(d,J=9.2Hz,3H),7.73-7.63(m,6H),5.22(d,J=3.2Hz,3H),4.97(dd,J=11.2,3.2H z,3H),4.50-4.47(m,5H),4.08-4.01(m,9H),3.91-3.86(m,5H),3.84-3.70(m,3H),3.43-3.40(m,3H),3.07-3.0 5(m,3H),2.81(d,J=9.2Hz,2H),2.68-2.67(m,1H),2.34-2.23(m,12H),2.18(s,9H),2.16-2.11(m,5H),2.03(s, 9H),1.90(s,9H),1.78(s,9H),1.72-1.67(m,14H),1.54-1.48(m,18H),1.43-1.37(m,13H),1.28-1.18(m,12H).
[0901] Compound 24-7:
[0902] A solution of compound 24-6 (1.0 g, 0.49 mmol) and TFA (12 mL) in DCM (30 mL) was stirred at room temperature for 4 h. LC-MS showed complete conversion. The solution was concentrated in vacuo and then basified with TEA. The crude compound 24-7 was used directly in the next step without further purification.
[0903] C 93 H 148 N 10 O 36 Calculated mass: 1981.0; Found: 991.4 [M+2H] 2+ ,ESI.
[0904] Compound 24-8:
[0905] A mixture of compound 24-7 (400 mg, 0.21 mmol), TEA (61.26 mg, 0.61 mmol), HATU (252.26 mg, 0.40 mmol) in DCM (5 mL) was stirred at room temperature for 1 h, then compound 11-2 (115.16 mg, 0.20 mmol) was added and stirred at room temperature overnight. LC-MS showed complete conversion. The reaction mixture was diluted with additional DCM (5 mL), washed with water (20 mL), concentrated and purified by preparative HPLC (C18 column, ACN / water) to obtain compound 24-8 (200 mg, 39% yield) as a white solid.
[0906] 1 H NMR (400MHz, DMSO-d6) δ7.83 (d, J=9.2Hz, 3H), 7.76-7.66 (m, 5H), 7.40-7.3 0(m,4H),7.26-7.22(m,5H),6.92-6.88(m,4H),5.22(d,J=3.2Hz,3H),4.99- 4.95(m,3H),4.66(t,J=5.6Hz,1H),4.48(d,J=8.4Hz,4H),4.43-4.42(m,1H ),4.05-3.97(m,9H),3.91-3.86(m,5H),3.74-3.62(m,11H),3.51(s,1H),3. 43-3.38(m,5H),3.06-2.92(m,13H),2.86-2.82(m,2H),2.34-2.22(m,6H), 2.11(s,9H),2.08-2.06(m,3H),2.05-2.02(m,8H),2.00(s,9H),1.96-1.94( m,3H),1.89(s,9H),1.85-1.82(m,3H),1.78(s,9H),1.72-1.62(m,5H),1.52 -1.42(m,18H),1.39-1.33(m,8H),1.28-1.22(m,9H),0.95(t,J=8.4Hz,1H).
[0907] Example 25
[0908]
[0909] Compound 25-1:
[0910] A solution of N-Boc-piperidine-4-pyrrolecarboxaldehyde (50 g, 234.44 mmol), malononitrile (18.59 g, 281.33 mmol) and diisopropylamine (11.86 g, 117.21 mmol) in H2O (200 mL) and EtOH (800 mL) was stirred at room temperature for 2 h. LC-MS showed complete conversion. The reaction mixture was washed with water (50 mL), dried over Na2SO4, concentrated and purified by silica gel column (0%-50% EA in PE) to give compound 25-1 (30.00 g, 46% yield).
[0911] C 14 H 19 Calculated value of N3O2 mass: 261.1; Measured value: 260.2 [MH] - ,ESI.
[0912] 1 H NMR (400MHz, DMSO-d6) δ7.84 (d, J = 10.2Hz, 1H), 3.97-3.89 (m, 2H), 2.94-2.72 (m, 3H), 1.69-1.59 (m, 2H), 1.45-1.34 (m, 13H).
[0913] Compound 25-2:
[0914] Compound 25-1 (30 g, 114.80 mmol) in MeOH (450 mL) was stirred at -5 °C. NaBH4 (4.34 g, 114.80 mmol) was added to the solution in batches and stirred for 3 h. The mixture was concentrated in vacuo. The residue was distributed between ethyl acetate (250 mL) and water (150 mL), and the ethyl acetate extract was washed with brine (100 mL), dried over sodium sulfate and concentrated in vacuo. The residue was purified by column chromatography, eluted with PE / EA = 3 / 1, to obtain compound 25-2 (19.4 g, 64% yield).
[0915] C 14 H 21 Calculated value of N3O2 mass: 263.2; Measured value: 262.3 [MH] - ,ESI.
[0916] 1H NMR(400MHz,DMSO-d6)δ4.87(t,J=7.6Hz,1H),3.95-3.87(m,2H),2.82-2.61(m,2H ), 1.98 (t, J = 7.2Hz, 2H), 1.70-1.56 (m, 3H), 1.42-1.35 (m, 9H), 1.11-0.98 (m, 2H).
[0917] Compound 25-3:
[0918] A mixture of compound 25-2 (15 g, 56.96 mmol), tert-butyl 3-bromopropionate (17.86 g, 85.44 mmol), t-BuOK (8.31 g, 74.05 mmol) and KI (9.46 g, 56.96 mmol) in DMSO (250 mL) was stirred at room temperature for 3 h. LC-MS showed complete conversion. The mixture was distributed between ethyl acetate (100 mL×3) and water (150 mL×3), and the ethyl acetate extract was washed with brine (100 mL), dried over sodium sulfate and concentrated in vacuo. The residue was purified by column chromatography, eluted with PE / EA=7 / 1, to obtain compound 25-3 (17.4 g, 94% yield).
[0919] C 21 H 33 Calculated value of N3O4 mass: 391.2; Found: 333.3 [M-Boc+MeCN+H] + ,ESI.
[0920] 1 H NMR(400MHz,DMSO-d6)δ3.96-3.87(m,2H),2.76(s,2H),2.55-2.50(m,2H),2.36-2.31(m,2 H), 2.05 (d, J = 6.2Hz, 2H), 1.85-1.74 (m, 3H), 1.42 (s, 9H), 1.39 (s, 9H), 1.21-1.08 (m, 2H).
[0921] Compound 25-4:
[0922] Cobalt chloride hexahydrate (29.17 g, 122.60 mmol) was added to a solution of compound 25-3 (12 g, 30.65 mmol) in MeOH (350 mL), and then sodium borohydride (23.19 g, 613.02 mmol) was slowly added to the reaction mixture at -20 ° C, and stirred for 1 h. The mixture was then stirred at room temperature for 1 h. The reaction mixture was concentrated to dryness and azeotropically dried with DMF. The crude compound 25-4 was used directly in the next step without further purification.
[0923] C 21 H 41 Calculated value of N3O4 mass: 399.3; Found: 400.4 [M+H] + ,ESI.
[0924] Compound 25-5:
[0925] A solution of Z-6-aminocaproic acid (17.52 g, 66.04 mmol), TEA (9.10 g, 90.05 mmol) and HATU (28.31 g, 75.04 mmol) in DMF (240 mL) was stirred at room temperature for 30 min, compound 25-4 (12 g, 30.03 mmol) was added and stirred at room temperature overnight. LC-MS showed complete conversion. Water (50 mL) and EA (50 mL) were added to the reaction mixture. The mixture was filtered, and the filtrate was distributed between ethyl acetate (100 mL × 3) and water (150 mL × 3), and the ethyl acetate extract was washed with brine (100 mL), dried over sodium sulfate and concentrated in vacuo. The residue was purified by preparative HPLC (C18 column, ACN / water) to obtain compound 25-5 (4.08 g, 14% yield).
[0926] C 49 H 75 N5O 10 Calculated mass: 893.6; Found: 894.7 [M+H] + ,ESI.
[0927] 1 H NMR (400MHz, DMSO-d6) δ7.68(t,J=6.1Hz,2H),7.38-7.27(m,10H),7.22(t,J=5.5Hz,2H),4.99(s,4H),3.89-3.79(m,2H),3.00-2.93(m,4H),2.92- 2.85(m,3H),2.73-2.56(m,2H),2.23-2.16(m,2H),2.13-2.06(m,4H),1.6 1-1.42(m,9H),1.42-1.34(m,24H),1.28-1.18(m,4H),1.05-0.99(m,2H).
[0928] Compound 25-6:
[0929] A mixture of compound 25-5 (3.0 g, 3.36 mmol), NH 3 .H 2 O (15 mL) and Pd / C (1.20 g) in MeOH (60 mL) was stirred at room temperature under a hydrogen atmosphere for 4 h. LC-MS showed complete conversion. The mixture was filtered and the filtrate was concentrated in vacuo. The crude compound 25-6 was used directly in the next step without further purification.
[0930] C 33 H 63 Calculated value of N5O6: 625.5; Found: 626.5 [M+H] + ,ESI.
[0931] Compound 25-7:
[0932] A mixture of compound 1-4 (3.30 g, 7.38 mmol), TEA (1.02 g, 10.07 mmol) and HATU (3.04 g, 8.05 mmol) in DCM (15 mL) was stirred at room temperature for 30 min. Compound 25-6 (2.10 g, 3.36 mmol) was added and stirred at room temperature overnight. LC-MS showed complete conversion. The reaction mixture was diluted by adding DCM (20 mL), washed with water (50 mL), concentrated and purified by preparative HPLC (C18 column, ACN / water) to obtain compound 25-7 (3.14 g, 86% yield).
[0933] 1 H NMR(400MHz,DMSO-d6)δ7.82(d,J=9.3Hz,2H),7.74-7.65(m,4H),5.21(d,J=3.4Hz,2H),4.99-4.93(m ,2H),4.48(d,J=8.5Hz,2H),4.05-3.98(m,6H),3.91-3.80(m,4H),3.74-3.67(m,2H),3.44-3.36(m,2H ),3.03-2.95(m,4H),2.91-2.86(m,3H),2.73-2.60(m,2H),2.24-2.17(m,2H),2.13-2.07(m,10H),2. 05-1.98(m,10H),1.89(s,6H),1.71(s,6H),1.61-1.32(m,41H),1.27-1.19(m,4H),1.04-0.99(m,2H).
[0934] Compound 25-8:
[0935] A solution of compound 25-7 (1.0 g, 673.53 μmol) and TFA (10 mL) in DCM (20 mL) was stirred at room temperature for 4 h. LC-MS showed complete conversion. The solution was concentrated in vacuo and then basified with TEA. The crude compound 25-8 was used directly in the next step without further purification.
[0936] C 62 H 101 N7O 24 Calculated mass: 1327.7; Found: 665.0 [M+2H] 2+ ,ESI.
[0937] Compound 25-9:
[0938] A mixture of compound 1-7 (1.43 g, 2.56 mmol), TEA (777 mg, 7.68 mmol) and HATU (1.06 g, 2.82 mmol) in DCM (30 mL) was stirred at room temperature for 30 min. The solution was then added to compound 22-8 (3.4 g, 2.56 mmol) and stirred at room temperature overnight. LC-MS showed complete conversion. The reaction mixture was diluted by adding DCM (20 mL), washed with water (50 mL), concentrated and purified by preparative HPLC (C18 column, ACN / water) to obtain compound 25-9 (2.5 g, 49% yield).
[0939] C 87 H 139 N9O 35 Calculated mass: 1869.9; Found: 936.3 [M+2H] 2+ ,ESI.
[0940] 1H NMR (400MHz, DMSO-d6) δ7.96-7.90(m,2H),7.87-7.75(m,5H),7.71(s,1H),5.21(d,J=3.4Hz,3H),4.99-4.94(m,3 H),4.52-4.47(m,3H),4.32-4.25(m,1H),4.05-3.98(m,9H),3.92-3.82(m,3H),3.80-3.67(m,5H),3.52-3.42(m,4 H),3.03-2.91(m,10H),2.89-2.80(m,2H),2.24(t,J=7.5Hz,2H),2.20-2.13(m,2H),2.13-2.07(m,13H),2.05-1.9 6(m,15H),1.89(s,9H),1.77(s,9H),1.68-1.55(m,4H),1.54-1.32(m,26H),1.28-1.18(m,6H),1.04-0.98(m,2H).
[0941] Compound 25-10:
[0942] The mixture of compound 25-9 (750mg, 400.84 μmol), DIEA (155mg, 1.20mmol), HOBT (217.12mg, 1.60mmol) and EDCI (307.36mg, 1.06mmol) in DCM (20mL) was stirred for 30min, compound 11-2 (229.57mg, 400.84 μmol) was added and stirred at room temperature for 3h. LC-MS shows complete conversion. The reaction mixture is diluted by adding DCM (20mL), washed with NaHCO (saturated aqueous, 30mL) and water (30mL), concentrated and purified by preparative HPLC (C18 column, ACN / water), to obtain compound 25-10 (500mg, 51% yield).
[0943] 1H NMR(400MHz, DMSO-d6)δ7.83(d,J=9.2Hz,3H),7.75-7.65(m,6H),7.41-7.34(m,2H),7.31(t,J=7.1Hz,2H),7.27-7.18(m,5H), 6.93-6.84(m,4H),5.22(d,J=3.0Hz,3H),5.00-4.90(m,3H),4.71-4.56(m,1H),4.48(d,J=8.4Hz,3H),4.28(d,J=10.7Hz,1H),4 .11-3.93(m,10H),3.92-3.82(m,3H),3.77-3.63(m,12H),3.51(s,1H),3.45-3.36(m,6H),3.05-2.79(m,15H),2.28-2.19(m,2H ),2.12-2.08(m,12H),2.06-1.98(m,17H),1.96-1.92(m,3H),1.89(s,9H),1.85-1.80(m,2H),1.77(s,9H),1.60-1.00(m,47H).
[0944] Example 26
[0945]
[0946] Compound 26-1:
[0947] A mixture of 5-(benzyloxy)-5-oxopentanoic acid (0.3 g, 1.35 mmol), compound 11-2 (773.14 mg, 1.35 mmol), DIEA (523.40 mg, 4.05 mmol), EDC (517.56 mg, 2.70 mmol), HOBT (364.81 mg, 2.70 mmol) in DCM (20 mL) was stirred at room temperature for 3 h. LC-MS showed complete conversion. The reaction mixture was diluted by adding DCM (20 mL), washed with NaHCO (saturated aqueous, 150 mL) and water (150 mL), concentrated and purified by column chromatography, eluted with DCM / MeOH=20:1 to obtain compound 26-1 (480 mg, 45% yield).
[0948] C 47 H 56 Calculated value of N2O8 mass: 776.4; Measured value: 799.3 [M+Na] + ,ESI.
[0949] Compound 26-2:
[0950] A mixture of compound 26-1 (0.48 g, 0.629 mmol) and Pd / C (48 mg) in MeOH (20 mL) was stirred at room temperature under H2 for 3 h. LC-MS showed complete conversion. The reaction mixture was concentrated and purified by column chromatography, eluting with DCM / MeOH=10:1 to give compound 26-2 (280 mg, 65% yield).
[0951] C 47 H 56 Calculated value of N2O8 mass: 686.3; Measured value: 725.3 [M+K] + ,ESI
[0952] 1 H NMR(400MHz,DMSO-d6)δ7.79-7.75(m,1H),7.40-7.35(m,2H),7.34-7.30(m,2H),7.27-7.2 0(m,5H),6.92-6.89(m,4H),3.98(s,1H),3.68(d,J=6.4Hz,2H),3.51(s,1H),3.40-3.38(m, 2H),3.00(t,J=6.4Hz,2H),2.93-2.92(m,2H),2.19(t,J=7.4Hz,2H),2.09-2.05(m,2H),2.0 3-1.88(m,4H),1.85-1.80(m,2H),1.71-1.68(m,2H),1.42-1.33(m,4H),1.24-1.18(m,4H).
[0953] Compound 26-3:
[0954] A mixture of compound 26-2 (3.1 g, 6.17 mmol) and Pd / C (2.97 g) in anhydrous MeOH (40 mL) was stirred at room temperature under H overnight. The mixture was filtered, and the filtrate was concentrated under reduced pressure to give crude compound 26-3 (1.4 g, 97% yield) as a white solid, which was used without purification.
[0955] Compound 26-4:
[0956] A mixture of compound 26-3 (1.50 g, 6.40 mmol), compound 1-7 (11.12 g, 19.84 mmol), EDCI (7.34 g, 38.41 mmol), HOBT (5.19 g, 38.41 mmol), DIEA (7.45 g, 57.61 mmol) in anhydrous DCM (50 mL) was stirred at room temperature under N2 atmosphere for 3 h. The mixture was concentrated in vacuo, then extracted with dichloromethane (100 mLx3) and washed with brine (100 mL), dried over sodium sulfate and concentrated in vacuo. The residue was purified by preparative HPLC (C18 column, ACN / water) to obtain compound 26-4 (6 g, 50% yield) as a light yellow solid.
[0957] C 88 H 136 N 10 O 33 Calculated mass: 1860.9; Found: 931.5 [M+2H] 2+ ,ESI.
[0958] Compound 26-5:
[0959] A mixture of compound 26-4 (1.01 g, 0.53 mmol) and PtO2 (0.243 g, 1.07 mmol) in AcOH (20 mL) was stirred overnight under H2. The reaction mixture was filtered and concentrated in vacuo. The residue was then purified by preparative HPLC (C18 column, ACN / water) to obtain compound 26-5 (640 mg, 64% yield) as a white solid.
[0960] C 88 H 142 N 10 O 33 Calculated mass: 1867.0; Found: 934.5 [M+2H] 2+ ,ESI.
[0961] 1H NMR (400MHz, DMSO-d6) δ7.86-7.84(m,3H),7.75-7.73(m,3H),7.68-7.61(m,2H),5.22(d,J=3.3Hz,3H),4.97( q,J=3.3Hz,3H),4.50-4.43(m,4H),4.03(s,9H),3.91-3.84(m,4H),3.75-3.70(m,3H),3.43-3.38(m,11H),3. 06-2.99(m,12H),2.83-2.77(m,1H),2.46-2.42(m,2H),2.27-2.23(m,4H),2.11-2.09(m,13H),2.07-2.00(m, 16H),1.90(s,9H),1.78(s,9H),1.68-1.62(m,5H),1.49-1.46(m,22H),1.39-1.36(m,9H),1.25-1.20(m,9H).
[0962] Compound 26-6:
[0963] A mixture of compound 26-5 (0.543 g, 0.29 mmol), compound 26-2 (200 mg, 2.12 mmol), DIEA (112 mg, 0.87 mmol), EDC (111 mg, 0.58 mmol) and HOBT (80 mg, 0.58 mmol) in DCM (20 mL) was stirred at room temperature for 3 h. LC-MS showed complete conversion. The reaction mixture was diluted by adding DCM (20 mL), washed with NaHCO (saturated aqueous, 150 mL) and water (150 mL), concentrated and purified by preparative HPLC (C18 column, ACN / water) to obtain compound 26-6 (0.15 g, 20% yield).
[0964] Calculated mass of C121H179O39N11: 3411.7; Found: 1117.2 [M-DMTr+2H] 2+ ,ESI.
[0965] 1H NMR(400MHz,DMSO-d6)δ7.84(d,J=9.3Hz,3H),7.78-7.72(m,5H),7.65(s,2 H),7.40-7.37(m,2H),7.32(t,J=7.1Hz,2H),7.26-7.20(m,6H),6.92-6.89( m,4H),5.22(d,J=3.4Hz,2H),4.98-4.95(m,2H),4.65(t,J=5.0Hz,1H),4.4 8(d,J=8.4Hz,2H),4.45-4.42(m,2H),4.05-4.03(m,9H),3.98(s,2H),3.91- 3.84(m,5H),3.74(s,7H),3.71-3.67(m,5H),3.51(s,1H),3.43-3.39(m,6H ),3.07-2.97(m,13H),2.92(s,2H),2.81-2.78(m,2H),2.34-2.22(m,8H),2. 13-2.07(m,16H),2.05-1.96(m,20H),1.89(s,11H),1.79-1.77(m,10H),1.7 0-1.62(m,7H),1.47-1.41(m,23H),1.40-1.35(m,14H),1.24-1.22(m,14H).
[0966] Example 27
[0967]
[0968] Compound 27-1:
[0969] By compound 11-6 (15g, 45.81mmol), Boc-8-aminocaprylic acid (13.07g, 50.39mmol), Et3N (6.95g, 68.72mmol) and HATU (19.01g, 50.39mmol) mixture is stirred at room temperature for 1h.Cieselguhr (15g), water (300mL) and EA (400mL) are added to the mixture.After stirring the reaction for 30min, filter.Filtrate is extracted with EA (400mL).Organic phase is washed with water (500mLx2) and salt solution (300mL), through Na2SO4 drying, concentrated under vacuum and purified by flash silica gel column chromatography (0%-10%MeOH), to give compound 27-1 (15g, 57% yield).
[0970] C 32 H 48 Calculated mass of N4O5: 568.3; Found: 569.4 [M+H]+ ,ESI.
[0971] 1 H NMR (400MHz, DMSO-d6) δ8.49-8.48(m,4H),7.46-6.77(m,6H),3.89(t,J=6.4Hz,2H),2. 91-2.86(m,2H),2.33-2.29(m,2H),1.98-1.92(m,4H),1.38(s,22H),1.32-1.24(m,6H).
[0972] Compound 27-2:
[0973] PtO2 (8 g, 35.23 mmol) was added to compound 27-1 (14.5 g, 25.49 mmol) in AcOH (120 mL). The reaction was stirred for 88 h under 0.4 MPa hydrogen atmosphere, and then the transparent liquid of the reaction mixture was poured out and concentrated under vacuum. Its pH was adjusted to 7-8 with saturated NaHCO3. The aqueous phase was concentrated under vacuum. THF (300 mL) was added to the residue and stirred for 30 min. The mixture was filtered and concentrated under vacuum to give crude compound 27-2 (15.32 g). 32 H 60 Calculated value of N4O5 mass: 580.5; Found: 581.6 [M+H] + ,ESI.
[0974] Compound 27-3:
[0975] By Boc-6-aminocaproic acid (12.80g, 55.38mmol), HATU (23.87g, 63.29mmol) and TEA (8.0g, 79.11mmol) mixture in DCM (60mL) is stirred at room temperature for 1h.Compound 27-2 (15.32g, 26.37mmol) in DCM (60mL) is added in reaction mixture and stirred at room temperature for 1.5h.Reaction is quenched with water (200mL), extracted with DCM (200mLx3).The organic phase merged is washed with salt water (200mL), through Na2SO4, dried, filtered, concentrated under vacuum and purified by flash silica gel column chromatography (0%-10% MeOH), to give compound 27-3 (23g, 75% yield).
[0976] C 54 H 98 N6O 11 Calculated mass: 1006.7; Found: 907.7 [M+H-Boc] + ,ESI.
[0977] 1 H NMR (400MHz, DMSO-d6) δ7.44-6.76 (m, 4H), 4.46 (d, J = 11.6Hz, 2H), 3.89 (d, J=12.0Hz,2H),3.06-2.86(m,10H),2.40-2.23(m,12H),1.70-1.16(m,68H).
[0978] Compound 27-4:
[0979] Compound 27-3 (10 g, 9.93 mmol) was dissolved in DCM (54 mL), and then TFA (59 mL) was added to the mixture. The reaction was stirred at 30 °C for 3 h. The reaction was concentrated under vacuum without further purification to give compound 27-4 (6.64 g).
[0980] C 35 H 66 Calculated value of N6O5: 650.5; Found: 651.6 [M+H] + ,ESI.
[0981] Compound 27-5:
[0982] A mixture of compound 1-4 (13.32 g, 29.77 mmol), HATU (13.10 g, 34.73 mmol) and TEA (5.02 g, 49.62 mmol, 6.92 mL) in DCM (50 mL) was stirred at room temperature for 2 h. Compound 27-4 was added to the mixture. And the reaction was stirred at room temperature for another 4 h. The reaction was concentrated under vacuum and purified by preparative HPLC to give compound 27-5 (13 g, 67% yield).
[0983] C 92 H 147 N9O 35 Calculated mass: 1938.0; Found: 970.1 [M+2H] 2+ ,ESI.
[0984] 1H NMR(400MHz,DMSO-d6)δ12.01(s,1H),7.86-7.50(m,7H),5.22-4.96(m,6H),4.50-4.48(m,4H),4.03-3.69(m,17H),3. 41-3.32(m,6H),3.01-2.60(m,8H),2.46-2.21(m,4H),2.15-1.78(m,42H),1.68-1.23(m,46H),0.95(t,J=7.6Hz,6H).
[0985] Compound 27-6:
[0986] By compound 27-5 (2.75g, 1.42mmol), DIEA (383.61mg, 2.97mmol, 517.00 μ L), EDCI (426.76mg, 2.23mmol) and HOBT (200.53mg, 1.48mmol) mixture in DCM (30mL) is stirred at room temperature for 30min.Compound 11-2 (0.85g, 1.48mmol) is added to the reaction mixture.The reaction is stirred at room temperature for 2h.The reaction is quenched with water (50mL), extracted with DCM (50mLx2).The organic phase merged is concentrated under vacuum and purified by preparative HPLC to give compound 27-6 (1.2g, 32% yield).
[0987] C 127 H 189 O 39 N 11 Calculated mass value: 2493.9; Found value: 1270.0 [M+2Na] 2+ ,ESI.
[0988] 1 H NMR (400MHz, DMSO-d6) δ7.84-7.72(m,7H),7.44-7.23(m,10H),6.92-6.88(m,4H),5.22(d,J=3.6Hz,3H),4.99-4.95(m,3H),4.66-4 .45(m,6H),4.03-3.69(m,26H),3.41-3.36(m,6H),3.01-2.86(m,14H),2.46-2.21(m,6H),2.15-1.78(m,52H),1.68-1.23(m,52H).
[0989] Example 28
[0990]
[0991]
[0992] Compound 28-1:
[0993] A mixture of 8-(Fmoc-amino)octanoic acid (1.27 g, 3.59 mmol), TEA (495.41 mg, 4.90 mmol) and HATU (1.35 g, 3.59 mmol) in DCM (15 mL) was stirred for 20 min, then compound 2-10 (1.5 g, 3.26 mmol) was added to the reaction mixture and continued to stir for 4 h. The mixture was distributed between DCM (50 mL) and water (35 mL), and the DCM extract was washed with brine (100 mL), dried over sodium sulfate, concentrated in vacuo and purified by flash Al2O3 column chromatography (DCM / MeOH=0%-6%) to give compound 28-1 (600 mg, 23% yield) as a white foamy solid.
[0994] 1 H NMR (400MHz, DMSO-d6) δ7.87(d,J=7.6Hz,2H),7.68(d,J=7.4Hz,2H),7.44-7.35(m,4H),7.34-7.28(m, 4H),7.27-7.17(m,6H),6.89(d,J=7.6Hz,4H),4.64(td,J=5.0,1.6Hz,1H),4.28(d,J=6.9Hz,2H),4.20 (t,J=6.8Hz,1H),3.96(s,1H),3.73(d,J=3.8Hz,6H),3.67(d,J=10.4Hz,2H),3.50(s,1H),3.39(t,J=5 .9Hz,2H),2.96(t,J=6.6Hz,2H),2.91(s,2H),2.06-1.74(m,6H),1.47-1.31(m,4H),1.26-1.13(m,6H).
[0995] Compound 28-2:
[0996] Piperidine (0.4 mL) was added to a solution of compound 28-1 (600 mg, 0.75 mmol) in MeOH (4 mL). After stirring overnight, the mixture was concentrated in vacuo to give crude compound 28-2 (600 mg) as a white solid, which was used without further purification.
[0997] C 35 H 44 Calculated value of N2O5 mass: 600.4; Found: 601.4 [M+H] + ,ESI.
[0998] Compound 28-3:
[0999] Compound 11-11 (1.75g, 915.47 μmol) is dissolved in DCM (30mL). DIEA (355mg, 2.75mmol), EDCI (351mg, 1.83mmol) and HOBT (247mg, 1.83mmol) are added to the mixture at 0 ° C. The reaction is stirred for 30min at 0 ° C. Compound 28-2 (550mg, 915.47 μmol) is added to the reaction mixture. The reaction mixture is stirred at room temperature for 2h. The reaction mixture is quenched with saturated NaHCO solution (40mL), extracted with DCM (30mLx2), washed with brine (30mL), dried over NaSO, concentrated and purified by preparative HPLC (C18 columns, ACN / water), to obtain compound 28-3 (1.1g, 48% yield) as a white foam solid.
[1000] 1 H NMR (400MHz, DMSO-d6) δ7.86-7.76(m,4H),7.73(t,J=5.4Hz,3H),7.46(s,1H),7.40-7.35(m,2H),7.31(t,J=7. 6Hz,2H),7.27-7.18(m,5H),6.93-6.85(m,4H),5.21(d,J=3.4Hz,3H),4.95(dd,J=11.2,3.4Hz,3H),4.65(t,J= 5.1Hz,1H),4.50-4.40(m,5H),4.10-3.94(m,10H),3.93-3.80(m,5H),3.70-3.64(m,11H),3.50(s,1H),3.45-3 .36(m,5H),3.08-3.75(m,14H),2.39-2.20(m,6H),2.15-1.92(m,31H),1.92-1.73(m,21H),1.67-1.13(m,52H).
[1001] Example 29
[1002]
[1003] Compound 29-1:
[1004] The mixture of compound 27-5 (2.74g, 1.41mmol), DIEA (365.70mg, 2.83mmol, 492.86 μ L), EDCI (406.83mg, 2.12mmol) and HOBT (191.17mg, 1.41mmol) in DCM (30mL) was stirred at room temperature for 30min. Compound 28-2 (0.85g, 1.41mmol) was added to the mixture. The reaction was continued to be stirred at room temperature for 2h. The reaction was quenched with water (50mL), extracted with DCM (50mLx2). The organic phase merged was concentrated under vacuum and purified by preparative HPLC to give compound 29-1 (1.1g, 29% yield).
[1005] C 129 H 193 O 39 N 11 Calculated mass: 2520.4; Found: 1284.0 [M+2Na] 2+ ,ESI.
[1006] 1 H NMR(400MHz, DMSO-d6)δ:7.84-7.72(m,7H),7.44-7.23(m,10H),6.92-6.88(m,4H),5.22(d,J=3.6Hz,3H),4.99-4.95(m,3H),4.66- 4.45(m,6H),4.03-3.69(m,26H),3.41-3.36(m,6H),3.01-2.86(m,14H),2.46-2.21(m,6H),2.15-1.78(m,52H),1.68-1.23(m,56H).
[1007] Example 30
[1008]
[1009] Compound 30-1:
[1010] A mixture of benzylamine (25 g, 233.31 mmol), polyoxymethylene (42.03 g, 1.40 mol) and K2CO3 (32.24 g, 233.31 mmol) in MeOH (30 mL) was stirred at room temperature overnight.
[1011] The reaction mixture was filtered and concentrated under vacuum. To the residue was added PE:EA = 1:1 (100 mL), then the mixture was filtered and concentrated under vacuum to give crude compound 30-1 (45.56 g) as a colorless oil.
[1012] 1 H NMR(400MHz, DMSO-d6)δ:7.33-7.27(m,5H),4.27(s,4H),4.04(s,2H),3.30(s,6H).
[1013] Compound 30-2:
[1014] By 3-((benzyloxy)methyl)cyclobutanone (23.38g, 122.92mmol), compound 30-1 (24g, 122.92mmol) in MeCN (200mL) mixture (in a dropping funnel), and trimethylchlorosilane (26.70g, 245.84mmol) in MeCN (200mL) (in another dropping funnel) under stirring at 40 ℃ in 3h mixed dropwise in acetonitrile (200mL). The reaction was stirred overnight at 20 ℃. With saturated NaHCO3 pH was adjusted to 7-8 and ACN was removed under vacuum. The aqueous layer was extracted with EA (200mLx3). The combined organic phases were concentrated under vacuum. The residue was purified by C18 reverse phase column and flash column chromatography to give 30-2 (1.5g, 4% yield).
[1015] C 21 H 23 Calculated mass of O2N: 321.2; Found: 322.1 [M+H] + ,ESI.
[1016] 1 H NMR(400MHz,DMSO-d6)δ7.35-7.24(m,10H),4.48(s,2H),3.61(s,2H),3.40(d, J=6.8Hz,2H),3.33-3.08(m,4H),2.88(d,J=2.0Hz,2H),2.24(t,J=6.8Hz,1H).
[1017] Compound 30-3:
[1018] Methoxymethyl (triphenyl) phosphine chloride (2.88g, 8.40mmol) is dissolved in THF (30mL). KOtBu (1.05g, 9.33mmol) is added to the mixture at 0°C. The reaction mixture is stirred for another 30min at 0°C. Compound 30-2 (1.5g, 4.67mmol) is added to the mixture. The mixture is warmed to room temperature and stirred at room temperature overnight. The reaction mixture is quenched with saturated citric acid, and pH is adjusted to 6-7. The reaction mixture is extracted with EA (50mLx3), washed with brine (20mL), dried over Na2SO4, concentrated under vacuum and purified by flash silica gel column chromatography (10%-30% MeOH in DCM), to give compound 30-3 (1.5g, 92% yield) in an oily state.
[1019] C 23 H 27 Calculated mass of O2N: 349.20; Found: 350.2 [M+H] + ,ESI.
[1020] 1 H NMR(400MHz,DMSO-d6)δ7.37-7.26(m,10H),6.02(s,1H),4.47(s,2H),3.85(s,2H),3.54(d ,J=7.6Hz,2H),3.46(s,3H),3.13-3.09(m,4H),2.88(d,J=2Hz,2H),2.24(t,J=6.8Hz,1H).
[1021] Compound 30-4:
[1022] 2,2,2-trichloroacetic acid (883.64mg, 5.41mmol) in water (15mL) is added to compound 30-3 (1.5g, 4.29mmol) in ACN (45mL).The reaction is stirred at room temperature overnight.The reaction is saturated with NaHCO3quenched, and the pH is adjusted to 7-8.The reaction mixture is extracted with EA (20mLx3), washed with brine (10mL), dried over Na2SO4, concentrated under vacuum and purified by flash silica gel column chromatography (10%-30% EA in PE), to give compound 30-4 (600mg, 42% yield) in oil.
[1023] C 22 H 25 Calculated mass of O2N: 335.25; Found: 336.2 [M+H] + ,ESI.
[1024] 1H NMR(400MHz,DMSO-d6)δ9.90(s,1H),7.37-7.26(m,10H),4.41(s,2H),3.85(s,2H),3.44(d ,J=7.6Hz,2H),3.03-2.89(m,4H),2.86(d,J=4Hz,1H),2.69(s,2H),2.04(t,J=6.8Hz,1H).
[1025] Compound 30-5:
[1026] Compound 30-4 (600 mg, 1.79 mmol) was dissolved in MeOH (18 mL), and then NaBH4 (148.88 mg, 3.94 mmol) was slowly added in batches. The reaction was stirred at room temperature for 1 h. The reaction was quenched with water. The pH was adjusted to 6-7 with saturated citric acid. The reaction was concentrated under vacuum to remove MeOH. The residue was extracted with DCM (20 mLx3), washed with brine (10 mL), dried over Na2SO4, and concentrated under vacuum to give compound 30-5 (600 mg).
[1027] C 22 H 27 Calculated value of NO2 mass: 337.15; Measured value: 338.2 [M+H] + ,ESI.
[1028] 1H NMR(400MHz,DMSO-d6)δ7.37-7.26(m,10H),4.47(s,2H),3.90(s,2H),3.69(d,J=7.6Hz ,2H),3.62-3.59(m,4H),3.11(d,J=10.8Hz,2H),2.61-2.56(m,2H),2.19-2.04(m,2H).
[1029] Compound 30-6:
[1030] A mixture of compound 30-5 (200 mg, 592.67 μmol), Pd / C (100.00 mg, 823.38 μmol) in MeOH (6 mL) was stirred under 0.4 MPa H2 for 88 hr. The mixture was filtered and concentrated under vacuum, purified by preparative HPLC to give compound 30-6 (70 mg, 46% yield).
[1031] Calculated mass of C13H23NO2: 257.2; Measured value: 158.2 [M-Boc+H] + ,ESI.
[1032] 1H NMR (400MHz, CDCl3) δ3.96 (d, J = 8.0Hz, 4H), 3.70-3.68 (m, 4H), 3.25-3.17 (m, 4H), 2.36-2.30 (m, 2H), 2.00-1.95 (m, 2H), 1.49 (s, 9H).
[1033] Compound 30-7:
[1034] Compound 30-6 (1 g, 3.89 mmol) was dissolved in HCl / 1,4-dioxane (4 M, 10 mL). The reaction mixture was stirred at room temperature for 3 h. The reaction mixture was concentrated under vacuum to give the crude product 30-7 (610 mg), which was used in the next step without further purification.
[1035] Calculated value of C8H15NO2: 157.2; Found: 158.1 [M+H] + ,ESI.
[1036] Compound 30-8:
[1037] A mixture of DIEA (1.25 g, 9.70 mmol, 1.69 mL), HOBT (629.15 mg, 4.66 mmol), EDCI (892.59 mg, 4.66 mmol), Fmoc-6-aminocaproic acid (1.37 g, 3.88 mmol) in DCM (30 mL) was stirred at 0 ° C for 30 min. Compound 30-7 (610 mg, 3.88 mmol) was added to the reaction mixture and stirred at room temperature overnight. The reaction was quenched with water, washed with 10% citric acid (10 mL) and saturated NaHCO3 solution (10 mL) and brine (10 mL), dried over Na2SO4, concentrated under vacuum and purified by flash silica gel column chromatography (0%-10% MeOH) to give compound 30-8 (1.55 g, 81% yield).
[1038] C 29 H 36 Calculated value of N2O5 mass: 492.3; Found: 493.3 [M+H] + ,ESI.
[1039] 1H NMR (400MHz, DMSO-d6) δ7.90-7.68(m,4H),7.44-7.25(m,5H),4.56(t,J=5.2Hz,2H),4.31-4.20(m,3H),3.70-3.67 (m,4H),3.55(s,2H),3.31(s,4H),2.99-2.95(m,2H),2.29-2.21(m,2H),1.71(t,J=6.0Hz,2H),1.53-1.24(m,6H).
[1040] Compound 30-9:
[1041] Compound 30-8 (1.55 g, 3.15 mmol), DMAP (38.44 mg, 314.65 μmol), DIEA (610.00 mg, 4.72 mmol, 822.10 μL) were dissolved in DCM (50 mL). DMTrCl (1.17 g, 3.46 mmol) was added to the reaction mixture in batches at 0 ° C. The reaction was stirred at room temperature overnight. The reaction mixture was concentrated under vacuum and purified by rapid Al2O3 column chromatography (20%-50% EA in PE) to give compound 30-9 (1 g, 40% yield).
[1042] C 50 H 54 Calculated value of N2O7 mass: 794.4; Measured value: 817.4 [M+Na] + ,ESI.
[1043] 1 H NMR (400MHz, DMSO-d6) δ7.90-7.68(m,4H),7.44-7.25(m,14H),6.90(d,J=8.8Hz,4H),4.56(t,J=5.2Hz,1H),4.31-4.20(m,3H),3.7 4(s,6H),3.70-3.67(m,4H),3.55(s,2H),3.31(s,4H),2.99-2.95(m,2H),2.29-2.21(m,2H),1.89-1.67(m,2H),1.53-1.24(m,6H).
[1044] Compound 30-10:
[1045] Compound 30-9 (700 mg, 880.54 μmol) was dissolved in MeOH (14 mL), and piperidine (1.4 mL) was then added to the mixture. The reaction mixture was stirred at room temperature overnight. The reaction mixture was concentrated under vacuum and purified by rapid Al2O3 column chromatography (0%-10% MeOH) to give compound 30-10 (300 mg, 59% yield) as a white foamy solid.
[1046] C 35 H 44 Calculated value of N2O5 mass: 572.3; Measured value: 595.3 [M+Na] + ,ESI.
[1047] Compound 30-11:
[1048] By compound 11-11 (1.00g, 523.80 μmol), DIEA (169.25mg, 1.31mmol, 228.09 μL), HOBT (84.93mg, 628.57 μmol) and EDCI (120.50mg, 628.57 μmol) mixture in DCM (50mL) stir 30min at 0 DEG C.Compound 30-10 (300mg, 523.80 μmol) is added to the mixture.And the reaction is stirred at room temperature overnight.Reaction mixture is quenched with water (20mL), extracted with DCM (25mLx2), washed with brine (50mL), through Na2SO4, dried, concentrated under vacuum and purified by HPLC, to give compound 30-11 (595mg, 46% yield).
[1049] C 125 H 185 N 11 O 39 Calculated mass value: 2464.3; Found value: 1255.2 [M+2Na] 2+ ,ESI.
[1050] 1H NMR (400MHz, DMSO-d6) δ7.83-7.69(m,7H),7.43(s,1H),7.37-7.20(m,9H),6.91-6.89(m,J=8.8 Hz,4H),5.22(d,J=3.2Hz,3H),4.99-4.95(m,3H),4.49-4.46(m,6H),4.03(s,9H),3.91-3.85(m ,5H),3.74(s,6H),3.74-3.26(m,9H),3.01-2.99(m,10H),2.90-2.87(m,2H),2.27-2.20(m,9H) ,2.12(s,11H),2.06-2.02(m,8H),2.02(s,11H),1.89(s,11H),1.78(s,9H),1.62-1.21(m,52H).
[1051] Example 31
[1052]
[1053] Compound 31-1:
[1054] A mixture of compound 11-11 (3.17 g, 1.66 mmol), HOBT (448.34 mg, 3.32 mmol), EDCI (954.11 mg, 4.98 mmol) and DIEA (857.66 mg, 6.64 mmol) in DCM (20 mL) was stirred for 15 min, then compound 9-9 (1.00 g, 1.66 mmol) was added to the reaction mixture and continued to stir for 4 h. The mixture was distributed between DCM (50 mL) and water (35 mL), and the DCM extracts were washed with brine (100 ml), dried over sodium sulfate and concentrated in vacuo. The residue was purified by reverse phase column (C18 column), to provide compound 31-1 (2.25 g, 54% yield).
[1055] 1H NMR (400MHz, DMSO-d6) δ7.85-7.78(m,4H),7.72(t,J=5.4Hz,3H),7.45(s,1H),7.27-7.20(m,6H),6.91-6.85(m,6H),5.21(d,J=3.4Hz ,3H),4.99-4.94(m,3H),4.64(t,J=5.1Hz,1H),4.50-4.41(m,5H),4.05-3.95(m,10H),3.91-3.83(m,5H),3.75-3.65(m,14H),3.51(s ,1H),3.44-3.31(m,5H),3.06-2.94(m,10H),2.90(s,2H),2.89-2.78(m,2H),2.41-2.30(m,2H),2.28-2.21(m,4H),2.10(s,9H),2.08 -2.00(m,10H),1.99(s,11H),1.96-1.92(m,2H),1.89(s,9H),1.86-1.80(m,2H),1.77(s,9H),1.66-1.31(m,35H),1.30-1.13(m,13H).
[1056] Compound 31-2:
[1057] To the solution of compound 31-1 (150mg, 0.06mmol) in anhydrous DCM (1.0mL), DMAP (14mg, 0.12mmol) and TEA (24mg, 0.24mmol) were added, followed by succinic anhydride (20mg, 0.2mmol). The reaction mixture was stirred at room temperature for 3h, and LCMS showed that the starting material was completely consumed. The reaction mixture was diluted with DCM (10mL) and washed with H2O (3mLx4), then washed with brine (3mLx4), and the organic layer was concentrated to give compound 31-2 (130mg, 97% yield) as a white solid.
[1058] C 130 H 191 N 11 O 43 Calculated mass: 2594.31; Found: 1297.4 [M+2H] 2+ ,ESI.
[1059] 1HNMR(600MHz,DMSO-d6)δ7.92-7.69(m,7H),7.50-7.41(m,1H),7.31-7.12(m,9H ),6.92-6.89(m,6H),5.21(d,J=6.0Hz,3H),4.98-4.95(m,3H),4.52-4.41(m,5H ),4.07-4.01(m,12H),3.90-3.83(m,5H),3.80-3.64(m,14H),3.49-3.25(m,17H ),3.05-2.84(m,14H),2.47-2.23(m,8H),2.12-1.77(m,52H)1.61-1.21(m,46H).
[1060] Solid support 31-3:
[1061] Natural amino-LCAA-CPG (loading value: 75umol / g, ) was washed with ACN (100 mLx2), DMF (100 mLx2) and DCM (100 mLx2), then dried under high vacuum overnight.
[1062] To the solution of succinate 31-2 (130mg, 0.05mmol) and HBTU (53mg, 0.14mmol) in anhydrous DMF (1.5mL), add DIPEA (30mg, 0.23mmol), by reaction mixture vibrated at room temperature 10min, then add natural amino-LCAA-CPG (300mg, load 75umol / g).Suspension is vibrated at room temperature 20h, then filtered, washed with DMF (20mLx5), ACN (20mLx5), DCM (20mLx5) until TLC shows that eluent is spotless at 254nm.Solid support is dried under vacuum for 2h, to provide solid support (300mg). The unreacted amine on the solid support was capped by stirring with Ac2O / pyridine / N-methylimidazole (90 μL / 1.0mL / 80 μL) at room temperature for 1 h, and washed with DMF (20mLx5), ACN (20mLx5), DCM (20mLx5) until TLC showed that the eluent had no spots at 254nm. The solid support was dried under vacuum for 15h to give solid support 31-3 (300mg). For load calculation, 5.3mg of dry loaded CPG was taken and 20mL of 3% DCA was added on DCM. The solution was shaken and the UV absorbance at 482nm was measured. Ensure that the absorbance value is less than 1.0 unit to ensure that there is no signal saturation. Then the following equation is applied:
[1063] Load (umol / g) = (total amount of DCA added (mL)) * (absorbance at 482nm) * 1000) / 78.3 * (mg of CPG taken)
[1064] Total amount of DCA added (mL) = 20 mL
[1065] Absorbance at 482nm = 0.681
[1066] mg of CPG taken = 5.3 mg
[1067] Loading (umol / g) = ((20)*(0.681)*1000) / 78.3*(5.3) = 32.82 umol / g.
[1068] Example 32
[1069] Synthesis of GalNAc-conjugated and non-conjugated oligonucleotides and siRNA
[1070] GalNAc-conjugated phosphoramidites:
[1071] The syntheses of all other GalNAc-conjugated phosphoramidites were performed according to the procedures described in Examples 2-7, 9, and 11.
[1072] GalNAc conjugated and loaded onto solid support:
[1073] The syntheses of all other GalNAc-conjugated succinates loaded onto solid supports were performed according to the procedures described in Examples 2, 4, 9-11 and 31.
[1074] siRNA sequences and chemical modifications used to target human proprotein convertase subtilisin / kexin type 9 (hPCSK9):
[1075] Sense strand (5' to 3'):
[1076] (1)CmsUmsAmGmAmCmCfUmGfUmdTUmUmGmCmUmUmUmUmGmUm-GalNAc:
[1077] (2)GalNAc-CmUmAmGmAmCmCfUmGfUmdTUmUmGmCmUmUmUmUm sGmsUm
[1078] (3)GalNAc-CmUmAmGmAmCmCfUmGfUmdTUmUmGmCmUmUmUmUm GmUm-GalNAc
[1079] Antisense strand (5' to 3'):
[1080] AmsCfsAmAfAfAfGmCfAmAfAmAfCmAfGmGfUmCfUmAmGmsAmsAm
[1081] siRNA sequences and chemical modifications used to target mouse complement component 3 (mC3):
[1082] Sense strand (5' to 3'):
[1083] (1)UmsGmsGmUmCmAmAfGfGfUmCmUmUmCmUmCmUmCmUm-GalNAc
[1084] (2)GalNAc-UmGmGmUmCmAmAfGfGfUmCmUmUmCmUmCmUmsCmsUm
[1085] Antisense strand (5' to 3'):
[1086] (E)-VP-UmGfAmGfAmGfAmAfGmAfCmCfUmUfGmAfCmsCfsAm
[1087] siRNA sequences and chemical modifications used to target mouse transthyretin (mTTR):
[1088] Sense strand (5' to 3'):
[1089] (1)AfsAmsCfAmGfUmGfUmUfCfUfUmGfCmUfCmUfAmUfAmAf-GalNAc
[1090] (2)GalNAc-AfAmCfAmGfUmGfUmUfCfUfUmGfCmUfCmUfAmUfsAmsAf
[1091] Antisense strand (5' to 3'):
[1092] UmsUfAmUfAmGfAmGfCmAfAmGmAmAfCmAfCmUfGmUfUmsUmsUm
[1093] s: phosphorothioate, or phosphodiester,
[1094] m: 2'-OMe;
[1095] f: 2'-F;
[1096] (E)-VP: (E)-vinylphosphonate.
[1097] General preparation procedure:
[1098] 1. Loading: CPG (0.19 g, 500 A, about 10 μmol) pre-loaded with GalNAc or nucleoside in a 5 mL syringe.
[1099] 2. Washing: acetonitrile (2.0 mL, 0.3 min, at room temperature, repeated twice).
[1100] 3. Detritylation: 3% trichloroacetic acid in dichloromethane (2.0 mL, 0.7 min, at room temperature, repeated four times).
[1101] 4. Washing: acetonitrile (2.0 mL, 0.3 min, at room temperature, repeated twice).
[1102] 5. Coupling: 0.067 M reactant monomer in acetonitrile (1.0 mL) and 0.30 M 5-(benzylthio)-1H-tetrazolyl (BTT) in acetonitrile (1.0 mL) as activator (7.0 min, at room temperature, repeated three times)
[1103] 6. Sulfurization or oxidation: N,N-dimethyl-N'-(3-thioxo-3H-1,2,4-dithiazol-5-yl)formamidine (DDTT, 4.80 M, in pyridine / acetonitrile = 2 / 1, 2.0 mL, 1 min, at room temperature, twice) or 0.05 M I2 (in pyridine / H2O = 80 / 20 (v / v) , 2.0 mL, 1 min, at room temperature, twice).
[1104] 7. End-capping: 1-methylimidazole (NMI) / acetonitrile = 15 / 85 (v / v) (2.0 mL) and acetic anhydride / acetonitrile = 20 / 80 (v / v) (0.9 mL, 1 min, at room temperature, once).
[1105] 8. Washing: acetonitrile (2.6 mL, 0.3 min, at room temperature, repeated twice).
[1106] 9. The synthesis program automatically cycles 19 times.
[1107] 10. The solid support was immersed in 10% DEA for 20 min. The solid support was suspended in NH3·H2O (5 mL) and stirred at 40°C for 16 h in a 48 mL sealed tube. The reaction mixture was cooled to 25°C. The solid support was then filtered and the aqueous phase was concentrated in vacuo to give a yellow solution.
[1108] 11. Add 40 mL of ethanol to the filtrate (10 mL), followed by 0.3 mL of NaCl (3 M). Let the centrifuge tube stand at -20°C for 20 min. Then centrifuge the tube. Discard the supernatant and collect the remaining solid.
[1109] 12. The white solid was purified by preparative HPLC (column: O-C18 150*40mm*10μm; mobile phase: [0.1M TEAB-ACN]; B%: 14%-24%, 30min).
[1110] 13. The desired compound was obtained as a white solid after lyophilization.
[1111] Annealing steps:
[1112] 1. Calculate the molar value of the duplex (e.g., 2 mg of duplex, molar value = 2 mg / molecular weight of duplex, free acid), which is the molar value of the single strand.
[1113] 2. Dissolve the sense strand and antisense strand separately in ultrapure water (DNase / RNase-free, sterile) at 25° C. Quantify the concentration of oligonucleotides by UV-vis.
[1114] 3. Mix the two solutions in a 1:1 molar ratio.
[1115] 4. Place the mixed sample at room temperature for 10 minutes and test by HPLC to monitor whether the ratio is appropriate.
[1116] 5. The solution was aliquoted into tubes and lyophilized to give siRNA samples.
[1117] Table 1. siRNA IDs and their GalNAc types and positions on the sense strand
[1118]
[1119]
[1120]
[1121]
[1122]
[1123]
[1124]
[1125]
[1126]
[1127] Bioassay
[1128] GalNAc-conjugated siRNAs against human proprotein convertase subtilisin / Kexin type 9 (hPCSK9), mouse complement component 3 (mC3), or mouse transthyretin (mTTR) genes in the present invention were tested for free uptake in primary human hepatocytes (PHH), primary mouse hepatocytes (PMH), and wild-type mice. Efficacy was determined by reduction of hPCSK9, mC3, or mTTR mRNA levels using real-time quantitative RT-PCR assays.
[1129] The competitive activity of the GalNAc-conjugated siRNA for the hPCSK9 gene of the present invention and the reporter gene siRNA-8 (GalNAc-1 conjugated siRNA labeled with Cy3 dye) in binding to the asialoglycoprotein receptor (ASGPR) in the human liver cancer cell line HepG2 was also detected. The competitive activity was determined by the reduction of the mean fluorescence intensity (measured by flow cytometry) in the cells.
[1130] 1. Cell Culture
[1131] Human HepG2 cells were purchased from ATCC and passaged at 70% confluence in the culture medium DMEM (Invitrogen) supplemented with 10% fetal bovine serum (FBS, Invitrogen).
[1132] Frozen vials of primary human hepatocytes (PHH) purchased from Invitrogen were thawed in cryopreserved hepatocyte recovery medium (CHRM, Gibco) and plated at approximately 1.0×10 4% CO in plating medium (Williams Medium E, Gibco, A1217601) supplemented with a hepatocyte plating supplement pack (Gibco, CM3000) on collagen I-coated 96-well plates (Gibco, A1142803). 5 Cells were plated at a density of 100 ul of culture medium per well for 4-6 hours. The plating medium was then replaced with an incubation medium (Williams Medium E, Gibco, A1217601, supplemented with a hepatocyte maintenance supplement pack (Gibco, CM4000)) and treated with GalNAc-conjugated siRNA for free uptake.
[1133] Frozen vials of PMH purchased from Xenotech were thawed in OptiThaw Hepatocyte Medium and plated in OptiPlate Hepatocyte Medium on collagen I-coated 96-well plates (Gibco, A1142803) at approximately 1.0×10 5Cells were plated at a density of 100 ul of medium per well for 4-6 hours. Then, the plating medium was replaced with incubation medium (OptiCulture medium) and treated with GalNAc-conjugated siRNA for free uptake.
[1134] 2. siRNA of hPCSK9, mC3, and mTTR (Example 32)
[1135] hPCSK9 siRNA was synthesized by solid phase oligonucleotide synthesis according to the following published sequence:
[1136] Sense strand 5'-3': CUAGACCUGUTUUGCUUUUGU
[1137] Antisense strand 3'-5': AAGAUCUGGACAAAACGAAAACA
[1138] siRNA for mC3 was synthesized by solid phase oligonucleotide synthesis according to the following published sequence:
[1139] Sense strand 5'-3': UGGUCAAGGUCUUCUCUCU
[1140] Antisense strand 3'-5': ACCAGUUCCAGAAGAGAGU
[1141] siRNA for mTTR was synthesized by solid phase oligonucleotide synthesis according to the following published sequence:
[1142] Sense strand 5'-3': AACAGUGUUCUUGCUCUAUAA
[1143] Antisense strand 3'-5': UUUUGUCACAAGAACGAGAUAUU
[1144] 3. Free intake
[1145] The plating medium of the indicated PHH or PMH cells was replaced with pre-warmed incubation medium (containing siRNA with various final concentrations: 100, 20, 4, 0.8, 0.16, 0.032, 0.0064, 0.00128, 0.000256 nM). After 48 hours of incubation, mRNA was extracted for RT-qPCR.
[1146] 4. mRNA Isolation
[1147] Using Dynabeads TM mRNA DIRECT TMPurification kit (Invitrogen, catalog number 61012) isolates the mRNA of PHH or PMH. Discard incubation medium and add 100ul lysis / binding buffer provided in the kit to cells. Collect cell lysate after incubation at room temperature for 15-30min and mix with magnetic Dynabeads subsequently. After incubation for 5min, Dynabeads are washed with the buffer provided in the kit, air-dried, and then subjected to cDNA synthesis.
[1148] 5. cDNA Synthesis
[1149] After mRNA isolation, reverse transcription was immediately performed using the SuperScript VILO cDNA Synthesis Kit (Invitrogen life technology).
[1150] 6. Gene expression analysis (RT-qPCR).
[1151] All probes used for RNA quantification were obtained by Life Technologies using its TaqMan gene expression system with dual-labeled probes. The target gene expression in each well was normalized to TATA-box binding protein (TBP) as a control. Ct values were measured using the Quantstudio 5 real-time PCR system (Invitrogen life technology). To calculate relative fold changes, real-time data were compared with C T The TaqMan probes were analyzed using the PCR method and normalized to the relative target mRNA levels in untreated cells. The TaqMan probe catalog numbers are as follows
[1152] Target genes:
[1153] Human PCSK9-FAM (Assay ID: Hs00545399_m1)
[1154] Mouse C3-FAM (Assay ID: Mm01232779_m1)
[1155] Mouse TTR-FAM (Assay ID: Mm00443267_m1)
[1156] Housekeeping genes:
[1157] Human TBP-VIC (Assay ID: Hs00427620_m1)
[1158] Mouse TBP-VIC (Assay ID: Mm01277042_m1)
[1159] Example 1. Triantennary GalNAc-siRNA free uptake assay in PHH
[1160] Triantennary GalNAc-conjugated siRNA targeting hPCSK9 mRNA was assayed to determine its target mRNA knockdown activity in PHH. Plateable human cryopreserved primary hepatocytes were purchased from Gibco (Catalog No.: HMCPUS, Lot No.: Hu8115). The cells were thawed at 37°C immediately after being removed from liquid nitrogen and then transferred to pre-warmed thawing medium (Gibco, CM7000) before complete thawing. The cells were centrifuged at 100g for 10 min at room temperature, the thawing medium was removed, and plating medium (Williams E medium, Gibco, A1217601) supplemented with a hepatocyte plating supplement pack (Gibco, CM3000) was added to plate the cells on a collagen I-coated 96-well plate (Gibco, A1142803) at a density of approximately 1.0 x 10 5 cells / 100ul culture medium / well. After incubation at 37°C for 4 hours, the plating medium was replaced with incubation medium (Williams Medium E (Gibco, A1217601), supplemented with a hepatocyte maintenance supplement pack (Gibco, CM4000)) containing novel GalNAc-conjugated siRNA (5-fold dilution from 100nM to 0.000256nM; except for siRNA-14 and siRNA-16, which were 3-fold dilutions from 100nM to 0.01nM). The data were biologically replicated twice. Cells were harvested 48 hours after the addition of siRNA and then incubated with Dynabeads according to the manufacturer's instructions. TM mRNA DIRECT TM Purification kit (Invitrogen, catalog number 61012) was used for mRNA RNA separation, and cDNA synthesis was performed with SuperScript VILO cDNA synthesis kit (Invitrogen Life Technologies). TaqMan gene expression assay (ThermoFisher) was used to measure the hPCSK9 mRNA level in each well, normalized to hTBP mRNA, and performed in duplicate by real-time qPCR on Quantstudio 5 real-time PCR system (Invitrogen Life Technologies). Data were calculated using the Δ-ΔCt method and normalized to the relative target mRNA level in untreated cells. Dose-response curves were drawn using a four-parameter logistic model with GraphPad Prism 9.3.1.
[1161] The data show the maximum effect of the novel GalNAc conjugate on hPCSK9 mRNA levels. The GalNAc moiety L96 (siRNA-1) was used as a positive control in the assay. If the remaining hPCSK9 mRNA level in the GalNAc conjugate treatment is lower than L96, we believe that the novel GacNAc is superior to siRNA-1. Otherwise, the novel GacNAc is worse than siRNA-1. The ranking of all triantennary GalNAcs shown in Table 2 is determined by the average maximum effect at 100nM in two biological replicates. The maximum effect multiple is calculated by dividing the percentage of remaining mRNA in cells treated with siRNA-1 by the percentage in other GalNAc-siRNA treatments. The results of the free uptake assay in PHH showed that the maximum effect of the designed triantennary GalNAc was about 35% remaining target mRNA, which is comparable to siRNA-1.
[1162] Table 2. Ranking of triantennary GalNAcs based on maximal effect in the PHH free uptake assay.
[1163]
[1164]
[1165] Example 2. (1+1+1) trivalent GalNAc-siRNA free uptake assay in PHH
[1166] The (1+1+1) trivalent GalNAc-conjugated siRNA targeting hPCSK9 mRNA was assayed to determine its target mRNA knockdown activity in PHH. The methods and procedures for PHH free uptake, mRNA separation and RT-qPCR are exactly the same as those for the triantennary GalNAc-conjugated siRNA described above. The ranking of (1+1+1) trivalent GalNAc conjugates is shown in Table 3. The ranking is based on the maximum effect on the remaining target mRNA percentage. The data of cells treated with siRNA at 100nM show the maximum effect of the novel GalNAc conjugate on hPCSK9 mRNA levels. The positive controls are siRNA-2 and siRNA-29.
[1167] Table 3. Ranking of (1+1+1) trivalent GalNAc based on maximal effect in the PHH free uptake assay.
[1168]
[1169] The results of free uptake assays in PHH showed that the designed (1+1+1) trivalent GalNAc conjugate (which had the greatest effect on the remaining target mRNA after knockdown of less than 50%) was more effective than siRNA-2 and siRNA-29 (control). Although siRNA-5 and siRNA-3 had the same siRNA sequence and chemical modifications compared to the others, their inhibition of target mRNA was as low as less than 30%.
[1170] Example 3. Competition assay to detect GalNAc uptake activity in HepG2 cells.
[1171] GalNAc is a high affinity ligand for ASGPR. To further compare the ASGPR-mediated uptake and efficacy of different GalNAc-conjugated siRNAs, we used Cy3-labeled GalNAc-siRNA (siRNA-8) as a reporter gene and mixed it with different concentrations of GalNAc-siRNA to measure siRNA-8 internalization in hepatocytes by flow cytometry. As the amount of GalNAc-siRNA increased, the internalization of the reporter gene decreased. We selected siRNAs with higher or lower GalNAc efficiency compared to the positive control in the PHH free uptake assay for competition assay. HepG2 cells were seeded in 384-well plates (1x 10 4 cells / well) and allowed to attach and equilibrate at 37°C for at least 16h. Cy3-labeled GalNAc-siRNA (siRNA-8) was mixed with 8 points of 3-fold dilutions of the designed GalNAc-siRNA in culture medium. HepG2 cells were placed on ice for siRNA treatment. The old culture medium of HepG2 cells was replaced with culture medium containing siRNA, and the cells were cultured continuously at 37°C for 2h. After incubation, the cycling cells were placed on ice, washed three times with ice-cold PBS (pH=7.4, Thermo Fisher Scientific), digested with trypsin at 37°C for 10min, and then the trypsin treatment was stopped with ice-cold culture medium. The cells were then transferred to a new 96-well plate and the culture medium was replaced with EasySep on ice. TM Buffer (Stemcell Technologies). Then BD LSRFortessa TM The mean fluorescence intensity of cells was analyzed by flow cytometry using X-20 (BD Biosciences). Internalized siRNA was expressed as mean fluorescence intensity (MFI). Dose response curves were plotted using GraphPad Prism version 9.3.1 using a four-parameter logistic model.
[1172] Table 4. Ranking of triantennary GalNAc based on maximum effect in competition assay.
[1173]
[1174] Table 5. Ranking of (1+1+1) trivalent GalNAc based on maximum effect in competition assay.
[1175]
[1176] Meanwhile, the binding affinity of GalNAc-siRNA to ASGPR was tested on a Biacore 8K machine (Biacore AB, equipped with a NiHC200M chip) by surface plasmon resonance (SPR) assay. Here, a homemade His-tagged human ASPGR1 CRD domain of the H1 subunit (aa154-281) was immobilized on the chip. The results of the binding affinity are also shown in Tables 4 and 5.
[1177] The results of the competition assay showed that all triantennary GalNAc conjugates could inhibit siRNA-8 internalization at 6uM (from 36% to 47%) and had similar binding affinity to ASGPR as tested by SPR.
[1178] The results of the competition assay showed that siRNA-2 could not inhibit the internalization of Cy3-labeled GalNAc-siRNA (siRNA-8) at 6uM, while other siRNAs with different (1+1+1) trivalent GalNAc could inhibit and had similar binding affinity to ASGPR as tested by SPR.
[1179] Example 4. Triantennary and (1+1+1) trivalent GalNAc-siRNA in free uptake assay in PMH
[1180] We selected two triantennary GalNAcs (GalNAc-6 at the 3' end of the sense strand and GalNac-7 at the 3' end of the sense strand) for further analysis of PMH free uptake assay. siRNA-24 and siRNA-27 (conjugated with GalNAc-6 at the 3' end of the sense strand) target mC3 and mTTR, respectively. siRNA-25 and siRNA-28 (conjugated with GalNAc-7 at the 3' end of the sense strand) target mC3 and mTTR mRNA, respectively.
[1181] We also selected three (1+1+1) trivalent GalNAc (GalNAc-3 at the 5' end of the sense strand and GalNAc-5 at the 5' end of the sense strand) for further analysis of PMH free uptake assay. Three (1+1+1) trivalent GalNAc were conjugated with siRNA-37 and siRNA-38 (targeting mTTR mRNA), respectively.
[1182] Triantennary or (1+1+1) trivalent GalNAc-conjugated siRNAs targeting mC3 mRNA or mTTR were assayed to determine their target mRNA knockdown activity in PMH. Cells were thawed at 37°C immediately after removal from liquid nitrogen and then transferred to pre-warmed OptiThaw Hepatocyte Medium before complete thawing. Cells were centrifuged at 100 g for 10 min at room temperature, the thawing medium was removed, and OptiPlate Hepatocyte Medium was added to plate cells on collagen I-coated 96-well plates (Gibco, A1142803) at a density of approximately 1.0x10 5 cells / 100ul medium / well. After incubation at 37°C for 4 hours, the plating medium was replaced with OptiCulture medium (containing novel GalNAc-conjugated siRNA, diluted 5-fold from 100nM to 0.000256nM). Cells were harvested 48 hours after adding siRNA and then incubated with Dynabeads according to the manufacturer's instructions. TM mRNA DIRECT TM Purification kit (Invitrogen, catalog number 61012) was used for mRNA RNA isolation, and cDNA synthesis was performed with SuperScriptVILO cDNA synthesis kit (Invitrogen Life Technologies). TaqMan gene expression assay (Thermo Fisher Scientific) was used to measure the mC3 mRNA level in each well, normalized to mTBP mRNA, and performed in duplicate by real-time qPCR on the Quantstudio5 real-time PCR system (Invitrogen Life Technologies). Data were calculated using the Δ-ΔCt method and normalized to the relative target mRNA level in untreated cells. Dose-response curves were drawn using a four-parameter logistic model using GraphPadPrism version 9.3.1.
[1183] Table 6. Ranking of triantennary GalNAcs based on maximum effect in PMH free uptake assay targeting mC3 mRNA.
[1184]
[1185] Table 7. Ranking of triantennary GalNAcs based on maximum effect in PMH free uptake assay targeting mTTR mRNA.
[1186]
[1187] Table 8. Ranking of 1+1+1 GalNAc based on maximum effect in PMH free uptake assay targeting mTTR mRNA.
[1188]
[1189] The results in Tables 6 and 7 indicate that the designed triantennary GalNAc is more effective than the control (siRNA-23 and siRNA-26), and the results in Table 8 indicate that the designed (1+1+1) trivalent GalNAc is more effective than the control (siRNA-40).
[1190] Example 5. In vivo studies of triantennary and (1+1+1) trivalent GalNAc-siRNA
[1191] In vivo study procedures
[1192] Male C57BL / 6 mice of about 6-8 weeks of age were obtained from Jackson Laboratories. The animals were weighed and then assigned to each group to ensure that the average body weight and weight change of each group were similar. The test article (GalNAc-conjugated siRNA) was prepared in 1 mg / mL sterile phosphate buffered saline (PBS). siRNA concentration and quality were measured using QIAxpert (Qiagen). Mice were subcutaneously administered siRNA or PBS control (vehicle) at 5 mL / kg. Blood was collected using a retro-orbital blood sampling procedure and then serum was prepared. After serum was obtained, it was transferred to a 1.5 mL tube and stored at -80 ° C. Baseline blood samples were collected 2 days before injection. Blood was collected again on the 7th day after administration. Animals were killed on the 14th day, and blood was subsequently collected and livers were obtained. One lobe of the liver was stored in 2.5 mL of RNAlater (ThermoFisher Scientific) and stored at 4 ° C for RNA extraction later. The other lobe of the liver was snap frozen and stored at -80°C.
[1193] For serum proteins, mTTR levels were measured using an ELISA kit from LS Bio (Catalog No. LS-F7530), and mC3 levels were measured using an ELISA kit from Abcam (Catalog No. ab263884).
[1194] For liver gene expression, liver tissue was homogenized in RNAlater and then mRNADIRECT TM mRNA was isolated using a purification kit (Thermo Fisher Scientific). TM IV VILO TM cDNA generation was performed using a master mix (Thermo Fisher Scientific). Real-time PCR reactions were performed using gene-specific TaqMan assays (Thermo Fisher Scientific).
[1195] Summary of in vivo results
[1196] After administration, siRNA-23, siRNA-24, and siRNA-25 showed a sustainable reduction in serum mC3 protein until the last time point examined (day 14). In the siRNA-24 or siRNA-25 treated groups, the mC3 protein levels on days 7 and 14 were statistically significantly lower than those in the vehicle treated group. Compared with siRNA-23, siRNA-24 and siRNA-25 showed a better trend of mC3 knockdown ( Figure 1 In addition, siRNA-24 and siRNA-25 significantly reduced mC3 mRNA levels in the liver at day 14 compared with the vehicle group ( Figure 2 ).
[1197]
[1198] Similarly, sustained knockdown of mTTR protein by siRNA-37, -38, -39, and -40 was observed until day 14 after administration. All siRNAs significantly reduced mTTR protein levels on days 7 and 14, as well as mTTR mRNA levels on day 14, compared to the vehicle-treated group.
[1199]
[1200] Our data indicate that the designed GalNAc conjugates have good expression knockdown.
Claims
1. A targeting ligand having a structure shown in formula (III-b), (III-c) or (III-d): R1 is hydrogen or a protecting group; R2 is hydrogen, or a solid support optionally attached via a linker group, or a phosphoramidite; R is a carbohydrate or a derivative thereof having a hydroxyl protecting group connected via a linker group; m is independently selected from 0, 1, 2, 3, 4 and 5; n is independently selected from 1, 2, 3, 4 and 5; Each of r, s and t is independently selected from 0, 1 and 2; Each of m1 and n1 is independently selected from 0, 1, 2, 3 and 4.
2. A targeting ligand having a structure shown in formula (III) or (III-a): is a single bond or a double bond; R1 is hydrogen or a protecting group; R2 is hydrogen, or a solid support optionally attached via a linker group, or a phosphoramidite; R is a carbohydrate or a derivative thereof having a hydroxyl protecting group connected via a linker group; R b are independently selected from the group consisting of hydrogen and oxo; Each of m and n is independently selected from 1, 2, 3, 4 and 5; Each of m1 and n1 is independently selected from 0, 1, 2, 3 and 4.
3. The targeting ligand of claim 1 or 2, wherein R has a structure shown in formula (IV), (IV-a), (IV-b) or (IV-c): A is for C 3-10 Cycloalkyl or 4-12 membered heterocyclic group; Each of L1, L2, L3, L4 and L5 is independently selected from the group consisting of: Absent, O, S, SS, NH, CO, CONH, NHCO and 4-10 membered heterocyclyl; Each of R4, R6, R7 and R8 is independently selected from the group consisting of CH2, OCH2CH2 and CH2CH2O; R5 is independently selected from the group consisting of absent, CH2, OCH2, CH2O, OCH2CH2, CH2CH2O, NHCH2, CH2NH, NHCH2CH2, CH2CH2NH, C 0-6 Alkyl (C 3-8 Cycloalkyl) and C 0-6 Alkyl (4-10 membered heterocyclic group); R9 is carbohydrate; Each of t1, t2, t3, t4 and t5 is independently selected from 0, 1, 2, 3, 4, 5 and 6.
4. The targeting ligand of claim 3, wherein R has a structure shown in formula (IV-1), (IV-a-1), (IV-b-1) or (IV-c-1): in, A is Each of L1, L3, L4 and L5 is independently selected from the group consisting of absent, O, S, SS, NH, CO, CONH and NHCO; L2 does not exist, and is O, S, SS, NH, CO, CONH, NHCO and R5 is independently selected from the group consisting of: absent, CH2, CH2O, CH2NH, C 3-6 Cycloalkyl, C 3-6 Cycloalkyl C 1-3 alkyl, 4-8 membered heterocyclyl containing 1, 2 or 3 heteroatoms selected from N or O, and 4-8 membered heterocyclyl containing 1, 2 or 3 ring heteroatoms selected from N or O 1-3 alkyl.
5. The targeting ligand of claim 3, wherein the R5 is independently selected from -OCH2-, -NHCH2-, 6. The targeting ligand of claim 3, wherein R9 is selected from the group consisting of galactose, galactosamine, N-acetylgalactosamine (GalNAc), D-galactosamine alcohol, mannose, mannosamine, mannose-6-phosphate, glucose, glucosamine, N-acetyl-glucosamine (GluNAc), glucose-6-phosphate, glucosamine alcohol, glucose glyceraldehyde, fucose, fucosamine, fucose, lactose, allose, aloesin, galactose, galactosamine ... Preferably, R9 is N-acetylgalactosamine.
7. The targeting ligand of claim 3, wherein R has a structure shown in formula (IV-d), (IV-e), (IV-f), (IV-da), (IV-ea) or (IV-fa): in, R5 is independently selected from the group consisting of OCH2, NHCH2, and a 4-6 membered heterocyclic group containing 1 or 2 heteroatoms selected from N or O; m is independently selected from 0, 1, 2, 3, 4, 5 and 6; n is independently selected from 1, 2, 3, 4, 5, 6, 7, 8, 9 and 10; and r is independently selected from 0, 1, 2, 3, 4 and 5.
8. The targeting ligand of claim 3, wherein R is: s is independently selected from 0, 1, 2 and 3; r is independently selected from 0, 1, 2, 3, 4 and 5; n is independently selected from 1, 2, 3, 4, 5, 6, 7, 8, 9 and 10.
9. The targeting ligand of claim 3, wherein the targeting ligand is: R p is H or a hydroxyl protecting group, preferably, the hydroxyl protecting group is acetyl; X is O or S; Each of m and n is independently selected from 1 or 2; Each of m1 and n1 is independently selected from 1, 2 or 3.
10. The targeting ligand of claim 3 or 9, wherein R1 is hydrogen, or a substituted or unsubstituted triphenylmethyl hydroxy protecting group; preferably, R1 is 11. The targeting ligand of claim 3 or 9, wherein R2 is hydrogen, It is a solid support.
12. The targeting ligand of claim 3, wherein the targeting ligand is: X is O or S.
13. The targeting ligand of claims 1-12, linked to a therapeutic agent for use as a medicament.
14. A therapeutic compound or a pharmaceutically acceptable salt thereof, comprising at least one therapeutic oligonucleotide conjugated to a targeting ligand as claimed in claims 1 to 12.
15. The therapeutic compound or pharmaceutically acceptable salt thereof of claim 14, wherein the therapeutic compound is: NA is an oligonucleotide; X is O or S.
16. The therapeutic compound of claim 14, wherein the oligonucleotide is an antisense oligonucleotide; preferably, the oligonucleotide is siRNA.
17. A pharmaceutical composition comprising the therapeutic compound of claim 14 or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, diluent or excipient.
18. A method of treating a disease or condition that would benefit from administration of a therapeutic compound according to claim 14 or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition according to claim 17.
19. A method of synthesizing the therapeutic compound of claim 14, the method comprising: A targeting ligand as described in claims 1-12 is provided, and the targeting ligand is conjugated to an oligonucleotide; preferably, the targeting ligand is conjugated to the 3' end or the 5' end of the oligonucleotide; more preferably, the oligonucleotide is siRNA.
20. A compound of formula (Va), (Vb), or (Vc), or a tautomer or a pharmaceutically acceptable salt thereof: is a single bond or a double bond; R b independently selected from the group consisting of hydrogen and oxo; Each of m and n is independently selected from 1, 2, 3, 4 and 5 Each of m1 and n1 is independently selected from 0, 1, 2, 3 and 4.
21. A compound having formula (VI-a), (VI-b), or (VI-c), or a tautomer or a pharmaceutically acceptable salt thereof: m is independently selected from 0, 1, 2, 3, 4, and 5; n is independently selected from 1, 2, 3, 4 and 5; Each of r, s and t is independently selected from 0, 1 and 2; Each of m1 and n1 is independently selected from 0, 1, 2, 3 and 4.
22. A compound having the following structure: or a tautomer or a pharmaceutically acceptable salt thereof.
Citation Information
Cited By
Sirna, conjugate which contain sirna, pharmaceutical composition and uses thereof
WO2026200858A1
